DrugBankID,DrugName,DrugType,PubchemSubstanceID,DrugsLink,DrugSeq,DrugDescription,Drug_Class,Drug_Class_1,Drug_Class_2,Drug_Class_3,Drug_Class_4,Drug_Class_5,Drug_Class_6,Drug_Class_7,UniProtIDTarget,GeneName,TargetName,TargetSequence,TargetDescription,DrugMolType,TargetSpecies,drug_A,drug_C,drug_D,drug_E,drug_F,drug_G,drug_H,drug_I,drug_K,drug_L,drug_M,drug_N,drug_P,drug_Q,drug_R,drug_S,drug_T,drug_V,drug_W,drug_Y,TargetSequenceAminoAcid
DB00001,Lepirudin,BiotechDrug,46507011.0,http://www.drugs.com/cdi/lepirudin.html,LTYTDCTESGQNLCLCEGSNVCGQGNKCILGSDGEKNQCVTGEGTPKPQSHNDGDFEEIPEEYLQ,drugbank_drug|DB00001 DB00001 sequence,"Anticoagulants, Cardiovascular",72,-1,-1,-1,-1,-1,-1,P00734,F2,Prothrombin,ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGCCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGGGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGCGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACGGATGTGTTCTGGGCC,drugbank_target|P00734 Prothrombin (DB00001; DB00006; DB00055; DB00100; DB00170; DB00278; DB01123; DB01225; DB01593; DB01725; DB01766; DB01767; DB02287; DB02723; DB03136; DB03159; DB03847; DB03865; DB04136; DB04591; DB04697; DB04722; DB04771; DB04772; DB0,BiotechDrug,Humans,0,6,4,8,1,9,1,2,3,5,0,5,3,5,0,4,5,2,0,2,ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGCCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGGGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGCGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACGGATGTGTTCTGGGCC
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P00533,EGFR,Epidermal growth factor receptor,ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAGACCATCCAGGAGGTG,drugbank_target|P00533 Epidermal growth factor receptor (DB00002; DB00281; DB00317; DB00530; DB01259; DB01269; DB03496; DB04988; DB05101; DB05294; DB05374; DB05424; DB05524; DB05944; DB06021; DB07602; DB07662; DB08916; DB09330; DB09559; DB10772; DB11731; ,BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAGACCATCCAGGAGGTG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P00533,EGFR,Epidermal growth factor receptor,ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAGACCATCCAGGAGGTG,drugbank_target|P00533 Epidermal growth factor receptor (DB00002; DB00281; DB00317; DB00530; DB01259; DB01269; DB03496; DB04988; DB05101; DB05294; DB05374; DB05424; DB05524; DB05944; DB06021; DB07602; DB07662; DB08916; DB09330; DB09559; DB10772; DB11731; ,BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGCGACCCTCCGGGACGGCCGGGGCAGCGCTCCTGGCGCTGCTGGCTGCGCTCTGCCCGGCGAGTCGGGCTCTGGAGGAAAAGAAAGTTTGCCAAGGCACGAGTAACAAGCTCACGCAGTTGGGCACTTTTGAAGATCATTTTCTCAGCCTCCAGAGGATGTTCAATAACTGTGAGGTGGTCCTTGGGAATTTGGAAATTACCTATGTGCAGAGGAATTATGATCTTTCCTTCTTAAAGACCATCCAGGAGGTG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,DILLTQSPVILSVSPGERVSFSCRASQSIGTNIHWYQQRTNGSPRLLIKYASESISGIPSRFSGSGSGTDFTLSINSVESEDIADYYCQQNNNWPTTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00002 Cetuximab light chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,9,12,8,13,3,10,11,16,0,11,10,12,8,34,16,14,3,8,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00002,Cetuximab,BiotechDrug,46507042.0,http://www.drugs.com/cdi/cetuximab.html,QVQLKQSGPGLVQPSQSLSITCTVSGFSLTNYGVHWVRQSPGKGLEWLGVIWSGGNTDYNTPFTSRLSINKDNSKSQVFFKMNSLQSNDTAIYYCARALTYYDYEFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB00002 Cetuximab heavy chain,"Antineoplastics EGFR Inhibitors, Antineoplastics Monoclonal Antibody",481,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,12,7,8,5,10,21,4,6,16,22,2,11,21,11,3,35,23,22,5,11,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00003,Dornase alfa,BiotechDrug,46507792.0,http://www.drugs.com/cdi/dornase-alfa.html,LKIAAFNIQTFGETKMSNATLVSYIVQILSRYDIALVQEVRDSHLTAVGKLLDNLNQDAPDTYHYVVSEPLGRNSYKERYLFVYRPDQVSAVDSYYYDDGCEPCGNDTFNREPAIVRFFSRFTEVREFAIVPLHAAPGDAVAEIDALYDVYLDVQEKWGLEDVMLMGDFNAGCSYVRPSQWSSIRLWTSPTFQWLIPDSADTTATPTHCAYDRIVVAGMLLRGAVVPDSALPFNFQAAYGLSDQLAQAISDHYPV,drugbank_drug|DB00003 Dornase alfa sequence,"Enzymes, Mucolytic",14,-1,-1,-1,-1,-1,-1,,,,,,,,25,4,22,11,12,12,5,12,5,22,4,9,14,11,13,18,13,23,4,16,
DB00004,Denileukin diftitox,BiotechDrug,46506950.0,http://www.drugs.com/cdi/denileukin-diftitox.html,MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTA,drugbank_drug|DB00004 DB00004 sequence,Interleukin Inhibitors,112,-1,-1,-1,-1,-1,-1,P31785,IL2RG,Cytokine receptor common subunit gamma,ATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGAGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTCTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTTCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCCCAGCCTACCAACCTC,drugbank_target|P31785 Cytokine receptor common subunit gamma (DB00004; DB00041; DB05943),BiotechDrug,Humans,16,2,16,22,8,22,3,10,25,16,6,13,8,9,8,25,13,19,3,11,ATGTTGAAGCCATCATTACCATTCACATCCCTCTTATTCCTGCAGCTGCCCCTGCTGGGAGTGGGGCTGAACACGACAATTCTGACGCCCAATGGGAATGAAGACACCACAGCTGATTTCTTCCTGACCACTATGCCCACTGACTCCCTCAGTGTTTCCACTCTGCCCCTCCCAGAGGTTCAGTGTTTTGTGTTCAATGTCGAGTACATGAATTGCACTTGGAACAGCAGCTCTGAGCCCCAGCCTACCAACCTC
DB00004,Denileukin diftitox,BiotechDrug,46506950.0,http://www.drugs.com/cdi/denileukin-diftitox.html,MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTA,drugbank_drug|DB00004 DB00004 sequence,Interleukin Inhibitors,112,-1,-1,-1,-1,-1,-1,P14784,IL2RB,Interleukin-2 receptor subunit beta,ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCTACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCGAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAAGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGTCAAGCATCCTGGGCC,drugbank_target|P14784 Interleukin-2 receptor subunit beta (DB00004; DB00041; DB00074; DB00111),BiotechDrug,Humans,16,2,16,22,8,22,3,10,25,16,6,13,8,9,8,25,13,19,3,11,ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCTACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCGAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAAGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGTCAAGCATCCTGGGCC
DB00004,Denileukin diftitox,BiotechDrug,46506950.0,http://www.drugs.com/cdi/denileukin-diftitox.html,MGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGIQKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALKVDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQAKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKTKIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTA,drugbank_drug|DB00004 DB00004 sequence,Interleukin Inhibitors,112,-1,-1,-1,-1,-1,-1,P01589,IL2RA,Interleukin-2 receptor subunit alpha,ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAGGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCCTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGCGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGTCAATGCACAAGCTCT,drugbank_target|P01589 Interleukin-2 receptor subunit alpha (DB00004; DB00041; DB00074; DB00111; DB15628; DB16411),BiotechDrug,Humans,16,2,16,22,8,22,3,10,25,16,6,13,8,9,8,25,13,19,3,11,ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAGGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCCTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGCGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGTCAATGCACAAGCTCT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P01374,LTA,Lymphotoxin-alpha,ATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTCCTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTCACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACCCTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGAGCAAACACGGACCGT,drugbank_target|P01374 Lymphotoxin-alpha (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGACACCACCTGAACGTCTCTTCCTCCCAAGGGTGTGTGGCACCACCCTACACCTCCTCCTTCTGGGGCTGCTGCTGGTTCTGCTGCCTGGGGCCCAGGGGCTCCCTGGTGTTGGCCTCACACCTTCAGCTGCCCAGACTGCCCGTCAGCACCCCAAGATGCATCTTGCCCACAGCACCCTCAAACCTGCTGCTCACCTCATTGGAGACCCCAGCAAGCAGAACTCACTGCTCTGGAGAGCAAACACGGACCGT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P01375,TNF,Tumor necrosis factor,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT,drugbank_target|P01375 Tumor necrosis factor (DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01407; DB01411; DB01427; DB04297; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05744; DB05758; DB05767; DB05869; DB05879; DB,BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00005,Etanercept,BiotechDrug,46506732.0,http://www.drugs.com/cdi/etanercept.html,LPAQVAFTPYAPEPGSTCRLREYYDQTAQMCCSKCSPGQHAKVFCTKTSDTVCDSCEDSTYTQLWNWVPECLSCGSRCSSDQVETQACTREQNRICTCRPGWYCALSKQEGCRLCAPLRKCRPGFGVARPGTETSDVVCKPCAPGTFSNTTSSTDICRPHQICNVVAIPGNASMDAVCTSTSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGDEPKSCDKTHTCPPCPAPELL,drugbank_drug|DB00005  Etanercept Sequence,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors",80,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,25,10,12,5,14,5,4,8,12,4,5,31,13,13,27,28,13,3,5,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00008,Peginterferon alfa-2a,BiotechDrug,46504860.0,http://www.drugs.com/cdi/peginterferon-alfa-2a.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00008 Peginterferon alfa-2a sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00009; DB11300; DB11571; DB11572),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00009; DB11300; DB11571; DB11572),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00009; DB11300; DB11571; DB11572),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00009; DB11300; DB11571; DB11572),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02679,FGG,Fibrinogen gamma chain,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG,drugbank_target|P02679 Fibrinogen gamma chain (DB00364),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGAGTTGGTCCTTGCACCCCCGGAATTTAATTCTCTACTTCTATGCTCTTTTATTTCTCTCTTCAACATGTGTAGCATATGTTGCTACCAGAGACAACTGCTGCATCTTAGATGAAAGATTCGGTAGTTATTGTCCAACTACCTGTGGCATTGCAGATTTCCTGTCTACTTATCAAACCAAAGTAGACAAGGATCTACAGTCTTTGGAAGACATCTTACATCAAGTTGAAAACAAAACATCAGAAGTCAAACAG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P05121,SERPINE1,Plasminogen activator inhibitor 1,ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAAGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTGAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTATGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAGATTCAAGCAGCTATG,drugbank_target|P05121 Plasminogen activator inhibitor 1 (DB00009; DB00013; DB00015; DB00029; DB00031; DB00055; DB00197; DB02587; DB05254; DB09130; DB13242),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAAGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTGAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTATGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAGATTCAAGCAGCTATG
DB00009,Alteplase,BiotechDrug,46507035.0,http://www.drugs.com/cdi/alteplase.html,SYQVICRDEKTQMIYQQHQSWLRPVLRSNRVEYCWCNSGRAQCHSVPVKSCSEPRCFNGGTCQQALYFSDFVCQCPEGFAGKCCEIDTRATCYEDQGISYRGTWSTAESGAECTNWNSSALAQKPYSGRRPDAIRLGLGNHNYCRNPDRDSKPWCYVFKAGKYSSEFCSTPACSEGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEY,drugbank_drug|DB00009 Alteplase sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P00747,PLG,Plasminogen,ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAGCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAGCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACCTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGGAAGTCCTCCATAATC,drugbank_target|P00747 Plasminogen (DB00009; DB00013; DB00015; DB00029; DB00031; DB00086; DB00302; DB00513; DB03709; DB04925; DB06692; DB09130; DB12831),BiotechDrug,Humans,17,21,10,12,7,21,6,7,11,13,2,15,13,13,17,26,12,9,8,15,ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAGCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAGCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACCTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGGAAGTCCTCCATAATC
DB00010,Sermorelin,BiotechDrug,46507399.0,http://www.drugs.com/cdi/sermorelin-acetate.html,YADAIFTNSYRKVLGQLSARKLLQDIMSRQ,drugbank_drug|DB00010 DB00010 sequence,Growth Hormone Analogs,207,-1,-1,-1,-1,-1,-1,Q02643,GHRHR,Growth hormone-releasing hormone receptor,ATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTATTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCCTGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGATGGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGATTTCTTCTCTCACTTC,drugbank_target|Q02643 Growth hormone-releasing hormone receptor (DB00010; DB08869),BiotechDrug,Humans,3,0,2,0,1,1,0,2,2,4,1,1,0,3,3,3,1,1,0,2,ATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTATTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCCTGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGATGGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGATTTCTTCTCTCACTTC
DB00012,Darbepoetin alfa,BiotechDrug,46504480.0,http://www.drugs.com/cdi/darbepoetin-alfa-albumin.html,MGVHECPAWLWLLLSLLSLPLGLPVLGAPPRLICDSRVLERYLLEAKEAENITTGCNETCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQVNETLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR,drugbank_drug|DB00012 Darbepoetin alfa,Hematopoietic Growth Factors,90,-1,-1,-1,-1,-1,-1,P19235,EPOR,Erythropoietin receptor,ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCTGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCCTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTGGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCCTACCAGCTCGAGGAT,drugbank_target|P19235 Erythropoietin receptor (DB00012; DB00016; DB07637; DB08894; DB09107),BiotechDrug,Humans,19,5,6,13,4,12,2,5,8,33,2,8,9,7,13,12,13,14,4,4,ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCTGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCCTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTGGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCCTACCAGCTCGAGGAT
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P00747,PLG,Plasminogen,ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAGCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAGCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACCTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGGAAGTCCTCCATAATC,drugbank_target|P00747 Plasminogen (DB00009; DB00013; DB00015; DB00029; DB00031; DB00086; DB00302; DB00513; DB03709; DB04925; DB06692; DB09130; DB12831),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAGCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAGCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACCTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGGAAGTCCTCCATAATC
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P05121,SERPINE1,Plasminogen activator inhibitor 1,ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAAGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTGAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTATGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAGATTCAAGCAGCTATG,drugbank_target|P05121 Plasminogen activator inhibitor 1 (DB00009; DB00013; DB00015; DB00029; DB00031; DB00055; DB00197; DB02587; DB05254; DB09130; DB13242),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGCAGATGTCTCCAGCCCTCACCTGCCTAGTCCTGGGCCTGGCCCTTGTCTTTGGTGAAGGGTCTGCTGTGCACCATCCCCCATCCTACGTGGCCCACCTGGCCTCAGACTTCGGGGTGAGGGTGTTTCAGCAGGTGGCGCAGGCCTCCAAGGACCGCAACGTGGTTTTCTCACCCTATGGGGTGGCCTCGGTGTTGGCCATGCTCCAGCTGACAACAGGAGGAGAAACCCAGCAGCAGATTCAAGCAGCTATG
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00009; DB00015; DB00029; DB00031; DB01593; DB04919; DB05099; DB05675; DB06245; DB11300; DB11311; DB11571; DB11572; DB13151; DB14487; DB14533; DB14548),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00015,Reteplase,BiotechDrug,46506092.0,http://www.drugs.com/cdi/reteplase.html,SYQGNSDCYFGNGSAYRGTHSLTESGASCLPWNSMILIGKVYTAQNPSAQALGLGKHNYCRNPDGDAKPWCHVLKNRRLTWEYCDVPSCSTCGLRQYSQPQFRIKGGLFADIASHPWQAAIFAKHRRSPGERFLCGGILISSCWILSAAHCFQERFPPHHLTVILGRTYRVVPGEEEQKFEVEKYIVHKEFDDDTYDNDIALLQLKSDSSRCAQESSVVRTVCLPPADLQLPDWTECELSGYGKHEALSPFYSER,drugbank_drug|DB00015 DB00015 sequence,Thrombolytics,194,-1,-1,-1,-1,-1,-1,P02671,FGA,Fibrinogen alpha chain,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA,drugbank_target|P02671 Fibrinogen alpha chain (DB00364),BiotechDrug,Humans,17,13,13,15,10,19,10,11,11,22,1,8,15,12,15,24,10,11,6,12,ATGTTTTCCATGAGGATCGTCTGCCTGGTCCTAAGTGTGGTGGGCACAGCATGGACTGCAGATAGTGGTGAAGGTGACTTTCTAGCTGAAGGAGGAGGCGTGCGTGGCCCAAGGGTTGTGGAAAGACATCAATCTGCCTGCAAAGATTCAGACTGGCCCTTCTGCTCTGATGAAGACTGGAACTACAAATGCCCTTCTGGCTGCAGGATGAAAGGGTTGATTGATGAAGTCAATCAAGATTTTACAAACAGAATA
DB00016,Erythropoietin,BiotechDrug,46508122.0,http://www.drugs.com/cdi/epoetin-alfa.html,APPRLICDSRVLERYLLEAKEAENITTGCAEHCSLNENITVPDTKVNFYAWKRMEVGQQAVEVWQGLALLSEAVLRGQALLVNSSQPWEPLQLHVDKAVSGLRSLTTLLRALGAQKEAISPPDAASAAPLRTITADTFRKLFRVYSNFLRGKLKLYTGEACRTGDR,drugbank_drug|DB00016 DB00016 (Erythropoietin) sequence,"Hematopoietic Growth Factors, Erythropoiesis-Stimulating Agents, Recombinant Human Erythropoietins",90,-1,-1,-1,-1,-1,-1,P19235,EPOR,Erythropoietin receptor,ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCTGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCCTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTGGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCCTACCAGCTCGAGGAT,drugbank_target|P19235 Erythropoietin receptor (DB00012; DB00016; DB07637; DB08894; DB09107),BiotechDrug,Humans,19,4,6,12,4,9,2,5,8,23,1,6,8,7,13,10,11,11,3,4,ATGGACCACCTCGGGGCGTCCCTCTGGCCCCAGGTCGGCTCCCTTTGTCTCCTGCTCGCTGGGGCCGCCTGGGCGCCCCCGCCTAACCTCCCGGACCCCAAGTTCGAGAGCAAAGCGGCCTTGCTGGCGGCCCGGGGGCCCGAAGAGCTTCTGTGCTTCACCGAGCGGTTGGAGGACTTGGTGTGTTTCTGGGAGGAAGCGGCGAGCGCTGGGGTGGGCCCGGGCAACTACAGCTTCTCCTACCAGCTCGAGGAT
DB00017,Salmon calcitonin,BiotechDrug,46506061.0,,CSNLSTCVLGKLSQELHKLQTYPRTNTGSGTP,drugbank_drug|DB00017 DB00017 sequence,Calcium Metabolism Modifiers,65,-1,-1,-1,-1,-1,-1,P30988,CALCR,Calcitonin receptor,ATGCAATTTTCTGGAGAGAAGATTAGTGGACAAAGAGATCTTCAAAAATCAAAAATGAGGTTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACCCCAATTCTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTTTACGTCGTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAGCAGTTACCCGCATACCAAGGA,drugbank_target|P30988 Calcitonin receptor (DB00017; DB01278),BiotechDrug,Humans,0,2,0,1,0,3,1,0,2,5,0,2,2,2,1,4,5,1,0,1,ATGCAATTTTCTGGAGAGAAGATTAGTGGACAAAGAGATCTTCAAAAATCAAAAATGAGGTTCACATTTACAAGCCGGTGCTTGGCACTGTTTCTTCTTCTAAATCACCCAACCCCAATTCTTCCTGCCTTTTCAAATCAAACCTATCCAACAATAGAGCCCAAGCCATTTCTTTACGTCGTAGGACGAAAGAAGATGATGGATGCACAGTACAAATGCTATGACCGAATGCAGCAGTTACCCGCATACCAAGGA
DB00019,Pegfilgrastim,BiotechDrug,46505853.0,http://www.drugs.com/cdi/pegfilgrastim.html,MTPLGPASSLPQSFLLKCLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLAQP,drugbank_drug|DB00019  Pegfilgrastim sequence,Hematopoietic Growth Factors,90,-1,-1,-1,-1,-1,-1,Q99062,CSF3R,Granulocyte colony-stimulating factor receptor,ATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCCGGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGATCCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAGATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGATGGGACCCAGGAATCT,drugbank_target|Q99062 Granulocyte colony-stimulating factor receptor (DB00019; DB00099; DB05249; DB13144; DB13200; DB15001; DB18704),BiotechDrug,Humans,19,5,4,9,6,14,5,4,4,33,4,0,13,17,5,14,7,7,2,3,ATGGCAAGGCTGGGAAACTGCAGCCTGACTTGGGCTGCCCTGATCATCCTGCTGCTCCCCGGAAGTCTGGAGGAGTGCGGGCACATCAGTGTCTCAGCCCCCATCGTCCACCTGGGGGATCCCATCACAGCCTCCTGCATCATCAAGCAGAACTGCAGCCATCTGGACCCGGAGCCACAGATTCTGTGGAGACTGGGAGCAGAGCTTCAGCCCGGGGGCAGGCAGCAGCGTCTGTCTGATGGGACCCAGGAATCT
DB00020,Sargramostim,BiotechDrug,46507000.0,http://www.drugs.com/cdi/sargramostim.html,APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE,drugbank_drug|DB00020 DB00020 sequence,Hematopoietic Growth Factors,90,-1,-1,-1,-1,-1,-1,P13727,PRG2,Bone marrow proteoglycan,ATGAAACTCCCCTTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGGTCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAGACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGGGGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCAGATATGGTGGACAAA,drugbank_target|P13727 Bone marrow proteoglycan (DB00020; DB06752),BiotechDrug,Humans,8,4,4,13,5,3,3,5,6,15,4,4,11,8,5,9,11,5,2,2,ATGAAACTCCCCTTACTTCTGGCTCTTCTATTTGGGGCAGTTTCTGCTCTTCATCTAAGGTCTGAGACTTCCACCTTTGAGACCCCTTTGGGTGCTAAGACGCTGCCTGAGGATGAGGAGACACCAGAGCAGGAGATGGAGGAGACCCCTTGCAGGGAGCTGGAGGAAGAGGAGGAGTGGGGCTCTGGAAGTGAAGATGCCTCCAAGAAAGATGGGGCTGTTGAGTCTATCTCAGTGCCAGATATGGTGGACAAA
DB00020,Sargramostim,BiotechDrug,46507000.0,http://www.drugs.com/cdi/sargramostim.html,APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE,drugbank_drug|DB00020 DB00020 sequence,Hematopoietic Growth Factors,90,-1,-1,-1,-1,-1,-1,P34741,SDC2,Syndecan-2,ATGCGGCGCGCGTGGATCCTGCTCACCTTGGGCTTGGTGGCCTGCGTGTCGGCGGAGTCGAGAGCAGAGCTGACATCTGATAAAGACATGTACCTTGACAACAGCTCCATTGAAGAAGCTTCAGGAGTGTATCCTATTGATGACGATGACTACGCTTCTGCGTCTGGCTCGGGAGCTGATGAGGATGTAGAGAGTCCAGAGCTGACAACATCTCGACCACTTCCAAAGATACTGTTGACTAGTGCTGCTCCAAAA,drugbank_target|P34741 Syndecan-2 (DB00020),BiotechDrug,Humans,8,4,4,13,5,3,3,5,6,15,4,4,11,8,5,9,11,5,2,2,ATGCGGCGCGCGTGGATCCTGCTCACCTTGGGCTTGGTGGCCTGCGTGTCGGCGGAGTCGAGAGCAGAGCTGACATCTGATAAAGACATGTACCTTGACAACAGCTCCATTGAAGAAGCTTCAGGAGTGTATCCTATTGATGACGATGACTACGCTTCTGCGTCTGGCTCGGGAGCTGATGAGGATGTAGAGAGTCCAGAGCTGACAACATCTCGACCACTTCCAAAGATACTGTTGACTAGTGCTGCTCCAAAA
DB00020,Sargramostim,BiotechDrug,46507000.0,http://www.drugs.com/cdi/sargramostim.html,APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE,drugbank_drug|DB00020 DB00020 sequence,Hematopoietic Growth Factors,90,-1,-1,-1,-1,-1,-1,P32927,CSF2RB,Cytokine receptor common subunit beta,ATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGCCTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACCAGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACCCTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGACATGCCCTGGTCAGCC,drugbank_target|P32927 Cytokine receptor common subunit beta (DB00020; DB05264; DB05943),BiotechDrug,Humans,8,4,4,13,5,3,3,5,6,15,4,4,11,8,5,9,11,5,2,2,ATGGTGCTGGCCCAGGGGCTGCTCTCCATGGCCCTGCTGGCCCTGTGCTGGGAGCGCAGCCTGGCAGGGGCAGAAGAAACCATCCCGCTGCAGACCCTGCGCTGCTACAACGACTACACCAGCCACATCACCTGCAGGTGGGCAGACACCCAGGATGCCCAGCGGCTCGTCAACGTGACCCTCATTCGCCGGGTGAATGAGGACCTCCTGGAGCCAGTGTCCTGTGACCTCAGTGATGACATGCCCTGGTCAGCC
DB00020,Sargramostim,BiotechDrug,46507000.0,http://www.drugs.com/cdi/sargramostim.html,APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE,drugbank_drug|DB00020 DB00020 sequence,Hematopoietic Growth Factors,90,-1,-1,-1,-1,-1,-1,P26951,IL3RA,Interleukin-3 receptor subunit alpha,ATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAGGAAGGTGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGATTTCTTGAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTGTACTTGAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCTCAGGGAACACGTATC,drugbank_target|P26951 Interleukin-3 receptor subunit alpha (DB00020; DB14731),BiotechDrug,Humans,8,4,4,13,5,3,3,5,6,15,4,4,11,8,5,9,11,5,2,2,ATGGTCCTCCTTTGGCTCACGCTGCTCCTGATCGCCCTGCCCTGTCTCCTGCAAACGAAGGAAGGTGGGAAGCCTTGGGCAGGTGCGGAGAATCTGACCTGCTGGATTCATGACGTGGATTTCTTGAGCTGCAGCTGGGCGGTAGGCCCGGGGGCCCCCGCGGACGTCCAGTACGACCTGTACTTGAACGTTGCCAACAGGCGTCAACAGTACGAGTGTCTTCACTACAAAACGGATGCTCAGGGAACACGTATC
DB00020,Sargramostim,BiotechDrug,46507000.0,http://www.drugs.com/cdi/sargramostim.html,APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLELYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFDCWEPVQE,drugbank_drug|DB00020 DB00020 sequence,Hematopoietic Growth Factors,90,-1,-1,-1,-1,-1,-1,P15509,CSF2RA,Granulocyte-macrophage colony-stimulating factor receptor subunit alpha,ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCAGAGAAATCGGATCTGCGAACAGTGGCACCAGCCTCTAGTCTCAATGTGAGGTTTGACTCCAGGACGATGAATTTAAGCTGGGACTGCCAAGAAAACACAACCTTCAGCAAGTGTTTCTTAACTGACAAGAAGAACAGAGTCGTGGAACCCAGGCTCAGTAACAACGAATGTTCGTGCACATTTCGTGAA,drugbank_target|P15509 Granulocyte-macrophage colony-stimulating factor receptor subunit alpha (DB00020; DB05194; DB05386; DB10770; DB10772; DB11338),BiotechDrug,Humans,8,4,4,13,5,3,3,5,6,15,4,4,11,8,5,9,11,5,2,2,ATGCTTCTCCTGGTGACAAGCCTTCTGCTCTGTGAGTTACCACACCCAGCATTCCTCCTGATCCCAGAGAAATCGGATCTGCGAACAGTGGCACCAGCCTCTAGTCTCAATGTGAGGTTTGACTCCAGGACGATGAATTTAAGCTGGGACTGCCAAGAAAACACAACCTTCAGCAAGTGTTTCTTAACTGACAAGAAGAACAGAGTCGTGGAACCCAGGCTCAGTAACAACGAATGTTCGTGCACATTTCGTGAA
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00022,Peginterferon alfa-2b,BiotechDrug,46506669.0,http://www.drugs.com/cdi/peginterferon-alfa-2b.html,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00022 DB00022 sequence,Hepatitis B Hepatitis C Agents,251,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,10,21,5,4,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00024,Thyrotropin alfa,BiotechDrug,46505696.0,http://www.drugs.com/cdi/thyrotropin-alfa.html,FCIPTEYTMHIERRECAYCLTINTTICAGYCMTRDINGKLFLPKYALSQDVCTYRDFIYRTVEIPGCPLHVAPYFSYPVALSCKCGKCNTDYSDCIHEAIKTNYCTKPQKSY,drugbank_drug|DB00024 Beta chain,"Diagnostics, Endocrine",377,-1,-1,-1,-1,-1,-1,P16473,TSHR,Thyrotropin receptor,ATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGCGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACCTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATTGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGAATCTACGTATCTATA,drugbank_target|P16473 Thyrotropin receptor (DB00024),BiotechDrug,Humans,6,12,5,5,4,4,3,9,7,6,2,4,7,2,5,5,11,4,0,11,ATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGCGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACCTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATTGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGAATCTACGTATCTATA
DB00024,Thyrotropin alfa,BiotechDrug,46505696.0,http://www.drugs.com/cdi/thyrotropin-alfa.html,APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS,drugbank_drug|DB00024 Alpha chain,"Diagnostics, Endocrine",377,-1,-1,-1,-1,-1,-1,P16473,TSHR,Thyrotropin receptor,ATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGCGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACCTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATTGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGAATCTACGTATCTATA,drugbank_target|P16473 Thyrotropin receptor (DB00024),BiotechDrug,Humans,5,10,2,4,4,4,3,1,6,4,3,4,7,5,3,8,8,7,0,4,ATGAGGCCGGCGGACTTGCTGCAGCTGGTGCTGCTGCTCGACCTGCCCAGGGACCTGGGCGGAATGGGGTGTTCGTCTCCACCCTGCGAGTGCCATCAGGAGGAGGACTTCAGAGTCACCTGCAAGGATATTCAACGCATCCCCAGCTTACCGCCCAGTACGCAGACTCTGAAGCTTATTGAGACTCACCTGAGAACTATTCCAAGTCATGCATTTTCTAATCTGCCCAATATTTCCAGAATCTACGTATCTATA
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,Q8NI22,MCFD2,Multiple coagulation factor deficiency protein 2,ATGACCATGAGATCCCTGCTCAGAACCCCCTTCCTGTGTGGCCTGCTCTGGGCCTTTTGTGCCCCAGGCGCCAGGGCTGAGGAGCCTGCAGCCAGCTTCTCCCAACCCGGCAGCATGGGCCTGGATAAGAACACAGTGCACGACCAAGAGCATATCATGGAGCATCTAGAAGGTGTCATCAACAAACCAGAGGCGGAGATGTCGCCACAAGAATTGCAGCTCCATTACTTCAAAATGCATGATTATGATGGCAAT,drugbank_target|Q8NI22 Multiple coagulation factor deficiency protein 2 (DB00025; DB13998; DB13999),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGACCATGAGATCCCTGCTCAGAACCCCCTTCCTGTGTGGCCTGCTCTGGGCCTTTTGTGCCCCAGGCGCCAGGGCTGAGGAGCCTGCAGCCAGCTTCTCCCAACCCGGCAGCATGGGCCTGGATAAGAACACAGTGCACGACCAAGAGCATATCATGGAGCATCTAGAAGGTGTCATCAACAAACCAGAGGCGGAGATGTCGCCACAAGAATTGCAGCTCCATTACTTCAAAATGCATGATTATGATGGCAAT
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P07307,ASGR2,Asialoglycoprotein receptor 2,ATGGCCAAGGACTTTCAAGATATCCAGCAGCTGAGCTCGGAGGAAAATGACCATCCTTTCCATCAAGGTGAGGGGCCAGGCACTCGCAGGCTGAATCCCAGGAGAGGAAATCCATTTTTGAAAGGGCCACCTCCTGCCCAGCCCCTGGCACAGCGTCTCTGCTCCATGGTCTGCTTCAGTCTGCTTGCCCTGAGCTTCAACATCCTGCTGCTGGTGGTCATCTGTGTGACTGGGTCCCAAAGTGAGGGTCACAGG,drugbank_target|P07307 Asialoglycoprotein receptor 2 (DB00025; DB13998; DB13999),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGGCCAAGGACTTTCAAGATATCCAGCAGCTGAGCTCGGAGGAAAATGACCATCCTTTCCATCAAGGTGAGGGGCCAGGCACTCGCAGGCTGAATCCCAGGAGAGGAAATCCATTTTTGAAAGGGCCACCTCCTGCCCAGCCCCTGGCACAGCGTCTCTGCTCCATGGTCTGCTTCAGTCTGCTTGCCCTGAGCTTCAACATCCTGCTGCTGGTGGTCATCTGTGTGACTGGGTCCCAAAGTGAGGGTCACAGG
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P27797,CALR,Calreticulin,ATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCTGCCGTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCCAAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAGGAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGTTTCGAGCCTTTCAGC,drugbank_target|P27797 Calreticulin (DB00025; DB00031; DB01065; DB06245; DB09130; DB11093; DB11348; DB13998; DB13999; DB14481),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGCTGCTATCCGTGCCGCTGCTGCTCGGCCTCCTCGGCCTGGCCGTCGCCGAGCCTGCCGTCTACTTCAAGGAGCAGTTTCTGGACGGAGACGGGTGGACTTCCCGCTGGATCGAATCCAAACACAAGTCAGATTTTGGCAAATTCGTTCTCAGTTCCGGCAAGTTCTACGGTGACGAGGAGAAAGATAAAGGTTTGCAGACAAGCCAGGATGCACGCTTTTATGCTCTGTCGGCCAGTTTCGAGCCTTTCAGC
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P00740,F9,Coagulation factor IX,ATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTTGAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACT,drugbank_target|P00740 Coagulation factor IX (DB00025; DB00170; DB05131; DB09109; DB09332; DB13150; DB13192; DB13923; DB13998; DB13999; DB14738; DB16662),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGCAGCGCGTGAACATGATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGCTGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAGGTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTTGAGAGAGAATGTATGGAAGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACT
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P04275,VWF,von Willebrand factor,ATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACCCTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGTGACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTCCTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAGAGAGTGAGCCTCTCC,drugbank_target|P04275 von Willebrand factor (DB00025; DB05202; DB06081; DB09108; DB09329; DB11606; DB11607; DB13998; DB13999; DB14738; DB15164; DB16007),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGATTCCTGCCAGATTTGCCGGGGTGCTGCTTGCTCTGGCCCTCATTTTGCCAGGGACCCTTTGTGCAGAAGGAACTCGCGGCAGGTCATCCACGGCCCGATGCAGCCTTTTCGGAAGTGACTTCGTCAACACCTTTGATGGGAGCATGTACAGCTTTGCGGGATACTGCAGTTACCTCCTGGCAGGGGGCTGCCAGAAACGCTCCTTCTCGATTATTGGGGACTTCCAGAATGGCAAGAGAGTGAGCCTCTCC
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P00742,F10,Coagulation factor X,ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAA,drugbank_target|P00742 Coagulation factor X (DB00025; DB00036; DB00100; DB00569; DB01109; DB01225; DB03847; DB04673; DB05362; DB05713; DB06228; DB06245; DB06406; DB06552; DB06605; DB06635; DB06920; DB07211; DB07261; DB07277; DB07278; DB07605; DB07629; DB0,BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAA
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P11021,HSPA5,78 kDa glucose-regulated protein,ATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAGGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACCTACTCCTGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGCATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCCAAGAACCAGCTCACC,drugbank_target|P11021 78 kDa glucose-regulated protein (DB00025; DB00945; DB09130; DB13998; DB13999),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGAAGCTCTCCCTGGTGGCCGCGATGCTGCTGCTGCTCAGCGCGGCGCGGGCCGAGGAGGAGGACAAGAAGGAGGACGTGGGCACGGTGGTCGGCATCGACCTGGGGACCACCTACTCCTGCGTCGGCGTGTTCAAGAACGGCCGCGTGGAGATCATCGCCAACGATCAGGGCAACCGCATCACGCCGTCCTATGTCGCCTTCACTCCTGAAGGGGAACGTCTGATTGGCGATGCCGCCAAGAACCAGCTCACC
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,Q07954,LRP1,Prolow-density lipoprotein receptor-related protein 1,ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCTATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGTATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCCCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTGGGTACTGAGCTGTGT,drugbank_target|Q07954 Prolow-density lipoprotein receptor-related protein 1 (DB00025; DB00031; DB00100; DB06245; DB13133; DB13152; DB13998; DB13999),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCTATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGTATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCCCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTGGGTACTGAGCTGTGT
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P49257,LMAN1,Protein ERGIC-53,ATGGCGGGATCCAGGCAAAGGGGTCTCCGGGCCAGAGTTCGGCCGCTGTTCTGCGCCTTGCTGCTGTCACTCGGTCGCTTCGTCCGGGGCGACGGCGTGGGAGGAGACCCCGCGGTCGCGTTGCCACATCGCCGTTTCGAGTACAAATACAGCTTCAAGGGGCCGCACCTGGTGCAGAGCGACGGGACCGTGCCCTTCTGGGCCCACGCGGGGAATGCTATTCCAAGTTCAGATCAAATTCGAGTAGCACCATCT,drugbank_target|P49257 Protein ERGIC-53 (DB00025; DB13998; DB13999),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGGCGGGATCCAGGCAAAGGGGTCTCCGGGCCAGAGTTCGGCCGCTGTTCTGCGCCTTGCTGCTGTCACTCGGTCGCTTCGTCCGGGGCGACGGCGTGGGAGGAGACCCCGCGGTCGCGTTGCCACATCGCCGTTTCGAGTACAAATACAGCTTCAAGGGGCCGCACCTGGTGCAGAGCGACGGGACCGTGCCCTTCTGGGCCCACGCGGGGAATGCTATTCCAAGTTCAGATCAAATTCGAGTAGCACCATCT
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P27824,CANX,Calnexin,ATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCTCATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAAGAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTACAAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTGTCAGGGTGGATTTTA,drugbank_target|P27824 Calnexin (DB00025; DB00031; DB06245; DB11093; DB11348; DB13998; DB13999; DB14481),BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGGAAGGGAAGTGGTTGCTGTGTATGTTACTGGTGCTTGGAACTGCTATTGTTGAGGCTCATGATGGACATGATGATGATGTGATTGATATTGAGGATGACCTTGACGATGTCATTGAAGAGGTAGAAGACTCAAAACCAGATACCACTGCTCCTCCTTCATCTCCCAAGGTTACTTACAAAGCTCCAGTTCCAACAGGGGAAGTATATTTTGCTGATTCTTTTGACAGAGGAACTCTGTCAGGGTGGATTTTA
DB00025,"Antihemophilic factor, human recombinant",BiotechDrug,46506209.0,http://www.drugs.com/cdi/antihemophilic-factor-human.html,ATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTLFVEFTDHLFNIAKPRPPWMGLLGPTIQAEVYDTVVITLKNMASHPVSLHAVGVSYWKASEGAEYDDQTSQREKEDDKVFPGGSHTYVWQVLKENGPMASDPLCLTYSYLSHVDLVKDLNSGLIGALLVCREGSLAKEKTQTLHKFILLFAVFDEGKSWHSETKNSLMQDRDAASARAWPKMHTVNGYVNRSLPGLIGCHRKSVYW,drugbank_drug|DB00025 DB00025 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,O14832,PHYH,"Phytanoyl-CoA dioxygenase, peroxisomal",ATGAGAGATGTGACCATTTCGAAATCCGAATATGCTCCAAGTGAGAAGATGATCACGAAGGTCCAGGATTTCCAGGAAGATAAGGAGCTCTTCAGATACTGCACTCTCCCCGAGATTCTGAAATATGTGGAGTGCTTCACTGGACCTAATATTATGGCCATGCACACAATGTTGATAAACAAACCTCCAGATTCTGGCAAGAAGACGTCCCGTCACCCCCTGCACCAGGACCTGCACTATTTCCCCTTCAGGCCC,"drugbank_target|O14832 Phytanoyl-CoA dioxygenase, peroxisomal (DB00025; DB00126; DB13998; DB13999)",BiotechDrug,Humans,17,3,15,13,10,16,9,6,17,26,6,8,15,7,11,21,14,22,7,12,ATGAGAGATGTGACCATTTCGAAATCCGAATATGCTCCAAGTGAGAAGATGATCACGAAGGTCCAGGATTTCCAGGAAGATAAGGAGCTCTTCAGATACTGCACTCTCCCCGAGATTCTGAAATATGTGGAGTGCTTCACTGGACCTAATATTATGGCCATGCACACAATGTTGATAAACAAACCTCCAGATTCTGGCAAGAAGACGTCCCGTCACCCCCTGCACCAGGACCTGCACTATTTCCCCTTCAGGCCC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P0C0L5,C4B,Complement C4-B,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC,drugbank_target|P0C0L5 Complement C4-B (DB00028; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P0C0L4,C4A,Complement C4-A,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC,drugbank_target|P0C0L4 Complement C4-A (DB00028),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P0C0L5,C4B,Complement C4-B,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC,drugbank_target|P0C0L5 Complement C4-B (DB00028; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P01031,C5,Complement C5,ATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAGCAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTGATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCTGATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAAAACTCTGCAATCTTA,drugbank_target|P01031 Complement C5 (DB00028; DB01257; DB01593; DB09130; DB11580; DB14487; DB14533; DB14548; DB15165; DB15218; DB15636; DB16416),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAGCAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTGATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCTGATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAAAACTCTGCAATCTTA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,Q92637,FCGR1B,High affinity immunoglobulin gamma Fc receptor IB,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACA,drugbank_target|Q92637 High affinity immunoglobulin gamma Fc receptor IB (DB00028),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,Q92637,FCGR1B,High affinity immunoglobulin gamma Fc receptor IB,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACA,drugbank_target|Q92637 High affinity immunoglobulin gamma Fc receptor IB (DB00028),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGGCTGGCTACTACTGCAGGTCTCCAGCAGAGTCTTCATGGAAGGAGAACCTCTGGCCTTGAGGTGTCATGCGTGGAAGGATAAGCTGGTGTACAATGTGCTTTACTATCGAAATGGCAAAGCCTTTAAGTTTTTCCACTGGAATTCTAACCTCACCATTCTGAAAACCAACATAAGTCACAATGGCACCTACCATTGCTCAGGCATGGGAAAGCATCGCTACACA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P0C0L4,C4A,Complement C4-A,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC,drugbank_target|P0C0L4 Complement C4-A (DB00028),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGAGGCTGCTCTGGGGGCTGATCTGGGCATCCAGCTTCTTCACCTTATCTCTGCAGAAGCCCAGGTTGCTCTTGTTCTCTCCTTCTGTGGTTCATCTGGGGGTCCCCCTATCGGTGGGGGTGCAGCTCCAGGATGTGCCCCGAGGACAGGTAGTGAAAGGATCAGTGTTCCTGAGAAACCCATCTCGTAATAATGTCCCCTGCTCCCCAAAGGTGGACTTCACCCTTAGCTCAGAAAGAGACTTCGCACTCCTC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P01031,C5,Complement C5,ATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAGCAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTGATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCTGATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAAAACTCTGCAATCTTA,drugbank_target|P01031 Complement C5 (DB00028; DB01257; DB01593; DB09130; DB11580; DB14487; DB14533; DB14548; DB15165; DB15218; DB15636; DB16416),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGGGCCTTTTGGGAATACTTTGTTTTTTAATCTTCCTGGGGAAAACCTGGGGACAGGAGCAAACATATGTCATTTCAGCACCAAAAATATTCCGTGTTGGAGCATCTGAAAATATTGTGATTCAAGTTTATGGATACACTGAAGCATTTGATGCAACAATCTCTATTAAAAGTTATCCTGATAAAAAATTTAGTTACTCCTCAGGCCATGTTCATTTATCCTCAGAGAATAAATTCCAAAACTCTGCAATCTTA
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,PSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATEVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECSPLVLQESGPGLVKPSEALSLTCTVSGDSINTILYYWSWI,drugbank_drug|DB00028 IGG1,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P01024,C3,Complement C3,ATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGCTCTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATCTTGCGGCTGGAGAGCGAGGAGACCATGGTGCTGGAGGCCCACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCACGACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAGACTGTGCTGACCCCTGCCACCAACCACATGGGCAAC,drugbank_target|P01024 Complement C3 (DB00028; DB01593; DB01915; DB06492; DB09130; DB14487; DB14533; DB14548; DB16694),BiotechDrug,Humans,18,6,8,14,5,21,3,7,15,16,0,9,18,11,3,38,23,22,5,13,ATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGCTCTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATCTTGCGGCTGGAGAGCGAGGAGACCATGGTGCTGGAGGCCCACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCACGACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAGACTGTGCTGACCCCTGCCACCAACCACATGGGCAAC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00028,Human immunoglobulin G,BiotechDrug,46508774.0,http://www.drugs.com/cdi/immune-globulin-human.html,ELVMTQSPSSLSASVGDRVNIACRASQGISSALAWYQQKPGKAPRLLIYDASNLESGVPSRFSGSGSGTDFTLTISSLQPEDFAIYYCQQFNSYPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECQVKLLEQSGAEVKKPGASVKVSCKASGYSFTSYGLHWVRQA,drugbank_drug|DB00028 IgA2,Immune Globulins,250,-1,-1,-1,-1,-1,-1,P01024,C3,Complement C3,ATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGCTCTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATCTTGCGGCTGGAGAGCGAGGAGACCATGGTGCTGGAGGCCCACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCACGACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAGACTGTGCTGACCCCTGCCACCAACCACATGGGCAAC,drugbank_target|P01024 Complement C3 (DB00028; DB01593; DB01915; DB06492; DB09130; DB14487; DB14533; DB14548; DB16694),BiotechDrug,Humans,19,6,9,13,10,18,3,7,17,20,1,8,12,16,8,39,15,20,3,11,ATGGGACCCACCTCAGGTCCCAGCCTGCTGCTCCTGCTACTAACCCACCTCCCCCTGGCTCTGGGGAGTCCCATGTACTCTATCATCACCCCCAACATCTTGCGGCTGGAGAGCGAGGAGACCATGGTGCTGGAGGCCCACGACGCGCAAGGGGATGTTCCAGTCACTGTTACTGTCCACGACTTCCCAGGCAAAAAACTAGTGCTGTCCAGTGAGAAGACTGTGCTGACCCCTGCCACCAACCACATGGGCAAC
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKT,drugbank_drug|DB00030 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKT,drugbank_drug|DB00030 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,Q16270,IGFBP7,Insulin-like growth factor-binding protein 7,ATGGAGCGGCCGTCGCTGCGCGCCCTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTCCTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGCCCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGCCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTACTGCGCGCCGGGCATG,drugbank_target|Q16270 Insulin-like growth factor-binding protein 7 (DB00030),BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGGAGCGGCCGTCGCTGCGCGCCCTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTCCTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGCCCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGCCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTACTGCGCGCCGGGCATG
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00030 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P48745,NOV,Protein NOV homolog,ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTCCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCGGGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGCTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCATGCGACGAGAGCAGT,drugbank_target|P48745 Protein NOV homolog (DB00030),BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTCCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCGGGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGCTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCATGCGACGAGAGCAGT
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00030 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKT,drugbank_drug|DB00030 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P98164,LRP2,Low-density lipoprotein receptor-related protein 2,ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTAGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGCATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATTGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGCATCCCCAACTCCTGG,drugbank_target|P98164 Low-density lipoprotein receptor-related protein 2 (DB00013; DB00030; DB16662),BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTAGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGCATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATTGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGCATCCCCAACTCCTGG
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKT,drugbank_drug|DB00030 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P16870,CPE,Carboxypeptidase E,ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGGTGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGCCGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGCGAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGGCGCAGCTTCGAGGGC,drugbank_target|P16870 Carboxypeptidase E (DB00030),BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGGTGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGCCGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGCGAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGGCGCAGCTTCGAGGGC
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00030 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKT,drugbank_drug|DB00030 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P48745,NOV,Protein NOV homolog,ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTCCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCGGGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGCTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCATGCGACGAGAGCAGT,drugbank_target|P48745 Protein NOV homolog (DB00030),BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGCAGAGTGTGCAGAGCACGAGCTTTTGTCTCCGAAAGCAGTGCCTTTGCCTGACCTTCCTGCTTCTCCATCTCCTGGGACAGGTCGCTGCGACTCAGCGCTGCCCTCCCCAGTGCCCGGGCCGGTGCCCTGCGACGCCGCCGACCTGCGCCCCCGGGGTGCGCGCGGTGCTGGACGGCTGCTCATGCTGTCTGGTGTGTGCCCGCCAGCGTGGCGAGAGCTGCTCAGATCTGGAGCCATGCGACGAGAGCAGT
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00030 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,Q16270,IGFBP7,Insulin-like growth factor-binding protein 7,ATGGAGCGGCCGTCGCTGCGCGCCCTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTCCTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGCCCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGCCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTACTGCGCGCCGGGCATG,drugbank_target|Q16270 Insulin-like growth factor-binding protein 7 (DB00030),BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGAGCGGCCGTCGCTGCGCGCCCTGCTCCTCGGCGCCGCTGGGCTGCTGCTCCTGCTCCTGCCCCTCTCCTCTTCCTCCTCTTCGGACACCTGCGGCCCCTGCGAGCCGGCCTCCTGCCCGCCCCTGCCCCCGCTGGGCTGCCTGCTGGGCGAGACCCGCGACGCGTGCGGCTGCTGCCCTATGTGCGCCCGCGGCGAGGGCGAGCCGTGCGGGGGTGGCGGCGCCGGCAGGGGGTACTGCGCGCCGGGCATG
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00030 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P16870,CPE,Carboxypeptidase E,ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGGTGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGCCGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGCGAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGGCGCAGCTTCGAGGGC,drugbank_target|P16870 Carboxypeptidase E (DB00030),BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGCCGGGCGAGGGGGCAGCGCGCTGCTGGCTCTGTGCGGGGCACTGGCTGCCTGCGGGTGGCTCCTGGGCGCCGAAGCCCAGGAGCCCGGGGCGCCCGCGGCGGGCATGAGGCGGCGCCGGCGGCTGCAGCAAGAGGACGGCATCTCCTTCGAGTACCACCGCTACCCCGAGCTGCGCGAGGCGCTCGTGTCCGTGTGGCTGCAGTGCACCGCCATCAGCAGGATTTACACGGTGGGGCGCAGCTTCGAGGGC
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKT,drugbank_drug|DB00030 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB00030,Insulin human,BiotechDrug,46506231.0,http://www.drugs.com/pro/humulin-r.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00030 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P98164,LRP2,Low-density lipoprotein receptor-related protein 2,ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTAGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGCATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATTGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGCATCCCCAACTCCTGG,drugbank_target|P98164 Low-density lipoprotein receptor-related protein 2 (DB00013; DB00030; DB16662),BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGATCGCGGGCCGGCAGCAGTGGCGTGCACGCTGCTCCTGGCTCTCGTCGCCTGCCTAGCGCCGGCCAGTGGCCAAGAATGTGACAGTGCGCATTTTCGCTGTGGAAGTGGGCATTGCATCCCTGCAGACTGGAGGTGTGATGGGACCAAAGACTGTTCAGATGACGCGGATGAAATTGGCTGCGCTGTTGTGACCTGCCAGCAGGGCTATTTCAAGTGCCAGAGTGAGGGACAATGCATCCCCAACTCCTGG
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00034,Interferon alfa-2a,BiotechDrug,46506712.0,http://www.drugs.com/cdi/interferon-alfa-2a-solution.html,CDLPQTHSLGSRRTLMLLAQMRKISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMKEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00034 DB00034 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,11,21,5,4,5,12,9,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00036,Coagulation factor VIIa Recombinant Human,BiotechDrug,46507544.0,http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html,ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLT,drugbank_drug|DB00036 DB00036 sequence,Coagulation Factors,83,-1,-1,-1,-1,-1,-1,P38435,GGCX,Vitamin K-dependent gamma-carboxylase,ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGACAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTTGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGACCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCCCAGGAGCGGGGGCTC,drugbank_target|P38435 Vitamin K-dependent gamma-carboxylase (DB00036; DB00100; DB00142; DB00170; DB01022; DB01125; DB09332; DB13152),BiotechDrug,Humans,14,19,13,21,7,21,8,14,13,22,0,11,12,13,13,17,12,15,4,6,ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGACAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTTGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGACCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCCCAGGAGCGGGGGCTC
DB00036,Coagulation factor VIIa Recombinant Human,BiotechDrug,46507544.0,http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html,ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLT,drugbank_drug|DB00036 DB00036 sequence,Coagulation Factors,83,-1,-1,-1,-1,-1,-1,P08709,F7,Coagulation factor VII,ATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGGCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGCGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAGCAGTGCTCCTTCGAG,drugbank_target|P08709 Coagulation factor VII (DB00036; DB00100; DB04590; DB04593; DB04606; DB04758; DB04767; DB06552; DB07207; DB07247; DB07376; DB08232; DB09332; DB13151; DB13152; DB13933),BiotechDrug,Humans,14,19,13,21,7,21,8,14,13,22,0,11,12,13,13,17,12,15,4,6,ATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGGCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGCGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAGCAGTGCTCCTTCGAG
DB00036,Coagulation factor VIIa Recombinant Human,BiotechDrug,46507544.0,http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html,ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLT,drugbank_drug|DB00036 DB00036 sequence,Coagulation Factors,83,-1,-1,-1,-1,-1,-1,P10646,TFPI,Tissue factor pathway inhibitor,ATGATTTACACAATGAAGAAAGTACATGCACTTTGGGCTTCTGTATGCCTGCTGCTTAATCTTGCCCCTGCCCCTCTTAATGCTGATTCTGAGGAAGATGAAGAACACACAATTATCACAGATACGGAGTTGCCACCACTGAAACTTATGCATTCATTTTGTGCATTCAAGGCGGATGATGGCCCATGTAAAGCAATCATGAAAAGATTTTTCTTCAATATTTTCACTCGACAGTGCGAAGAATTTATATATGGG,drugbank_target|P10646 Tissue factor pathway inhibitor (DB00036; DB14562),BiotechDrug,Humans,14,19,13,21,7,21,8,14,13,22,0,11,12,13,13,17,12,15,4,6,ATGATTTACACAATGAAGAAAGTACATGCACTTTGGGCTTCTGTATGCCTGCTGCTTAATCTTGCCCCTGCCCCTCTTAATGCTGATTCTGAGGAAGATGAAGAACACACAATTATCACAGATACGGAGTTGCCACCACTGAAACTTATGCATTCATTTTGTGCATTCAAGGCGGATGATGGCCCATGTAAAGCAATCATGAAAAGATTTTTCTTCAATATTTTCACTCGACAGTGCGAAGAATTTATATATGGG
DB00036,Coagulation factor VIIa Recombinant Human,BiotechDrug,46507544.0,http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html,ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLT,drugbank_drug|DB00036 DB00036 sequence,Coagulation Factors,83,-1,-1,-1,-1,-1,-1,P00742,F10,Coagulation factor X,ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAA,drugbank_target|P00742 Coagulation factor X (DB00025; DB00036; DB00100; DB00569; DB01109; DB01225; DB03847; DB04673; DB05362; DB05713; DB06228; DB06245; DB06406; DB06552; DB06605; DB06635; DB06920; DB07211; DB07261; DB07277; DB07278; DB07605; DB07629; DB0,BiotechDrug,Humans,14,19,13,21,7,21,8,14,13,22,0,11,12,13,13,17,12,15,4,6,ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAA
DB00036,Coagulation factor VIIa Recombinant Human,BiotechDrug,46507544.0,http://www.drugs.com/cdi/coagulation-factor-viia-recombinant.html,ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGSCKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLT,drugbank_drug|DB00036 DB00036 sequence,Coagulation Factors,83,-1,-1,-1,-1,-1,-1,P13726,F3,Tissue factor,ATGGAGACCCCTGCCTGGCCCCGGGTCCCGCGCCCCGAGACCGCCGTCGCTCGGACGCTCCTGCTCGGCTGGGTCTTCGCCCAGGTGGCCGGCGCTTCAGGCACTACAAATACTGTGGCAGCATATAATTTAACTTGGAAATCAACTAATTTCAAGACAATTTTGGAGTGGGAACCCAAACCCGTCAATCAAGTCTACACTGTTCAAATAAGCACTAAGTCAGGAGATTGGAAAAGCAAATGCTTTTACACAACA,drugbank_target|P13726 Tissue factor (DB00036; DB06552; DB07207; DB07247; DB08232; DB13150; DB16732),BiotechDrug,Humans,14,19,13,21,7,21,8,14,13,22,0,11,12,13,13,17,12,15,4,6,ATGGAGACCCCTGCCTGGCCCCGGGTCCCGCGCCCCGAGACCGCCGTCGCTCGGACGCTCCTGCTCGGCTGGGTCTTCGCCCAGGTGGCCGGCGCTTCAGGCACTACAAATACTGTGGCAGCATATAATTTAACTTGGAAATCAACTAATTTCAAGACAATTTTGGAGTGGGAACCCAAACCCGTCAATCAAGTCTACACTGTTCAAATAAGCACTAAGTCAGGAGATTGGAAAAGCAAATGCTTTTACACAACA
DB00038,Oprelvekin,BiotechDrug,46506470.0,http://www.drugs.com/cdi/oprelvekin.html,GPPPGPPRVSPDPRAELDSTVLLTRSLLADTRQLAAQLRDKFPADGDHNLDSLPTLAMSAGALGALQLPGVLTRLRADLLSYLRHVQWLRRAGGSSLKTLEPELGTLQARLDRLLRRLQLLMSRLALPQPPPDPPAPPLAPPSSAWGGIRAAHAILGGLHLTLDWAVRGLLLLKTRL,drugbank_drug|DB00038 DB00038 sequence,"Biological Response Modulators, Hematopoietic Growth Factors",96,-1,-1,-1,-1,-1,-1,Q14626,IL11RA,Interleukin-11 receptor subunit alpha,ATGAGCAGCAGCTGCTCAGGGCTGAGCAGGGTCCTGGTGGCCGTGGCTACAGCCCTGGTGTCTGCCTCCTCCCCCTGCCCCCAGGCCTGGGGCCCCCCAGGGGTCCAGTATGGGCAGCCAGGCAGGTCCGTGAAGCTGTGTTGTCCTGGAGTGACTGCCGGGGACCCAGTGTCCTGGTTTCGGGATGGGGAGCCAAAGCTGCTCCAGGGACCTGACTCTGGGCTAGGGCATGAACTGGTCCTGGCCCAGGCAGAC,drugbank_target|Q14626 Interleukin-11 receptor subunit alpha (DB00038),BiotechDrug,Humans,20,0,11,3,1,14,4,2,3,41,2,1,21,7,18,11,9,5,3,1,ATGAGCAGCAGCTGCTCAGGGCTGAGCAGGGTCCTGGTGGCCGTGGCTACAGCCCTGGTGTCTGCCTCCTCCCCCTGCCCCCAGGCCTGGGGCCCCCCAGGGGTCCAGTATGGGCAGCCAGGCAGGTCCGTGAAGCTGTGTTGTCCTGGAGTGACTGCCGGGGACCCAGTGTCCTGGTTTCGGGATGGGGAGCCAAAGCTGCTCCAGGGACCTGACTCTGGGCTAGGGCATGAACTGGTCCTGGCCCAGGCAGAC
DB00039,Palifermin,BiotechDrug,46506691.0,http://www.drugs.com/cdi/palifermin.html,MSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT,drugbank_drug|DB00039 Palifermin sequence,"Keratinocyte Growth Factors, Adjunct Chemoprotective Agents",101,-1,-1,-1,-1,-1,-1,P11362,FGFR1,Fibroblast growth factor receptor 1,ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACCGCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTGGAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGATGTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGCATCACAGGGGAGGAG,drugbank_target|P11362 Fibroblast growth factor receptor 1 (DB00039; DB00398; DB01109; DB02058; DB05014; DB07525; DB07840; DB08577; DB08896; DB08901; DB09078; DB09079; DB11800; DB11886; DB12010; DB12147; DB15102; DB15149; DB15685; DB15822),BiotechDrug,Humans,9,3,4,12,5,11,3,9,17,8,7,10,2,4,8,3,8,8,2,8,ATGTGGAGCTGGAAGTGCCTCCTCTTCTGGGCTGTGCTGGTCACAGCCACACTCTGCACCGCTAGGCCGTCCCCGACCTTGCCTGAACAAGCCCAGCCCTGGGGAGCCCCTGTGGAAGTGGAGTCCTTCCTGGTCCACCCCGGTGACCTGCTGCAGCTTCGCTGTCGGCTGCGGGACGATGTGCAGAGCATCAACTGGCTGCGGGACGGGGTGCAGCTGGCGGAAAGCAACCGCACCCGCATCACAGGGGAGGAG
DB00039,Palifermin,BiotechDrug,46506691.0,http://www.drugs.com/cdi/palifermin.html,MSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT,drugbank_drug|DB00039 Palifermin sequence,"Keratinocyte Growth Factors, Adjunct Chemoprotective Agents",101,-1,-1,-1,-1,-1,-1,P21802,FGFR2,Fibroblast growth factor receptor 2,ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGAGGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGGCCCAACAATAGGACA,drugbank_target|P21802 Fibroblast growth factor receptor 2 (DB00039; DB01109; DB01901; DB02058; DB02491; DB08896; DB08901; DB09078; DB09079; DB10770; DB10772; DB11886; DB12010; DB12147; DB15102; DB15149; DB15685; DB15822; DB17587),BiotechDrug,Humans,9,3,4,12,5,11,3,9,17,8,7,10,2,4,8,3,8,8,2,8,ATGGTCAGCTGGGGTCGTTTCATCTGCCTGGTCGTGGTCACCATGGCAACCTTGTCCCTGGCCCGGCCCTCCTTCAGTTTAGTTGAGGATACCACATTAGAGCCAGAAGAGCCACCAACCAAATACCAAATCTCTCAACCAGAAGTGTACGTGGCTGCGCCAGGGGAGTCGCTAGAGGTGCGCTGCCTGTTGAAAGATGCCGCCGTGATCAGTTGGACTAAGGATGGGGTGCACTTGGGGCCCAACAATAGGACA
DB00039,Palifermin,BiotechDrug,46506691.0,http://www.drugs.com/cdi/palifermin.html,MSYDYMEGGDIRVRRLFCRTQWYLRIDKRGKVKGTQEMKNNYNIMEIRTVAVGIVAIKGVESEFYLAMNKEGKLYAKKECNEDCNFKELILENHYNTYASAKWTHNGGEMFVALNQKGIPVRGKKTKKEQKTAHFLPMAIT,drugbank_drug|DB00039 Palifermin sequence,"Keratinocyte Growth Factors, Adjunct Chemoprotective Agents",101,-1,-1,-1,-1,-1,-1,P98160,HSPG2,Basement membrane-specific heparan sulfate proteoglycan core protein,ATGGGGTGGCGGGCGGCGGGCGCGCTGCTGCTGGCGCTGCTGCTGCACGGGCGGCTGCTGGCGGTGACCCATGGGCTGAGGGCATACGATGGCTTGTCTCTGCCTGAGGACATAGAGACCGTCACAGCAAGCCAAATGCGCTGGACACATTCGTACCTTTCTGATGATGAGGACATGCTGGCTGACAGCATCTCAGGAGACGACCTGGGCAGTGGGGACCTGGGCAGCGGGGACTTCCAGATGGTTTATTTCCGA,drugbank_target|P98160 Basement membrane-specific heparan sulfate proteoglycan core protein (DB00039; DB16662),BiotechDrug,Humans,9,3,4,12,5,11,3,9,17,8,7,10,2,4,8,3,8,8,2,8,ATGGGGTGGCGGGCGGCGGGCGCGCTGCTGCTGGCGCTGCTGCTGCACGGGCGGCTGCTGGCGGTGACCCATGGGCTGAGGGCATACGATGGCTTGTCTCTGCCTGAGGACATAGAGACCGTCACAGCAAGCCAAATGCGCTGGACACATTCGTACCTTTCTGATGATGAGGACATGCTGGCTGACAGCATCTCAGGAGACGACCTGGGCAGTGGGGACCTGGGCAGCGGGGACTTCCAGATGGTTTATTTCCGA
DB00040,Glucagon,BiotechDrug,46504732.0,http://www.drugs.com/cdi/glucagon.html,HSQGTFTSDYSKYLDSRRAQDFVQWLMNT,drugbank_drug|DB00040 Glucagon for Injection Sequence,Hypoglycemia Antidotes,4,-1,-1,-1,-1,-1,-1,O95838,GLP2R,Glucagon-like peptide 2 receptor,ATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGCGTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCACAGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCCATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAACAGGCATGTCTGAGA,drugbank_target|O95838 Glucagon-like peptide 2 receptor (DB00040; DB08900),BiotechDrug,Humans,1,0,3,0,2,1,1,0,1,2,1,1,0,3,2,4,3,1,1,2,ATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGCGTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCACAGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCCATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAACAGGCATGTCTGAGA
DB00040,Glucagon,BiotechDrug,46504732.0,http://www.drugs.com/cdi/glucagon.html,HSQGTFTSDYSKYLDSRRAQDFVQWLMNT,drugbank_drug|DB00040 Glucagon for Injection Sequence,Hypoglycemia Antidotes,4,-1,-1,-1,-1,-1,-1,P47871,GCGR,Glucagon receptor,ATGCCCCCCTGCCAGCCACAGCGACCCCTGCTGCTGTTGCTGCTGCTGCTGGCCTGCCAGCCACAGGTCCCCTCCGCTCAGGTGATGGACTTCCTGTTTGAGAAGTGGAAGCTCTACGGTGACCAGTGTCACCACAACCTGAGCCTGCTGCCCCCTCCCACGGAGCTGGTGTGCAACAGAACCTTCGACAAGTATTCCTGCTGGCCGGACACCCCCGCCAATACCACGGCCAACATCTCCTGCCCCTGGTACCTG,drugbank_target|P47871 Glucagon receptor (DB00040; DB15226),BiotechDrug,Humans,1,0,3,0,2,1,1,0,1,2,1,1,0,3,2,4,3,1,1,2,ATGCCCCCCTGCCAGCCACAGCGACCCCTGCTGCTGTTGCTGCTGCTGCTGGCCTGCCAGCCACAGGTCCCCTCCGCTCAGGTGATGGACTTCCTGTTTGAGAAGTGGAAGCTCTACGGTGACCAGTGTCACCACAACCTGAGCCTGCTGCCCCCTCCCACGGAGCTGGTGTGCAACAGAACCTTCGACAAGTATTCCTGCTGGCCGGACACCCCCGCCAATACCACGGCCAACATCTCCTGCCCCTGGTACCTG
DB00040,Glucagon,BiotechDrug,46504732.0,http://www.drugs.com/cdi/glucagon.html,HSQGTFTSDYSKYLDSRRAQDFVQWLMNT,drugbank_drug|DB00040 Glucagon for Injection Sequence,Hypoglycemia Antidotes,4,-1,-1,-1,-1,-1,-1,P43220,GLP1R,Glucagon-like peptide 1 receptor,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC,drugbank_target|P43220 Glucagon-like peptide 1 receptor (DB00040; DB01276; DB06655; DB09043; DB09045; DB09265; DB13928; DB14027; DB15171; DB15650; DB16697),BiotechDrug,Humans,1,0,3,0,2,1,1,0,1,2,1,1,0,3,2,4,3,1,1,2,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC
DB00042,Botulinum toxin type B,BiotechDrug,46504750.0,http://www.drugs.com/cdi/botulinum-toxin-type-b.html,MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKK,drugbank_drug|DB00042 Botulinum neurotoxin type B - Clostridium botulinum,Botulinum Toxins,235,-1,-1,-1,-1,-1,-1,P23763,VAMP1,Vesicle-associated membrane protein 1,ATGTCTGCTCCAGCTCAGCCACCTGCTGAAGGGACAGAAGGGACTGCCCCAGGTGGGGGTCCCCCTGGCCCTCCTCCTAACATGACCAGTAACAGACGACTACAGCAAACCCAGGCACAAGTGGAGGAGGTGGTGGACATCATACGTGTGAACGTGGACAAGGTCCTGGAGAGGGACCAGAAGCTGTCAGAGCTGGATGACCGAGCTGATGCCTTGCAGGCAGGAGCATCACAATTTGAGAGCAGTGCTGCCAAG,drugbank_target|P23763 Vesicle-associated membrane protein 1 (DB00042),BiotechDrug,Humans,7,2,13,17,17,19,4,29,18,17,8,27,17,4,12,9,9,13,1,12,ATGTCTGCTCCAGCTCAGCCACCTGCTGAAGGGACAGAAGGGACTGCCCCAGGTGGGGGTCCCCCTGGCCCTCCTCCTAACATGACCAGTAACAGACGACTACAGCAAACCCAGGCACAAGTGGAGGAGGTGGTGGACATCATACGTGTGAACGTGGACAAGGTCCTGGAGAGGGACCAGAAGCTGTCAGAGCTGGATGACCGAGCTGATGCCTTGCAGGCAGGAGCATCACAATTTGAGAGCAGTGCTGCCAAG
DB00042,Botulinum toxin type B,BiotechDrug,46504750.0,http://www.drugs.com/cdi/botulinum-toxin-type-b.html,MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKK,drugbank_drug|DB00042 Botulinum neurotoxin type B - Clostridium botulinum,Botulinum Toxins,235,-1,-1,-1,-1,-1,-1,P63027,VAMP2,Vesicle-associated membrane protein 2,ATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGGAGGGTGGTCCCCCTGCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCAGCAGACCCAGGCCCAGGTGGATGAGGTGGTGGACATCATGAGGGTGAACGTGGACAAGGTCCTGGAGCGAGACCAGAAGCTGTCGGAGCTGGACGACCGTGCAGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGCGCAGCCAAGCTCAAG,drugbank_target|P63027 Vesicle-associated membrane protein 2 (DB00042),BiotechDrug,Humans,7,2,13,17,17,19,4,29,18,17,8,27,17,4,12,9,9,13,1,12,ATGTCTGCTACCGCTGCCACGGCCCCCCCTGCTGCCCCGGCTGGGGAGGGTGGTCCCCCTGCACCCCCTCCAAACCTCACCAGTAACAGGAGACTGCAGCAGACCCAGGCCCAGGTGGATGAGGTGGTGGACATCATGAGGGTGAACGTGGACAAGGTCCTGGAGCGAGACCAGAAGCTGTCGGAGCTGGACGACCGTGCAGATGCACTCCAGGCGGGGGCCTCCCAGTTTGAAACAAGCGCAGCCAAGCTCAAG
DB00042,Botulinum toxin type B,BiotechDrug,46504750.0,http://www.drugs.com/cdi/botulinum-toxin-type-b.html,MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKK,drugbank_drug|DB00042 Botulinum neurotoxin type B - Clostridium botulinum,Botulinum Toxins,235,-1,-1,-1,-1,-1,-1,Q8N9I0,SYT2,Synaptotagmin-2,ATGAGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGGCTCCTGCCACCACCACCGCCACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGGGAGAGCCAGGAGGACATGTTTGCCAAACTGAAGGAGAAGTTATTCAATGAGATAAACAAGATTCCCTTACCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCTTCTCACCTGCTGCTTCTGCATCTGCAAG,drugbank_target|Q8N9I0 Synaptotagmin-2 (DB00042),BiotechDrug,Humans,7,2,13,17,17,19,4,29,18,17,8,27,17,4,12,9,9,13,1,12,ATGAGGAACATTTTCAAGAGGAACCAGGAGCCTATTGTGGCTCCTGCCACCACCACCGCCACGATGCCCATTGGACCCGTGGACAACTCCACTGAGAGTGGGGGTGCTGGGGAGAGCCAGGAGGACATGTTTGCCAAACTGAAGGAGAAGTTATTCAATGAGATAAACAAGATTCCCTTACCACCCTGGGCACTGATCGCCATTGCTGTGGTTGCTGGGCTCCTGCTTCTCACCTGCTGCTTCTGCATCTGCAAG
DB00043,Omalizumab,BiotechDrug,46507002.0,http://www.drugs.com/cdi/omalizumab.html,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00043 Omalizumab light chain,"Monoclonal Antibodies, Anti-asthmatics",73,-1,-1,-1,-1,-1,-1,Q01362,MS4A2,High affinity immunoglobulin epsilon receptor subunit beta,ATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTGCCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAGTCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTCCTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGCTCTGTACTTGATATT,drugbank_target|Q01362 High affinity immunoglobulin epsilon receptor subunit beta (DB00043),BiotechDrug,Humans,13,4,13,10,8,12,3,6,13,15,1,6,11,15,6,33,17,15,2,12,ATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTGCCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAGTCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTCCTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGCTCTGTACTTGATATT
DB00043,Omalizumab,BiotechDrug,46507002.0,http://www.drugs.com/cdi/omalizumab.html,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB00043 Omalizumab heavy chain,"Monoclonal Antibodies, Anti-asthmatics",73,-1,-1,-1,-1,-1,-1,P12319,FCER1A,High affinity immunoglobulin epsilon receptor subunit alpha,ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCAGATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGAATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGTTCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATTGTGAATGCCAAATTT,drugbank_target|P12319 High affinity immunoglobulin epsilon receptor subunit alpha (DB00043; DB00895; DB05797),BiotechDrug,Humans,15,7,9,7,9,25,6,6,13,20,2,8,19,7,7,36,20,22,6,11,ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCAGATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGAATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGTTCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATTGTGAATGCCAAATTT
DB00043,Omalizumab,BiotechDrug,46507002.0,http://www.drugs.com/cdi/omalizumab.html,EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYADSVKGRFTISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB00043 Omalizumab heavy chain,"Monoclonal Antibodies, Anti-asthmatics",73,-1,-1,-1,-1,-1,-1,Q01362,MS4A2,High affinity immunoglobulin epsilon receptor subunit beta,ATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTGCCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAGTCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTCCTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGCTCTGTACTTGATATT,drugbank_target|Q01362 High affinity immunoglobulin epsilon receptor subunit beta (DB00043),BiotechDrug,Humans,15,7,9,7,9,25,6,6,13,20,2,8,19,7,7,36,20,22,6,11,ATGGACACAGAAAGTAATAGGAGAGCAAATCTTGCTCTCCCACAGGAGCCTTCCAGTGTGCCTGCATTTGAAGTCTTGGAAATATCTCCCCAGGAAGTATCTTCAGGCAGACTATTGAAGTCGGCCTCATCCCCACCACTGCATACATGGCTGACAGTTTTGAAAAAAGAGCAGGAGTTCCTGGGGGTAACACAAATTCTGACTGCTATGATATGCCTTTGTTTTGGAACAGTTGTCTGCTCTGTACTTGATATT
DB00043,Omalizumab,BiotechDrug,46507002.0,http://www.drugs.com/cdi/omalizumab.html,DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00043 Omalizumab light chain,"Monoclonal Antibodies, Anti-asthmatics",73,-1,-1,-1,-1,-1,-1,P12319,FCER1A,High affinity immunoglobulin epsilon receptor subunit alpha,ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCAGATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGAATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGTTCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATTGTGAATGCCAAATTT,drugbank_target|P12319 High affinity immunoglobulin epsilon receptor subunit alpha (DB00043; DB00895; DB05797),BiotechDrug,Humans,13,4,13,10,8,12,3,6,13,15,1,6,11,15,6,33,17,15,2,12,ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCAGATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGAATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGTTCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATTGTGAATGCCAAATTT
DB00046,Insulin lispro,BiotechDrug,46507498.0,http://www.drugs.com/mtm/insulin-lispro.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00046 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB00046,Insulin lispro,BiotechDrug,46507498.0,http://www.drugs.com/mtm/insulin-lispro.html,FVNQHLCGSHLVEALYLVCGERGFFYTKPT,drugbank_drug|DB00046 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB00046,Insulin lispro,BiotechDrug,46507498.0,http://www.drugs.com/mtm/insulin-lispro.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB00046 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB00046,Insulin lispro,BiotechDrug,46507498.0,http://www.drugs.com/mtm/insulin-lispro.html,FVNQHLCGSHLVEALYLVCGERGFFYTKPT,drugbank_drug|DB00046 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,2,3,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB00047,Insulin glargine,BiotechDrug,46507981.0,http://www.drugs.com/cdi/insulin-glargine-cartridge-systems.html,GIVEQCCTSICSLYQLENYCG,drugbank_drug|DB00047 A chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,0,4,0,2,0,2,0,2,0,2,0,1,0,2,0,2,1,1,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB00047,Insulin glargine,BiotechDrug,46507981.0,http://www.drugs.com/cdi/insulin-glargine-cartridge-systems.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR,drugbank_drug|DB00047 B chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,3,1,2,3,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB00047,Insulin glargine,BiotechDrug,46507981.0,http://www.drugs.com/cdi/insulin-glargine-cartridge-systems.html,GIVEQCCTSICSLYQLENYCG,drugbank_drug|DB00047 A chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,0,4,0,2,0,2,0,2,0,2,0,1,0,2,0,2,1,1,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB00047,Insulin glargine,BiotechDrug,46507981.0,http://www.drugs.com/cdi/insulin-glargine-cartridge-systems.html,FVNQHLCGSHLVEALYLVCGERGFFYTPKTRR,drugbank_drug|DB00047 B chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,3,1,2,3,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB00049,Rasburicase,BiotechDrug,46504490.0,http://www.drugs.com/cdi/rasburicase.html,SAVKAARYGKDNVRVYKVHKDEKTGVQTVYEMTVCVLLEGEIETSYTKADNSVIVATDSIKNTIYITAKQNPVTPPELFGSILGTHFIEKYNHIHAAHVNIVCHRWTRMDIDGKPHPHSFIRDSEEKRNVQVDVVEGKGIDIKSSLSGLTVLKSTNSQFWGFLRDEYTTLKETWDRILSTDVDATWQWKNFSGLQEVRSHVPKFDATWATAREVTLKTFAEDNSASVQATMYKMAEQILARQQLIETVEYSLPNK,drugbank_drug|DB00049 DB00049 sequence,"Enzymes, Oncology",14,-1,-1,-1,-1,-1,-1,,,,,,,,17,2,15,18,8,11,9,16,20,15,4,11,7,10,11,18,24,24,6,9,
DB00051,Adalimumab,BiotechDrug,46504982.0,http://www.drugs.com/cdi/adalimumab.html,EVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSAITWNSGHIDYADSVEGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAKVSYLSTASSLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00051  Adalimumab Heavy chain:,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors, Inflammatory Bowel Disease Agents, Monoclonal Antibodies",80,-1,-1,-1,-1,-1,-1,P01375,TNF,Tumor necrosis factor,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT,drugbank_target|P01375 Tumor necrosis factor (DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01407; DB01411; DB01427; DB04297; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05744; DB05758; DB05767; DB05869; DB05879; DB,BiotechDrug,Humans,18,7,11,8,8,21,5,4,14,23,2,8,19,7,6,36,20,23,5,10,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT
DB00051,Adalimumab,BiotechDrug,46504982.0,http://www.drugs.com/cdi/adalimumab.html,DIQMTQSPSSLSASVGDRVTITCRASQGIRNYLAWYQQKPGKAPKLLIYAASTLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNRAPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00051  Adalimumab Light chain:,"Antipsoriatics, Systemic, DMARDs, TNF Inhibitors, Inflammatory Bowel Disease Agents, Monoclonal Antibodies",80,-1,-1,-1,-1,-1,-1,P01375,TNF,Tumor necrosis factor,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT,drugbank_target|P01375 Tumor necrosis factor (DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01407; DB01411; DB01427; DB04297; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05744; DB05758; DB05767; DB05869; DB05879; DB,BiotechDrug,Humans,15,5,9,9,7,13,2,7,13,15,1,7,11,15,9,30,18,15,2,11,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT
DB00052,Somatotropin,BiotechDrug,46506010.0,http://www.drugs.com/cdi/somatropin-rdna-origin-nonrefrigerated.html,FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF,drugbank_drug|DB00052 DB00052 sequence,Growth Hormone Analogs,207,-1,-1,-1,-1,-1,-1,P10912,GHR,Growth hormone receptor,ATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCTGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAATCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAGCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGACCCATACAGCTGTTC,drugbank_target|P10912 Growth hormone receptor (DB00052; DB00082; DB09098; DB14960; DB15093; DB16220),BiotechDrug,Humans,7,4,11,14,13,8,3,8,9,26,3,9,8,13,11,18,10,7,1,8,ATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCTGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAATCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAGCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGACCCATACAGCTGTTC
DB00052,Somatotropin,BiotechDrug,46506010.0,http://www.drugs.com/cdi/somatropin-rdna-origin-nonrefrigerated.html,FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF,drugbank_drug|DB00052 DB00052 sequence,Growth Hormone Analogs,207,-1,-1,-1,-1,-1,-1,P16471,PRLR,Prolactin receptor,ATGAAGGAAAATGTGGCATCTGCAACCGTTTTCACTCTGCTACTTTTTCTCAACACCTGCCTTCTGAATGGACAGTTACCTCCTGGAAAACCTGAGATCTTTAAATGTCGTTCTCCCAATAAGGAAACATTCACCTGCTGGTGGAGGCCTGGGACAGATGGAGGACTTCCTACCAATTATTCACTGACTTACCACAGGGAAGGAGAGACACTCATGCATGAATGTCCAGACTACATAACCGGTGGCCCCAACTCC,drugbank_target|P16471 Prolactin receptor (DB00052; DB16220),BiotechDrug,Humans,7,4,11,14,13,8,3,8,9,26,3,9,8,13,11,18,10,7,1,8,ATGAAGGAAAATGTGGCATCTGCAACCGTTTTCACTCTGCTACTTTTTCTCAACACCTGCCTTCTGAATGGACAGTTACCTCCTGGAAAACCTGAGATCTTTAAATGTCGTTCTCCCAATAAGGAAACATTCACCTGCTGGTGGAGGCCTGGGACAGATGGAGGACTTCCTACCAATTATTCACTGACTTACCACAGGGAAGGAGAGACACTCATGCATGAATGTCCAGACTACATAACCGGTGGCCCCAACTCC
DB00053,Imiglucerase,BiotechDrug,46508744.0,http://www.drugs.com/cdi/imiglucerase.html,ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEH,drugbank_drug|DB00053 DB00053 sequence,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,,,,,,,,22,6,10,11,15,19,6,10,12,27,4,9,20,12,10,20,18,9,4,11,
DB00054,Abciximab,BiotechDrug,46505910.0,http://www.drugs.com/cdi/abciximab.html,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH,"drugbank_drug|DB00054 pdb|6V4P|C Chain C, Abciximab, heavy chain","Antineoplastics CDK Inhibitors, Glycoprotein IIb/IIIa Inhibitors",318,-1,-1,-1,-1,-1,-1,P04004,VTN,Vitronectin,ATGGCACCCCTGAGACCCCTTCTCATACTGGCCCTGCTGGCATGGGTTGCTCTGGCTGACCAAGAGTCATGCAAGGGCCGCTGCACTGAGGGCTTCAACGTGGACAAGAAGTGCCAGTGTGACGAGCTCTGCTCTTACTACCAGAGCTGCTGCACAGACTATACGGCTGAGTGCAAGCCCCAAGTGACTCGCGGGGATGTGTTCACTATGCCGGAGGATGAGTACACGGTCTATGACGATGGCGAGGAGAAAAAC,drugbank_target|P04004 Vitronectin (DB00054; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,5,6,7,6,19,4,4,15,16,3,7,12,9,2,31,23,22,5,14,ATGGCACCCCTGAGACCCCTTCTCATACTGGCCCTGCTGGCATGGGTTGCTCTGGCTGACCAAGAGTCATGCAAGGGCCGCTGCACTGAGGGCTTCAACGTGGACAAGAAGTGCCAGTGTGACGAGCTCTGCTCTTACTACCAGAGCTGCTGCACAGACTATACGGCTGAGTGCAAGCCCCAAGTGACTCGCGGGGATGTGTTCACTATGCCGGAGGATGAGTACACGGTCTATGACGATGGCGAGGAGAAAAAC
DB00054,Abciximab,BiotechDrug,46505910.0,http://www.drugs.com/cdi/abciximab.html,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH,"drugbank_drug|DB00054 pdb|6V4P|C Chain C, Abciximab, heavy chain","Antineoplastics CDK Inhibitors, Glycoprotein IIb/IIIa Inhibitors",318,-1,-1,-1,-1,-1,-1,P08514,ITGA2B,Integrin alpha-IIb,ATGGCCAGAGCTTTGTGTCCACTGCAAGCCCTCTGGCTTCTGGAGTGGGTGCTGCTGCTCTTGGGACCTTGTGCTGCCCCTCCAGCCTGGGCCTTGAACCTGGACCCAGTGCAGCTCACCTTCTATGCAGGCCCCAATGGCAGCCAGTTTGGATTTTCACTGGACTTCCACAAGGACAGCCATGGGAGAGTGGCCATCGTGGTGGGCGCCCCGCGGACCCTGGGCCCCAGCCAGGAGGAGACGGGCGGCGTGTTC,drugbank_target|P08514 Integrin alpha-IIb (DB00054; DB00775; DB04863; DB06472),BiotechDrug,Humans,15,5,6,7,6,19,4,4,15,16,3,7,12,9,2,31,23,22,5,14,ATGGCCAGAGCTTTGTGTCCACTGCAAGCCCTCTGGCTTCTGGAGTGGGTGCTGCTGCTCTTGGGACCTTGTGCTGCCCCTCCAGCCTGGGCCTTGAACCTGGACCCAGTGCAGCTCACCTTCTATGCAGGCCCCAATGGCAGCCAGTTTGGATTTTCACTGGACTTCCACAAGGACAGCCATGGGAGAGTGGCCATCGTGGTGGGCGCCCCGCGGACCCTGGGCCCCAGCCAGGAGGAGACGGGCGGCGTGTTC
DB00054,Abciximab,BiotechDrug,46505910.0,http://www.drugs.com/cdi/abciximab.html,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH,"drugbank_drug|DB00054 pdb|6V4P|C Chain C, Abciximab, heavy chain","Antineoplastics CDK Inhibitors, Glycoprotein IIb/IIIa Inhibitors",318,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,15,5,6,7,6,19,4,4,15,16,3,7,12,9,2,31,23,22,5,14,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00054,Abciximab,BiotechDrug,46505910.0,http://www.drugs.com/cdi/abciximab.html,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH,"drugbank_drug|DB00054 pdb|6V4P|C Chain C, Abciximab, heavy chain","Antineoplastics CDK Inhibitors, Glycoprotein IIb/IIIa Inhibitors",318,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,15,5,6,7,6,19,4,4,15,16,3,7,12,9,2,31,23,22,5,14,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00054,Abciximab,BiotechDrug,46505910.0,http://www.drugs.com/cdi/abciximab.html,EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH,"drugbank_drug|DB00054 pdb|6V4P|C Chain C, Abciximab, heavy chain","Antineoplastics CDK Inhibitors, Glycoprotein IIb/IIIa Inhibitors",318,-1,-1,-1,-1,-1,-1,P05106,ITGB3,Integrin beta-3,ATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGCGACTGTGCTGGCGCTGGGGGCGCTGGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAGCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGCTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATCGAGTTCCCAGTGAGT,drugbank_target|P05106 Integrin beta-3 (DB00054; DB00063; DB00098; DB00451; DB00775; DB02709; DB04863; DB05787; DB06472; DB15598),BiotechDrug,Humans,15,5,6,7,6,19,4,4,15,16,3,7,12,9,2,31,23,22,5,14,ATGCGAGCGCGGCCGCGGCCCCGGCCGCTCTGGGCGACTGTGCTGGCGCTGGGGGCGCTGGCGGGCGTTGGCGTAGGAGGGCCCAACATCTGTACCACGCGAGGTGTGAGCTCCTGCCAGCAGTGCCTGGCTGTGAGCCCCATGTGTGCCTGGTGCTCTGATGAGGCCCTGCCTCTGGGCTCACCTCGCTGTGACCTGAAGGAGAATCTGCTGAAGGATAACTGTGCCCCAGAATCCATCGAGTTCCCAGTGAGT
DB00058,Alpha-1-proteinase inhibitor,BiotechDrug,46506364.0,,EDPQGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLP,drugbank_drug|DB00058 DB00058 sequence,"Pulmonary, Other, Alpha-1 proteinase inhibitor",432,-1,-1,-1,-1,-1,-1,P08246,ELANE,Neutrophil elastase,ATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTGCTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCGTGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATTGCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTGCGGGTGGTCCTGGGA,drugbank_target|P08246 Neutrophil elastase (DB00058; DB02341; DB03925; DB05161; DB12622; DB15588),BiotechDrug,Humans,15,1,18,20,20,13,9,11,20,28,5,13,9,14,5,12,20,15,2,5,ATGACCCTCGGCCGCCGACTCGCGTGTCTTTTCCTCGCCTGTGTCCTGCCGGCCTTGCTGCTGGGGGGCACCGCGCTGGCCTCGGAGATTGTGGGGGGCCGGCGAGCGCGGCCCCACGCGTGGCCCTTCATGGTGTCCCTGCAGCTGCGCGGAGGCCACTTCTGCGGCGCCACCCTGATTGCGCCCAACTTCGTCATGTCGGCCGCGCACTGCGTGGCGAATGTAAACGTCCGCGCGGTGCGGGTGGTCCTGGGA
DB00059,Pegaspargase,BiotechDrug,46505366.0,http://www.drugs.com/cdi/pegaspargase.html,MEFFKKTALAALVMGFSGAALALPNITILATGGTIAGGGDSATKSNYTVGKVGVENLVNAVPQLKDIANVKGEQVVNIGSQDMNDNVWLTLAKKINTDCDKTDGFVITHGTDTMEETAYFLDLTVKCDKPVVMVGAMRPSTSMSADGPFNLYNAVVTAADKASANRGVLVVMNDTVLDGRDVTKTNTTDVATFKSVNYGPLGYIHNGKIDYQRTPARKHTSDTPFDVSKLNELPKVGIVYNYANASDLPAKALVD,drugbank_drug|DB00059 DB00059 sequence,"Enzymes, Oncology",14,-1,-1,-1,-1,-1,-1,,,,,,,,26,2,21,6,8,21,3,10,19,19,8,19,10,4,5,12,25,28,1,8,
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00060,Interferon beta-1a,BiotechDrug,46504899.0,http://www.drugs.com/cdi/interferon-beta-1a.html,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00060 DB00060 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00061,Pegademase,BiotechDrug,46508490.0,http://www.drugs.com/cdi/pegademase-bovine.html,MAQTPAFNKPKVELHVHLDGAIKPETILYYGRKRGIALPADTPEELQNIIGMDKPLSLPEFLAKFDYYMPAIAGCREAVKRIAYEFVEMKAKDGVVYVEVRYSPHLLANSKVEPIPWNQAEGDLTPDEVVSLVNQGLQEGERDFGVKVRSILCCMRHQPSWSSEVVELCKKYREQTVVAIDLAGDETIEGSSLFPGHVKAYAEAVKSGVHRTVHAGEVGSANVVKEAVDTLKTERLGHGYHTLEDATLYNRLRQE,drugbank_drug|DB00061 DB00061 sequence,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,P62993,GRB2,Growth factor receptor-bound protein 2,ATGGAAGCCATCGCCAAATATGACTTCAAAGCTACTGCAGACGACGAGCTGAGCTTCAAAAGGGGGGACATCCTCAAGGTTTTGAACGAAGAATGTGATCAGAACTGGTACAAGGCAGAGCTTAATGGAAAAGACGGCTTCATTCCCAAGAACTACATAGAAATGAAACCACATCCGTGGTTTTTTGGCAAAATCCCCAGAGCCAAGGCAGAAGAAATGCTTAGCAAACAGCGGCACGATGGGGCCTTTCTTATC,drugbank_target|P62993 Growth factor receptor-bound protein 2 (DB00061; DB03276),BiotechDrug,Humans,22,4,12,25,6,18,9,11,17,22,5,7,14,8,13,12,11,26,2,11,ATGGAAGCCATCGCCAAATATGACTTCAAAGCTACTGCAGACGACGAGCTGAGCTTCAAAAGGGGGGACATCCTCAAGGTTTTGAACGAAGAATGTGATCAGAACTGGTACAAGGCAGAGCTTAATGGAAAAGACGGCTTCATTCCCAAGAACTACATAGAAATGAAACCACATCCGTGGTTTTTTGGCAAAATCCCCAGAGCCAAGGCAGAAGAAATGCTTAGCAAACAGCGGCACGATGGGGCCTTTCTTATC
DB00066,Follitropin,BiotechDrug,46508818.0,http://www.drugs.com/cdi/follitropin-alfa-powder.html,NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE,drugbank_drug|DB00066 Beta chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P23945,FSHR,Follicle-stimulating hormone receptor,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG,drugbank_target|P23945 Follicle-stimulating hormone receptor (DB00032; DB00066; DB00094; DB00097; DB04786; DB09066),BiotechDrug,Humans,6,12,6,8,3,6,3,6,7,5,1,3,5,2,5,7,12,6,1,7,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG
DB00066,Follitropin,BiotechDrug,46508818.0,http://www.drugs.com/cdi/follitropin-alfa-powder.html,APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS,drugbank_drug|DB00066 Alpha chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P23945,FSHR,Follicle-stimulating hormone receptor,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG,drugbank_target|P23945 Follicle-stimulating hormone receptor (DB00032; DB00066; DB00094; DB00097; DB04786; DB09066),BiotechDrug,Humans,5,10,2,4,4,4,3,1,6,4,3,4,7,5,3,8,8,7,0,4,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00068,Interferon beta-1b,BiotechDrug,46504458.0,http://www.drugs.com/cdi/interferon-beta-1b-solution.html,SYNLLGFLQRSSNFQSQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB00068 DB00068 sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,6,2,5,13,9,6,5,11,11,24,3,12,1,11,11,10,7,5,3,10,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00069,Interferon alfacon-1,BiotechDrug,46505985.0,http://www.drugs.com/cdi/interferon-alfacon-1.html,MCDLPQTHSLGNRRALILLAQMRRISPFSCLKDRHDFGFPQEEFDGNQFQKAQAISVLHEMIQQTFNLFSTKDSSAAWDESLLEKFYTELYQQLNDLEACVIQEVGVEETPLMNVDSILAVKKYFQRITLYLTEKKYSPCAWEVVRAEIMRSFSLSTNLQERLRRKE,drugbank_drug|DB00069  Interferon alfacon-1,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,10,4,8,15,10,4,3,8,9,20,5,6,5,13,11,13,8,8,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00070,Hyaluronidase (ovine),BiotechDrug,46505087.0,http://www.drugs.com/cdi/hyaluronidase.html,MWTGLGPAVTLALVLVVAWATELKPTAPPIFTGRPFVVAWDVPTQDCGPRHKMPLDPKDMKAFDVQASPNEGFVNQNITIFYRDRLGMYPHFNSVGGSVHGGVPQNGSLWVHLEMLKGHVEHYIRTQEPAGLAVIDWEDWRPVWVRNWQDKDVYRRLSRQLVASHHPDWPPERIVKEAQYEFEFAARQFMLETLRFVKAFRPRHLWGFYLFPDCYNHDYVQNWETYTGRCPDVEVSRNDQLSWLWAESTALFPSV,drugbank_drug|DB00070  Hyaluronidase Sequence,"Antidotes, Other, Extravasation Antidotes",272,-1,-1,-1,-1,-1,-1,P01137,TGFB1,Transforming growth factor beta-1,ATGCCGCCCTCCGGGCTGCGGCTGCTGCCGCTGCTGCTACCGCTGCTGTGGCTACTGGTGCTGACGCCTGGCCGGCCGGCCGCGGGACTATCCACCTGCAAGACTATCGACATGGAGCTGGTGAAGCGGAAGCGCATCGAGGCCATCCGCGGCCAGATCCTGTCCAAGCTGCGGCTCGCCAGCCCCCCGAGCCAGGGGGAGGTGCCGCCCGGCCCGCTGCCCGAGGCCGTGCTCGCCCTGTACAACAGCACCCGC,drugbank_target|P01137 Transforming growth factor beta-1 (DB00070; DB01162; DB06205; DB10770; DB10772; DB14740),BiotechDrug,Humans,17,3,15,14,14,15,10,6,8,20,6,9,21,11,17,10,12,25,13,9,ATGCCGCCCTCCGGGCTGCGGCTGCTGCCGCTGCTGCTACCGCTGCTGTGGCTACTGGTGCTGACGCCTGGCCGGCCGGCCGCGGGACTATCCACCTGCAAGACTATCGACATGGAGCTGGTGAAGCGGAAGCGCATCGAGGCCATCCGCGGCCAGATCCTGTCCAAGCTGCGGCTCGCCAGCCCCCCGAGCCAGGGGGAGGTGCCGCCCGGCCCGCTGCCCGAGGCCGTGCTCGCCCTGTACAACAGCACCCGC
DB00072,Trastuzumab,BiotechDrug,46507516.0,http://www.drugs.com/cdi/trastuzumab.html,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00072 Anti-HER2 Heavy chain (1 and 2),"Antineoplastics, Anti-HER2",227,-1,-1,-1,-1,-1,-1,P04626,ERBB2,Receptor tyrosine-protein kinase erbB-2,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC,drugbank_target|P04626 Receptor tyrosine-protein kinase erbB-2 (DB00072; DB01259; DB04988; DB05773; DB05944; DB06021; DB06366; DB08916; DB11652; DB11973; DB12010; DB12267; DB14967; DB15035),BiotechDrug,Humans,17,7,10,7,8,25,4,5,15,20,3,8,20,7,7,31,22,22,5,12,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC
DB00072,Trastuzumab,BiotechDrug,46507516.0,http://www.drugs.com/cdi/trastuzumab.html,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00072 Anti-HER2 Light chain (1 and 2),"Antineoplastics, Anti-HER2",227,-1,-1,-1,-1,-1,-1,P04626,ERBB2,Receptor tyrosine-protein kinase erbB-2,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC,drugbank_target|P04626 Receptor tyrosine-protein kinase erbB-2 (DB00072; DB01259; DB04988; DB05773; DB05944; DB06021; DB06366; DB08916; DB11652; DB11973; DB12010; DB12267; DB14967; DB15035),BiotechDrug,Humans,14,5,10,9,9,11,3,6,13,14,1,6,12,15,7,31,20,16,2,10,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC
DB00073,Rituximab,BiotechDrug,46505820.0,http://www.drugs.com/cdi/rituximab.html,QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00073 Rituximab light chain chimeric,"DMARDs, Other, Antineoplastics, Anti-CD20 Monoclonal Antibodies",158,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,15,5,6,11,7,13,3,7,13,13,1,7,13,12,6,35,17,16,4,9,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00073,Rituximab,BiotechDrug,46505820.0,http://www.drugs.com/cdi/rituximab.html,QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00073 Rituximab heavy chain chimeric,"DMARDs, Other, Antineoplastics, Anti-CD20 Monoclonal Antibodies",158,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,19,7,8,6,8,23,4,3,19,18,3,8,21,9,2,34,25,20,5,13,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00076,Digoxin Immune Fab (Ovine),BiotechDrug,46506432.0,http://www.drugs.com/cdi/digoxin-immune-fab.html,DVVMTQTPLSLPVSLGDQASISCRSSQSLVHSNGNTYLNWYLQKAGQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGIYFCSQTTHVPPTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC,drugbank_drug|DB00076 26-10 Light chain (murine),"Antidotes, Other",272,-1,-1,-1,-1,-1,-1,,,,,,,,8,5,12,9,9,15,4,9,13,16,2,12,11,9,8,32,20,14,3,8,
DB00076,Digoxin Immune Fab (Ovine),BiotechDrug,46506432.0,http://www.drugs.com/cdi/digoxin-immune-fab.html,EVQLQQSGPELVKPGASVRMSCKSSGYIFTDFYMNWVRQSHGKSLDYIGYISPYSGVTGYNQKFKGKATLTVDKSSSTAYMELRSLTSEDSAVYYCAGSSGNKWAMDYWGHGASVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEP,drugbank_drug|DB00076 26-10 Heavy chain (murine),"Antidotes, Other",272,-1,-1,-1,-1,-1,-1,,,,,,,,13,5,8,6,5,18,4,5,13,14,4,5,12,7,3,37,21,20,5,13,
DB00078,Ibritumomab tiuxetan,BiotechDrug,46506112.0,http://www.drugs.com/cdi/ibritumomab-tiuxetan-with-indium-111.html,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRADAAPTVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFN,drugbank_drug|DB00078 Ibritumomab tiuxetan light chain,"Antineoplastics, Anti-CD20 Monoclonal Antibodies",227,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,18,4,7,10,7,11,3,5,13,14,2,7,14,12,5,34,15,14,4,10,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00078,Ibritumomab tiuxetan,BiotechDrug,46506112.0,http://www.drugs.com/cdi/ibritumomab-tiuxetan-with-indium-111.html,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISL,drugbank_drug|DB00078 Ibritumomab tiuxetan heavy chain,"Antineoplastics, Anti-CD20 Monoclonal Antibodies",227,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,15,8,8,5,8,19,3,8,15,18,4,7,21,9,4,35,25,23,6,14,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Heavy Chain 2,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,16,7,8,6,9,20,4,4,17,18,4,8,20,9,4,36,24,22,5,14,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Light Chain 2,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,17,4,6,10,7,11,3,5,13,14,2,7,14,12,6,35,15,15,4,10,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,17,4,6,10,7,11,3,5,13,14,2,7,14,12,6,35,15,15,4,10,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,16,7,8,6,9,20,4,4,17,18,4,8,20,9,4,36,24,22,5,14,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,17,4,6,10,7,11,3,5,13,14,2,7,14,12,6,35,15,15,4,10,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,16,7,8,6,9,20,4,4,17,18,4,8,20,9,4,36,24,22,5,14,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QAYLQQSGAELVRPGASVKMSCKASGYTFTSYNMHWVKQTPRQGLEWIGAIYPGNGDTSYNQKFKGKATLTVDKSSSTAYMQLSSLTSEDSAVYFCARVVYYSNSYWYFDVWGTGTTVTVSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Heavy Chain 2,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,16,7,8,6,9,20,4,4,17,18,4,8,20,9,4,36,24,22,5,14,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00081,Tositumomab,BiotechDrug,46506662.0,http://www.drugs.com/cdi/iodine-i-131-tositumomab.html,QIVLSQSPAILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYAPSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQQWSFNPPTFGAGTKLELKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00081 Mouse-Human chimeric Anti-CD20 Light Chain 2,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,17,4,6,10,7,11,3,5,13,14,2,7,14,12,6,35,15,15,4,10,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB00082,Pegvisomant,BiotechDrug,46505507.0,http://www.drugs.com/cdi/pegvisomant.html,FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF,drugbank_drug|DB00082 DB00082 sequence,"Metabolic & Endocrine, Other",153,-1,-1,-1,-1,-1,-1,P10912,GHR,Growth hormone receptor,ATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCTGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAATCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAGCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGACCCATACAGCTGTTC,drugbank_target|P10912 Growth hormone receptor (DB00052; DB00082; DB09098; DB14960; DB15093; DB16220),BiotechDrug,Humans,7,4,11,14,13,8,3,8,9,26,3,9,8,13,11,18,10,7,1,8,ATGGATCTCTGGCAGCTGCTGTTGACCTTGGCACTGGCAGGATCAAGTGATGCTTTTTCTGGAAGTGAGGCCACAGCAGCTATCCTTAGCAGAGCACCCTGGAGTCTGCAAAGTGTTAATCCAGGCCTAAAGACAAATTCTTCTAAGGAGCCTAAATTCACCAAGTGCCGTTCACCTGAGCGAGAGACTTTTTCATGCCACTGGACAGATGAGGTTCATCATGGTACAAAGAACCTAGGACCCATACAGCTGTTC
DB00083,Botulinum toxin type A,BiotechDrug,46505347.0,,MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSG,drugbank_drug|DB00083 Botulinum Toxin Type A Sequence,"Neuromuscular Blockers, Depolarizing, Botulinum Toxins",141,-1,-1,-1,-1,-1,-1,P62745,RHOB,Rho-related GTP-binding protein RhoB,ATGGCGGCCATCCGCAAGAAGCTGGTGGTGGTGGGCGACGGCGCGTGTGGCAAGACGTGCCTGCTGATCGTGTTCAGTAAGGACGAGTTCCCCGAGGTGTACGTGCCCACCGTCTTCGAGAACTATGTGGCCGACATTGAGGTGGACGGCAAGCAGGTGGAGCTGGCGCTGTGGGACACGGCGGGCCAGGAGGACTACGACCGCCTGCGGCCGCTCTCCTACCCGGACACCGACGTCATTCTCATGTGCTTCTCG,drugbank_target|P62745 Rho-related GTP-binding protein RhoB (DB00083),BiotechDrug,Humans,11,2,15,16,14,19,5,21,14,18,4,19,17,7,9,14,17,18,2,13,ATGGCGGCCATCCGCAAGAAGCTGGTGGTGGTGGGCGACGGCGCGTGTGGCAAGACGTGCCTGCTGATCGTGTTCAGTAAGGACGAGTTCCCCGAGGTGTACGTGCCCACCGTCTTCGAGAACTATGTGGCCGACATTGAGGTGGACGGCAAGCAGGTGGAGCTGGCGCTGTGGGACACGGCGGGCCAGGAGGACTACGACCGCCTGCGGCCGCTCTCCTACCCGGACACCGACGTCATTCTCATGTGCTTCTCG
DB00083,Botulinum toxin type A,BiotechDrug,46505347.0,,MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSG,drugbank_drug|DB00083 Botulinum Toxin Type A Sequence,"Neuromuscular Blockers, Depolarizing, Botulinum Toxins",141,-1,-1,-1,-1,-1,-1,P60880,SNAP25,Synaptosomal-associated protein 25,ATGGCCGAAGACGCAGACATGCGCAATGAGCTGGAGGAGATGCAGCGAAGGGCTGACCAGTTGGCTGATGAGTCGCTGGAAAGCACCCGTCGTATGCTGCAACTGGTTGAAGAGAGTAAAGATGCTGGTATCAGGACTTTGGTTATGTTGGATGAACAAGGAGAACAACTCGATCGTGTCGAAGAAGGCATGAACCATATCAACCAAGACATGAAGGAGGCTGAGAAAAATTTAAAAGATTTAGGGAAATGCTGT,drugbank_target|P60880 Synaptosomal-associated protein 25 (DB00083; DB16820),BiotechDrug,Humans,11,2,15,16,14,19,5,21,14,18,4,19,17,7,9,14,17,18,2,13,ATGGCCGAAGACGCAGACATGCGCAATGAGCTGGAGGAGATGCAGCGAAGGGCTGACCAGTTGGCTGATGAGTCGCTGGAAAGCACCCGTCGTATGCTGCAACTGGTTGAAGAGAGTAAAGATGCTGGTATCAGGACTTTGGTTATGTTGGATGAACAAGGAGAACAACTCGATCGTGTCGAAGAAGGCATGAACCATATCAACCAAGACATGAAGGAGGCTGAGAAAAATTTAAAAGATTTAGGGAAATGCTGT
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE,drugbank_drug|DB00087 1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,13,4,7,6,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD,drugbank_drug|DB00087 8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,14,5,9,8,11,21,3,4,13,21,3,7,20,9,8,32,26,28,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE,drugbank_drug|DB00087 1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,13,4,7,6,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD,drugbank_drug|DB00087 8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,14,5,9,8,11,21,3,4,13,21,3,7,20,9,8,32,26,28,4,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD,drugbank_drug|DB00087 8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,14,5,9,8,11,21,3,4,13,21,3,7,20,9,8,32,26,28,4,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE,drugbank_drug|DB00087 1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,13,4,7,6,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV,drugbank_drug|DB00087 1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,13,4,7,5,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD,drugbank_drug|DB00087 8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,14,5,9,8,11,21,3,4,13,21,3,7,20,9,8,32,26,28,4,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD,drugbank_drug|DB00087 8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,14,5,9,8,11,21,3,4,13,21,3,7,20,9,8,32,26,28,4,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV,drugbank_drug|DB00087 1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,13,4,7,5,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD,drugbank_drug|DB00087 8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,14,5,9,8,11,21,3,4,13,21,3,7,20,9,8,32,26,28,4,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE,drugbank_drug|DB00087 1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,13,4,7,6,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV,drugbank_drug|DB00087 1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,13,4,7,5,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE,drugbank_drug|DB00087 1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,13,4,7,6,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVD,drugbank_drug|DB00087 8005_H|alemtuzumab|||H-GAMMA-1 (VH(1-121)+CH1(122-219)+HINGE-REGION(220-220)+CH2(221-330)+CH3(331-437))|||||||437||||MW 47976.2|MW 47976.2|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,14,5,9,8,11,21,3,4,13,21,3,7,20,9,8,32,26,28,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV,drugbank_drug|DB00087 1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,13,4,7,5,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE,drugbank_drug|DB00087 1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,13,4,7,6,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31358,CD52,CAMPATH-1 antigen,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA,drugbank_target|P31358 CAMPATH-1 antigen (DB00087),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGAAGCGCTTCCTCTTCCTCCTACTCACCATCAGCCTCCTGGTTATGGTACAGATACAAACTGGACTCTCAGGACAAAACGACACCAGCCAAACCAGCAGCCCCTCAGCATCCAGCAACATAAGCGGAGGCATTTTCCTTTTCTTCGTGGCCAATGCCATAATCCACCTCTTCTGCTTCAGTTGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV,drugbank_drug|DB00087 1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,13,4,7,5,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL,drugbank_drug|DB00087 1CE1:H CAMPATH-1H:Heavy Chain 1,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,14,7,9,7,11,21,4,3,15,21,2,7,23,9,7,32,26,24,4,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV,drugbank_drug|DB00087 1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,13,4,7,5,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 8005_L|alemtuzumab|||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1ce1_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-211))|||||||211||||MW 23282.0|MW 23282.0|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV,drugbank_drug|DB00087 1bey_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-210))|||||||219||||MW 23397.3|MW 23397.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,13,4,7,5,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGFTFTDFYMNWVRQPPGRGLEWIGFIRDKAKGYTTEYNPSVKGRVTMLVDTSKNQFSLRLSSVTAADTAVYYCAREGHTAAPFDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE,drugbank_drug|DB00087 1ce1_H|CAMPATH-1H|Humanized||VH-CH1 (VH(1-121)+CH1(122-219))|||||||220||||MW 23526.4|MW 23526.4|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,13,4,7,6,9,19,3,3,11,17,2,7,14,9,7,30,23,23,4,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00087 1CE1:L CAMPATH-1H:Light Chain 2,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,11,4,10,8,8,11,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00087,Alemtuzumab,BiotechDrug,46507379.0,http://www.drugs.com/cdi/alemtuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQNIDKYLNWYQQKPGKAPKLLIYNTNNLQTGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCLQHISRPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00087 1bey_L|CAMPATH-1H|Humanized||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(108-214))|||||||214||||MW 23571.3|MW 23571.3|,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,11,5,10,9,8,12,3,9,15,15,1,10,11,15,7,29,19,14,2,9,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00088,Alglucerase,BiotechDrug,46507500.0,http://www.drugs.com/cdi/alglucerase.html,ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEH,drugbank_drug|DB00088 DB00088 sequence,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,,,,,,,,22,6,10,11,15,19,6,10,12,27,4,9,20,12,10,20,18,9,4,11,
DB00090,Laronidase,BiotechDrug,46505612.0,http://www.drugs.com/cdi/laronidase.html,APHLVQVDAARALWPLRRFWRSTGFCPPLPHSQADQYVLSWDQQLNLAYVGAVPHRGIKQVRTHWLLELVTTRGSTGRGLSYNFTHLDGYLDLLRENQLLPGFELMGSASGHFTDFEDKQQVFEWKDLVSSLARRYIGRYGLAHVSKWNFETWNEPDHHDFDNVSMTMQGFLNYYDACSEGLRAASPALRLGGPGDSFHTPPRSPLSWGLLRHCHDGTNFFTGEAGVRLDYISLHRKGARSSISILEQEKVVAQQ,drugbank_drug|DB00090 DB00090 sequence,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,,,,,,,,17,3,15,11,13,22,13,5,6,31,3,8,13,13,19,20,12,14,8,9,
DB00092,Alefacept,BiotechDrug,46505772.0,http://www.drugs.com/cdi/alefacept.html,CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP,drugbank_drug|DB00092 Alefacept heavy chain,"Antipsoriatics, Systemic",80,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,6,12,10,15,11,9,6,16,14,23,7,15,21,7,9,26,20,15,2,11,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00092,Alefacept,BiotechDrug,46505772.0,http://www.drugs.com/cdi/alefacept.html,MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN,drugbank_drug|DB00092 Alefacept light chain,"Antipsoriatics, Systemic",80,-1,-1,-1,-1,-1,-1,P06729,CD2,T-cell surface antigen CD2,ATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGACATCAACTTGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAAACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAGATACATATAAG,drugbank_target|P06729 T-cell surface antigen CD2 (DB00092; DB06371),BiotechDrug,Humans,8,11,10,13,11,11,6,17,12,24,8,15,13,7,9,27,18,17,2,11,ATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGACATCAACTTGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAAACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAGATACATATAAG
DB00092,Alefacept,BiotechDrug,46505772.0,http://www.drugs.com/cdi/alefacept.html,MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN,drugbank_drug|DB00092 Alefacept light chain,"Antipsoriatics, Systemic",80,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,8,11,10,13,11,11,6,17,12,24,8,15,13,7,9,27,18,17,2,11,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00092,Alefacept,BiotechDrug,46505772.0,http://www.drugs.com/cdi/alefacept.html,CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP,drugbank_drug|DB00092 Alefacept heavy chain,"Antipsoriatics, Systemic",80,-1,-1,-1,-1,-1,-1,P06729,CD2,T-cell surface antigen CD2,ATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGACATCAACTTGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAAACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAGATACATATAAG,drugbank_target|P06729 T-cell surface antigen CD2 (DB00092; DB06371),BiotechDrug,Humans,6,12,10,15,11,9,6,16,14,23,7,15,21,7,9,26,20,15,2,11,ATGAGCTTTCCATGTAAATTTGTAGCCAGCTTCCTTCTGATTTTCAATGTTTCTTCCAAAGGTGCAGTCTCCAAAGAGATTACGAATGCCTTGGAAACCTGGGGTGCCTTGGGTCAGGACATCAACTTGGACATTCCTAGTTTTCAAATGAGTGATGATATTGACGATATAAAATGGGAAAAAACTTCAGACAAGAAAAAGATTGCACAATTCAGAAAAGAGAAAGAGACTTTCAAGGAAAAAGATACATATAAG
DB00092,Alefacept,BiotechDrug,46505772.0,http://www.drugs.com/cdi/alefacept.html,MVAGSDAGRALGVLSVVCLLHCFGFISCFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSN,drugbank_drug|DB00092 Alefacept light chain,"Antipsoriatics, Systemic",80,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,8,11,10,13,11,11,6,17,12,24,8,15,13,7,9,27,18,17,2,11,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00092,Alefacept,BiotechDrug,46505772.0,http://www.drugs.com/cdi/alefacept.html,CFSQQIYGVVYGNVTFHVPSNVPLKEVLWKKQKDKVAELENSEFRAFSSFKNRVYLDTVSGSLTIYNLTSSDEDEYEMESPNITDTMKFFLYVLESLPSPTLTCALTNGSIEVQCMIPEHYNSHRGLIMYSWDCPMEQCKRNSTSIYFKMENDLPQKIQCTLSNPLFNTTSSIILTTCIPSSGHSRHRYALIPIPLAVITTCIVLYMNGILKCDRKPDRTNSNRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP,drugbank_drug|DB00092 Alefacept heavy chain,"Antipsoriatics, Systemic",80,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,6,12,10,15,11,9,6,16,14,23,7,15,21,7,9,26,20,15,2,11,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00094,Urofollitropin,BiotechDrug,46507385.0,http://www.drugs.com/cdi/urofollitropin-purified.html,APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS,drugbank_drug|DB00094 Alpha chain,Ovulation Stimulators,338,-1,-1,-1,-1,-1,-1,P23945,FSHR,Follicle-stimulating hormone receptor,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG,drugbank_target|P23945 Follicle-stimulating hormone receptor (DB00032; DB00066; DB00094; DB00097; DB04786; DB09066),BiotechDrug,Humans,5,10,2,4,4,4,3,1,6,4,3,4,7,5,3,8,8,7,0,4,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG
DB00094,Urofollitropin,BiotechDrug,46507385.0,http://www.drugs.com/cdi/urofollitropin-purified.html,NSCELTNITIAIEKEECRFCISINTTWCAGYCYTRDLVYKDPARPKIQKTCTFKELVYETVRVPGCAHHADSLYTYPVATQCHCGKCDSDSTDCTVRGLGPSYCSFGEMKE,drugbank_drug|DB00094 Beta chain,Ovulation Stimulators,338,-1,-1,-1,-1,-1,-1,P23945,FSHR,Follicle-stimulating hormone receptor,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG,drugbank_target|P23945 Follicle-stimulating hormone receptor (DB00032; DB00066; DB00094; DB00097; DB04786; DB09066),BiotechDrug,Humans,6,12,6,8,3,6,3,6,7,5,1,3,5,2,5,7,12,6,1,7,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG
DB00095,Efalizumab,BiotechDrug,46505252.0,http://www.drugs.com/cdi/efalizumab.html,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR,drugbank_drug|DB00095 Light Chain Variable Region,Immunosuppressants,446,-1,-1,-1,-1,-1,-1,P20701,ITGAL,Integrin alpha-L,ATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTCGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGCGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCTCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGCCTGCCAGTCACCCTG,drugbank_target|P20701 Integrin alpha-L (DB00095; DB00098; DB00227; DB00641; DB01098; DB02177; DB03932; DB04724; DB06972; DB07486; DB08860; DB11611),BiotechDrug,Humans,5,2,4,3,4,9,1,6,7,8,1,1,6,9,4,16,11,4,1,5,ATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTCGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGCGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCTCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGCCTGCCAGTCACCCTG
DB00095,Efalizumab,BiotechDrug,46505252.0,http://www.drugs.com/cdi/efalizumab.html,DIQMTQSPSSLSASVGDRVTITCRASKTISKYLAWXQQKPGKAPKLLIYSGSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQHNEYPLTFGQGTKVEIKR,drugbank_drug|DB00095 Light Chain Variable Region,Immunosuppressants,446,-1,-1,-1,-1,-1,-1,P20702,ITGAX,Integrin alpha-X,ATGACCAGGACCAGGGCAGCACTCCTCCTGTTCACAGCCTTAGCAACTTCTCTAGGTTTCAACTTGGACACAGAGGAGCTGACAGCCTTCCGTGTGGACAGCGCTGGGTTTGGAGACAGCGTGGTCCAGTATGCCAACTCCTGGGTGGTGGTTGGAGCCCCCCAAAAGATAACAGCTGCCAACCAAACGGGTGGCCTCTACCAGTGTGGCTACAGCACTGGTGCCTGTGAGCCCATCGGCCTGCAGGTGCCCCCG,drugbank_target|P20702 Integrin alpha-X (DB00095),BiotechDrug,Humans,5,2,4,3,4,9,1,6,7,8,1,1,6,9,4,16,11,4,1,5,ATGACCAGGACCAGGGCAGCACTCCTCCTGTTCACAGCCTTAGCAACTTCTCTAGGTTTCAACTTGGACACAGAGGAGCTGACAGCCTTCCGTGTGGACAGCGCTGGGTTTGGAGACAGCGTGGTCCAGTATGCCAACTCCTGGGTGGTGGTTGGAGCCCCCCAAAAGATAACAGCTGCCAACCAAACGGGTGGCCTCTACCAGTGTGGCTACAGCACTGGTGCCTGTGAGCCCATCGGCCTGCAGGTGCCCCCG
DB00095,Efalizumab,BiotechDrug,46505252.0,http://www.drugs.com/cdi/efalizumab.html,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS,drugbank_drug|DB00095 Heavy Chain Variable Region,Immunosuppressants,446,-1,-1,-1,-1,-1,-1,P20701,ITGAL,Integrin alpha-L,ATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTCGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGCGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCTCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGCCTGCCAGTCACCCTG,drugbank_target|P20701 Integrin alpha-L (DB00095; DB00098; DB00227; DB00641; DB01098; DB02177; DB03932; DB04724; DB06972; DB07486; DB08860; DB11611),BiotechDrug,Humans,6,2,5,5,5,14,2,7,5,9,3,4,3,6,6,12,9,9,4,9,ATGAAGGATTCCTGCATCACTGTGATGGCCATGGCGCTGCTGTCTGGGTTCTTTTTCTTCGCGCCGGCCTCGAGCTACAACCTGGACGTGCGGGGCGCGCGGAGCTTCTCCCCACCGCGCGCCGGGAGGCACTTTGGATACCGCGTCCTGCAGGTCGGAAACGGGGTCATCGTGGGAGCTCCAGGGGAGGGGAACAGCACAGGAAGCCTCTATCAGTGCCAGTCGGGCACAGGACACTGCCTGCCAGTCACCCTG
DB00095,Efalizumab,BiotechDrug,46505252.0,http://www.drugs.com/cdi/efalizumab.html,EVQLVESGGGLVQPGGSLRLSCAASGYSFTGHWMNWVRQAPGKGLEWVGIMIHPSDSETRYNQKFKDIRFTISVDKSKNTLYLQMNSLRAEDTAVYYCARIGIYFYGTTYFDYIWGQGTLVTVSS,drugbank_drug|DB00095 Heavy Chain Variable Region,Immunosuppressants,446,-1,-1,-1,-1,-1,-1,P20702,ITGAX,Integrin alpha-X,ATGACCAGGACCAGGGCAGCACTCCTCCTGTTCACAGCCTTAGCAACTTCTCTAGGTTTCAACTTGGACACAGAGGAGCTGACAGCCTTCCGTGTGGACAGCGCTGGGTTTGGAGACAGCGTGGTCCAGTATGCCAACTCCTGGGTGGTGGTTGGAGCCCCCCAAAAGATAACAGCTGCCAACCAAACGGGTGGCCTCTACCAGTGTGGCTACAGCACTGGTGCCTGTGAGCCCATCGGCCTGCAGGTGCCCCCG,drugbank_target|P20702 Integrin alpha-X (DB00095),BiotechDrug,Humans,6,2,5,5,5,14,2,7,5,9,3,4,3,6,6,12,9,9,4,9,ATGACCAGGACCAGGGCAGCACTCCTCCTGTTCACAGCCTTAGCAACTTCTCTAGGTTTCAACTTGGACACAGAGGAGCTGACAGCCTTCCGTGTGGACAGCGCTGGGTTTGGAGACAGCGTGGTCCAGTATGCCAACTCCTGGGTGGTGGTTGGAGCCCCCCAAAAGATAACAGCTGCCAACCAAACGGGTGGCCTCTACCAGTGTGGCTACAGCACTGGTGCCTGTGAGCCCATCGGCCTGCAGGTGCCCCCG
DB00097,Choriogonadotropin alfa,BiotechDrug,46506863.0,http://www.drugs.com/cdi/choriogonadotropin-alfa.html,SKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ,drugbank_drug|DB00097 Beta chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P23945,FSHR,Follicle-stimulating hormone receptor,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG,drugbank_target|P23945 Follicle-stimulating hormone receptor (DB00032; DB00066; DB00094; DB00097; DB04786; DB09066),BiotechDrug,Humans,8,12,7,4,2,8,1,5,4,12,1,4,22,5,12,13,10,12,0,3,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG
DB00097,Choriogonadotropin alfa,BiotechDrug,46506863.0,http://www.drugs.com/cdi/choriogonadotropin-alfa.html,SKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ,drugbank_drug|DB00097 Beta chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P22888,LHCGR,Lutropin-choriogonadotropic hormone receptor,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC,drugbank_target|P22888 Lutropin-choriogonadotropic hormone receptor (DB00014; DB00032; DB00044; DB00050; DB00097; DB06719; DB09126),BiotechDrug,Humans,8,12,7,4,2,8,1,5,4,12,1,4,22,5,12,13,10,12,0,3,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC
DB00097,Choriogonadotropin alfa,BiotechDrug,46506863.0,http://www.drugs.com/cdi/choriogonadotropin-alfa.html,APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS,drugbank_drug|DB00097 Alpha chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P23945,FSHR,Follicle-stimulating hormone receptor,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG,drugbank_target|P23945 Follicle-stimulating hormone receptor (DB00032; DB00066; DB00094; DB00097; DB04786; DB09066),BiotechDrug,Humans,5,10,2,4,4,4,3,1,6,4,3,4,7,5,3,8,8,7,0,4,ATGGCCCTGCTCCTGGTCTCTTTGCTGGCATTCCTGAGCTTGGGCTCAGGATGTCATCATCGGATCTGTCACTGCTCTAACAGGGTTTTTCTCTGCCAAGAGAGCAAGGTGACAGAGATTCCTTCTGACCTCCCGAGGAATGCCATTGAACTGAGGTTTGTCCTCACCAAGCTTCGAGTCATCCAAAAAGGTGCATTTTCAGGATTTGGGGACCTGGAGAAAATAGAGATCTCTCAGAATGATGTCTTGGAGGTG
DB00097,Choriogonadotropin alfa,BiotechDrug,46506863.0,http://www.drugs.com/cdi/choriogonadotropin-alfa.html,APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS,drugbank_drug|DB00097 Alpha chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P22888,LHCGR,Lutropin-choriogonadotropic hormone receptor,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC,drugbank_target|P22888 Lutropin-choriogonadotropic hormone receptor (DB00014; DB00032; DB00044; DB00050; DB00097; DB06719; DB09126),BiotechDrug,Humans,5,10,2,4,4,4,3,1,6,4,3,4,7,5,3,8,8,7,0,4,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC
DB00100,Coagulation Factor IX (Recombinant),BiotechDrug,46508858.0,http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIP,drugbank_drug|DB00100 DB00100 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P00734,F2,Prothrombin,ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGCCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGGGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGCGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACGGATGTGTTCTGGGCC,drugbank_target|P00734 Prothrombin (DB00001; DB00006; DB00055; DB00100; DB00170; DB00278; DB01123; DB01225; DB01593; DB01725; DB01766; DB01767; DB02287; DB02723; DB03136; DB03159; DB03847; DB03865; DB04136; DB04591; DB04697; DB04722; DB04771; DB04772; DB0,BiotechDrug,Humans,12,17,12,31,13,18,3,11,15,8,1,19,9,11,10,15,17,24,4,5,ATGGCGCACGTCCGAGGCTTGCAGCTGCCTGGCTGCCTGGCCCTGGCTGCCCTGTGTAGCCTTGTGCACAGCCAGCATGTGTTCCTGGCTCCTCAGCAAGCACGGTCGCTGCTCCAGCGGGTCCGGCGAGCCAACACCTTCTTGGAGGAGGTGCGCAAGGGCAACCTGGAGCGAGAGTGCGTGGAGGAGACGTGCAGCTACGAGGAGGCCTTCGAGGCTCTGGAGTCCTCCACGGCTACGGATGTGTTCTGGGCC
DB00100,Coagulation Factor IX (Recombinant),BiotechDrug,46508858.0,http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIP,drugbank_drug|DB00100 DB00100 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P00451,F8,Coagulation factor VIII,ATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCCACCAGAAGATACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTCGGTGAGCTGCCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAACACCTCAGTCGTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATCGCTAAGCCAAGGCCA,drugbank_target|P00451 Coagulation factor VIII (DB00055; DB00100; DB06050; DB11300; DB11312; DB11571; DB11572; DB12872; DB13133; DB13151; DB13152; DB13933; DB14700; DB16007),BiotechDrug,Humans,12,17,12,31,13,18,3,11,15,8,1,19,9,11,10,15,17,24,4,5,ATGCAAATAGAGCTCTCCACCTGCTTCTTTCTGTGCCTTTTGCGATTCTGCTTTAGTGCCACCAGAAGATACTACCTGGGTGCAGTGGAACTGTCATGGGACTATATGCAAAGTGATCTCGGTGAGCTGCCTGTGGACGCAAGATTTCCTCCTAGAGTGCCAAAATCTTTTCCATTCAACACCTCAGTCGTGTACAAAAAGACTCTGTTTGTAGAATTCACGGATCACCTTTTCAACATCGCTAAGCCAAGGCCA
DB00100,Coagulation Factor IX (Recombinant),BiotechDrug,46508858.0,http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIP,drugbank_drug|DB00100 DB00100 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P08709,F7,Coagulation factor VII,ATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGGCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGCGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAGCAGTGCTCCTTCGAG,drugbank_target|P08709 Coagulation factor VII (DB00036; DB00100; DB04590; DB04593; DB04606; DB04758; DB04767; DB06552; DB07207; DB07247; DB07376; DB08232; DB09332; DB13151; DB13152; DB13933),BiotechDrug,Humans,12,17,12,31,13,18,3,11,15,8,1,19,9,11,10,15,17,24,4,5,ATGGTCTCCCAGGCCCTCAGGCTCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCCTGGCTGCAGGCGGGGTCGCTAAGGCCTCAGGAGGAGAAACACGGGACATGCCGTGGAAGCCGGGGCCTCACAGAGTCTTCGTAACCCAGGAGGAAGCCCACGGCGTCCTGCACCGGCGCCGGCGCGCCAACGCGTTCCTGGAGGAGCTGCGGCCGGGCTCCCTGGAGAGGGAGTGCAAGGAGGAGCAGTGCTCCTTCGAG
DB00100,Coagulation Factor IX (Recombinant),BiotechDrug,46508858.0,http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIP,drugbank_drug|DB00100 DB00100 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,Q07954,LRP1,Prolow-density lipoprotein receptor-related protein 1,ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCTATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGTATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCCCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTGGGTACTGAGCTGTGT,drugbank_target|Q07954 Prolow-density lipoprotein receptor-related protein 1 (DB00025; DB00031; DB00100; DB06245; DB13133; DB13152; DB13998; DB13999),BiotechDrug,Humans,12,17,12,31,13,18,3,11,15,8,1,19,9,11,10,15,17,24,4,5,ATGCTGACCCCGCCGTTGCTCCTGCTGCTGCCCCTGCTCTCAGCTCTGGTCGCGGCGGCTATCGACGCCCCTAAGACTTGCAGCCCCAAGCAGTTTGCCTGCAGAGATCAAATAACCTGTATCTCAAAGGGCTGGCGGTGCGACGGTGAGAGGGACTGCCCAGACGGATCTGACGAGGCCCCTGAGATTTGTCCACAGAGTAAGGCCCAGCGATGCCAGCCAAACGAGCATAACTGCCTGGGTACTGAGCTGTGT
DB00100,Coagulation Factor IX (Recombinant),BiotechDrug,46508858.0,http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIP,drugbank_drug|DB00100 DB00100 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P03951,F11,Coagulation factor XI,ATGATTTTCTTATATCAAGTGGTACATTTCATTTTATTTACTTCAGTTTCTGGTGAATGTGTGACTCAGTTGTTGAAGGACACCTGCTTTGAAGGAGGGGACATTACTACGGTCTTCACACCAAGCGCCAAGTACTGCCAGGTAGTCTGCACTTACCACCCAAGATGTTTACTCTTCACTTTCACGGCGGAATCACCATCTGAGGATCCCACCCGATGGTTTACTTGTGTCCTGAAAGACAGTGTTACAGAAACA,drugbank_target|P03951 Coagulation factor XI (DB00100; DB06404; DB07022; DB07023; DB07071; DB07074; DB07077; DB07212; DB07299; DB07887; DB09228; DB11300; DB11571; DB13152; DB14533; DB14548),BiotechDrug,Humans,12,17,12,31,13,18,3,11,15,8,1,19,9,11,10,15,17,24,4,5,ATGATTTTCTTATATCAAGTGGTACATTTCATTTTATTTACTTCAGTTTCTGGTGAATGTGTGACTCAGTTGTTGAAGGACACCTGCTTTGAAGGAGGGGACATTACTACGGTCTTCACACCAAGCGCCAAGTACTGCCAGGTAGTCTGCACTTACCACCCAAGATGTTTACTCTTCACTTTCACGGCGGAATCACCATCTGAGGATCCCACCCGATGGTTTACTTGTGTCCTGAAAGACAGTGTTACAGAAACA
DB00100,Coagulation Factor IX (Recombinant),BiotechDrug,46508858.0,http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIP,drugbank_drug|DB00100 DB00100 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P00742,F10,Coagulation factor X,ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAA,drugbank_target|P00742 Coagulation factor X (DB00025; DB00036; DB00100; DB00569; DB01109; DB01225; DB03847; DB04673; DB05362; DB05713; DB06228; DB06245; DB06406; DB06552; DB06605; DB06635; DB06920; DB07211; DB07261; DB07277; DB07278; DB07605; DB07629; DB0,BiotechDrug,Humans,12,17,12,31,13,18,3,11,15,8,1,19,9,11,10,15,17,24,4,5,ATGGGGCGCCCACTGCACCTCGTCCTGCTCAGTGCCTCCCTGGCTGGCCTCCTGCTGCTCGGGGAAAGTCTGTTCATCCGCAGGGAGCAGGCCAACAACATCCTGGCGAGGGTCACGAGGGCCAATTCCTTTCTTGAAGAGATGAAGAAAGGACACCTCGAAAGAGAGTGCATGGAAGAGACCTGCTCATACGAAGAGGCCCGCGAGGTCTTTGAGGACAGCGACAAGACGAATGAATTCTGGAATAAATACAAA
DB00100,Coagulation Factor IX (Recombinant),BiotechDrug,46508858.0,http://www.drugs.com/cdi/coagulation-factor-ix-injection-human.html,YNSGKLEEFVQGNLERECMEEKCSFEEAREVFENTERTTEFWKQYVDGDQCESNPCLNGGSCKDDINSYECWCPFGFEGKNCELDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTRAEAVFPDVDYVNSTEAETILDNITQSTQSFNDFTRVVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIP,drugbank_drug|DB00100 DB00100 sequence,"Coagulation Factors, Hemostatics",83,-1,-1,-1,-1,-1,-1,P38435,GGCX,Vitamin K-dependent gamma-carboxylase,ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGACAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTTGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGACCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCCCAGGAGCGGGGGCTC,drugbank_target|P38435 Vitamin K-dependent gamma-carboxylase (DB00036; DB00100; DB00142; DB00170; DB01022; DB01125; DB09332; DB13152),BiotechDrug,Humans,12,17,12,31,13,18,3,11,15,8,1,19,9,11,10,15,17,24,4,5,ATGGCGGTGTCTGCCGGGTCCGCGCGGACCTCGCCCAGCTCAGATAAAGTACAGAAAGACAAGGCTGAACTGATCTCAGGGCCCAGGCAGGACAGCCGAATAGGGAAACTCTTGGGTTTTGAGTGGACAGATTTGTCCAGTTGGCGGAGGCTGGTGACCCTGCTGAATCGACCAACGGACCCTGCAAGCTTAGCTGTCTTTCGTTTTCTTTTTGGGTTCTTGATGGTGCTAGACATTCCCCAGGAGCGGGGGCTC
DB00102,Becaplermin,BiotechDrug,46508246.0,http://www.drugs.com/cdi/becaplermin.html,SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT,drugbank_drug|DB00102 DB00102 sequence,"Metabolic & Endocrine, Other",153,-1,-1,-1,-1,-1,-1,P01023,A2M,Alpha-2-macroglobulin,ATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCCACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCACACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAGAATGACGTACTCCAC,drugbank_target|P01023 Alpha-2-macroglobulin (DB00102; DB00515; DB00626; DB01593; DB08888; DB12965; DB14487; DB14533; DB14548; DB17449),BiotechDrug,Humans,9,8,2,8,3,2,1,7,7,7,1,5,7,5,11,4,9,12,1,0,ATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCCACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCACACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAGAATGACGTACTCCAC
DB00102,Becaplermin,BiotechDrug,46508246.0,http://www.drugs.com/cdi/becaplermin.html,SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT,drugbank_drug|DB00102 DB00102 sequence,"Metabolic & Endocrine, Other",153,-1,-1,-1,-1,-1,-1,P16234,PDGFRA,Platelet-derived growth factor receptor alpha,ATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAGGGCTGAGCCTAATCCTCTGCCAGCTTTCATTACCCTCTATCCTTCCAAATGAAAATGAAAAGGTTGTGCAGCTGAATTCATCCTTTTCTCTGAGATGCTTTGGGGAGAGTGAAGTGAGCTGGCAGTACCCCATGTCTGAAGAAGAGAGCTCCGATGTGGAAATCAGAAATGAAGAAAACAACAGCGGCCTTTTTGTGACGGTCTTG,drugbank_target|P16234 Platelet-derived growth factor receptor alpha (DB00102; DB00619; DB01268; DB05146; DB06043; DB06589; DB06595; DB08896; DB08901; DB09078; DB09079; DB10772; DB11800; DB12010; DB12147; DB12742; DB14840),BiotechDrug,Humans,9,8,2,8,3,2,1,7,7,7,1,5,7,5,11,4,9,12,1,0,ATGGGGACTTCCCATCCGGCGTTCCTGGTCTTAGGCTGTCTTCTCACAGGGCTGAGCCTAATCCTCTGCCAGCTTTCATTACCCTCTATCCTTCCAAATGAAAATGAAAAGGTTGTGCAGCTGAATTCATCCTTTTCTCTGAGATGCTTTGGGGAGAGTGAAGTGAGCTGGCAGTACCCCATGTCTGAAGAAGAGAGCTCCGATGTGGAAATCAGAAATGAAGAAAACAACAGCGGCCTTTTTGTGACGGTCTTG
DB00102,Becaplermin,BiotechDrug,46508246.0,http://www.drugs.com/cdi/becaplermin.html,SLGSLTIAEPAMIAECKTRTEVFEISRRLIDRTNANFLVWPPCVEVQRCSGCCNNRNVQCRPTQVQLRPVQVRKIEIVRKKPIFKKATVTLEDHLACKCETVAAARPVT,drugbank_drug|DB00102 DB00102 sequence,"Metabolic & Endocrine, Other",153,-1,-1,-1,-1,-1,-1,P09619,PDGFRB,Platelet-derived growth factor receptor beta,ATGCGGCTTCCGGGTGCGATGCCAGCTCTGGCCCTCAAAGGCGAGCTGCTGTTGCTGTCTCTCCTGTTACTTCTGGAACCACAGATCTCTCAGGGCCTGGTCGTCACACCCCCGGGGCCAGAGCTTGTCCTCAATGTCTCCAGCACCTTCGTTCTGACCTGCTCGGGTTCAGCTCCGGTGGTGTGGGAACGGATGTCCCAGGAGCCCCCACAGGAAATGGCCAAGGCCCAGGATGGCACCTTCTCCAGCGTGCTC,drugbank_target|P09619 Platelet-derived growth factor receptor beta (DB00102; DB00398; DB00619; DB01254; DB01268; DB05014; DB05146; DB06589; DB06595; DB08896; DB09079; DB09221; DB09283; DB10770; DB11800; DB12010; DB12147; DB12978; DB14840; DB15822),BiotechDrug,Humans,9,8,2,8,3,2,1,7,7,7,1,5,7,5,11,4,9,12,1,0,ATGCGGCTTCCGGGTGCGATGCCAGCTCTGGCCCTCAAAGGCGAGCTGCTGTTGCTGTCTCTCCTGTTACTTCTGGAACCACAGATCTCTCAGGGCCTGGTCGTCACACCCCCGGGGCCAGAGCTTGTCCTCAATGTCTCCAGCACCTTCGTTCTGACCTGCTCGGGTTCAGCTCCGGTGGTGTGGGAACGGATGTCCCAGGAGCCCCCACAGGAAATGGCCAAGGCCCAGGATGGCACCTTCTCCAGCGTGCTC
DB00103,Agalsidase beta,BiotechDrug,46508538.0,http://www.drugs.com/cdi/agalsidase-beta.html,LDNGLARTPTMGWLHWERFMCNLDCQEEPDSCISEKLFMEMAELMVSEGWKDAGYEYLCIDDCWMAPQRDSEGRLQADPQRFPHGIRQLANYVHSKGLKLGIYADVGNKTCAGFPGSFGYYDIDAQTFADWGVDLLKFDGCYCDSLENLADGYKHMSLALNRTGRSIVYSCEWPLYMWPFQKPNYTEIRQYCNHWRNFADIDDSWKSIKSILDWTSFNQERIVDVAGPGGWNDPDMLVIGNFGLSWNQQVTQMAL,drugbank_drug|DB00103 DB00103 sequence,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,,,,,,,,15,10,23,13,11,21,5,12,10,22,10,13,11,12,11,15,8,9,12,12,
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P48551,IFNAR2,Interferon alpha/beta receptor 2,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT,drugbank_target|P48551 Interferon alpha/beta receptor 2 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05472; DB06152),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGCTTTTGAGCCAGAATGCCTTCATCTTCAGATCACTTAATTTGGTTCTCATGGTGTATATCAGCCTCGTGTTTGGTATTTCATATGATTCGCCTGATTACACAGATGAATCTTGCACTTTCAAGATATCATTGCGAAATTTCCGGTCCATCTTATCATGGGAATTAAAAAACCACTCCATTGTACCAACTCACTATACATTGCTGTATACAATCATGAGTAAACCAGAAGATTTGAAGGTGGTTAAGAACTGT
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00105,Interferon alfa-2b,BiotechDrug,46507075.0,,CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVRKYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE,drugbank_drug|DB00105 DB00105 sequence,"Biological Response Modifiers, Hepatitis B Hepatitis C Agents",472,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,8,4,8,14,10,5,3,8,9,21,5,5,5,12,10,14,10,7,2,5,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P05362,ICAM1,Intercellular adhesion molecule 1,ATGGCTCCCAGCAGCCCCCGGCCCGCGCTGCCCGCACTCCTGGTCCTGCTCGGGGCTCTGTTCCCAGGACCTGGCAATGCCCAGACATCTGTGTCCCCCTCAAAAGTCATCCTGCCCCGGGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTTGTTGGGCATAGAGACCCCGTTGCCTAAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAAGGTGTATGAACTGAGCAATGTGCAA,drugbank_target|P05362 Intercellular adhesion molecule 1 (DB00108; DB08818; DB12598),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTCCCAGCAGCCCCCGGCCCGCGCTGCCCGCACTCCTGGTCCTGCTCGGGGCTCTGTTCCCAGGACCTGGCAATGCCCAGACATCTGTGTCCCCCTCAAAAGTCATCCTGCCCCGGGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTTGTTGGGCATAGAGACCCCGTTGCCTAAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAAGGTGTATGAACTGAGCAATGTGCAA
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P05362,ICAM1,Intercellular adhesion molecule 1,ATGGCTCCCAGCAGCCCCCGGCCCGCGCTGCCCGCACTCCTGGTCCTGCTCGGGGCTCTGTTCCCAGGACCTGGCAATGCCCAGACATCTGTGTCCCCCTCAAAAGTCATCCTGCCCCGGGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTTGTTGGGCATAGAGACCCCGTTGCCTAAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAAGGTGTATGAACTGAGCAATGTGCAA,drugbank_target|P05362 Intercellular adhesion molecule 1 (DB00108; DB08818; DB12598),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTCCCAGCAGCCCCCGGCCCGCGCTGCCCGCACTCCTGGTCCTGCTCGGGGCTCTGTTCCCAGGACCTGGCAATGCCCAGACATCTGTGTCCCCCTCAAAAGTCATCCTGCCCCGGGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTTGTTGGGCATAGAGACCCCGTTGCCTAAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAAGGTGTATGAACTGAGCAATGTGCAA
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,QVQLVQSGAEVKKPGASVKVSCKASGFNIKDTYIHWVRQAPGQRLEWMGRIDPANGYTKYDPKFQGRVTITADTSASTAYMELSSLRSEDTAVYYCAREGYYGNYGVYAMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLM,drugbank_drug|DB00108 Heavy chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,18,7,10,9,8,21,3,4,16,16,4,6,21,8,8,32,21,24,4,15,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00108,Natalizumab,BiotechDrug,46505849.0,http://www.drugs.com/cdi/natalizumab.html,DIQMTQSPSSLSASVGDRVTITCKTSQDINKYMAWYQQTPGKAPRLLIHYTSALQPGIPSRFSGSGSGRDYTFTISSLQPEDIATYYCLQYDNLWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB00108 Light chain,"Inflammatory Bowel Disease Agents, Monoclonal Antibodies, Integrin Blockers",202,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,12,5,11,9,7,12,3,9,13,15,2,7,11,15,7,29,19,13,3,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB00109,Enfuvirtide,BiotechDrug,46506067.0,http://www.drugs.com/cdi/enfuvirtide.html,YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,drugbank_drug|DB00109 DB00109 sequence,"HIV, Fusion Inhibitors",199,-1,-1,-1,-1,-1,-1,Q53I07,gp41,Envelope glycoprotein,ATGGGCGCAGCGTCAATAACGCTGACGGTACAGACCAGACAATTATTGTCTGGGATAGCGCAACAGCAAAATAATTTGCTGAGGGCTATTGAGGCGCAACAACATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGGCTCTGGAAAGATACCTATGGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAAATCATTTGCACCACTGCTGTGCCTTGGAATACTTCTTGG,drugbank_target|Q53I07 Envelope glycoprotein (DB00109),BiotechDrug,Human immunodeficiency virus 1,1,0,1,6,1,0,1,2,2,6,0,3,0,4,0,4,1,0,3,1,ATGGGCGCAGCGTCAATAACGCTGACGGTACAGACCAGACAATTATTGTCTGGGATAGCGCAACAGCAAAATAATTTGCTGAGGGCTATTGAGGCGCAACAACATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCTCCAGGCAAGAGTCCTGGCTCTGGAAAGATACCTATGGGATCAACAGCTCCTGGGGATTTGGGGTTGCTCTGGAAAAATCATTTGCACCACTGCTGTGCCTTGGAATACTTCTTGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P00736,C1R,Complement C1r subcomponent,ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCCATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAACAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTCCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCTGATAAGAAAAGCCTG,drugbank_target|P00736 Complement C1r subcomponent (DB00110; DB00111; DB01593; DB06404; DB09228; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCCATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAACAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTCCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCTGATAAGAAAAGCCTG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P14784,IL2RB,Interleukin-2 receptor subunit beta,ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCTACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCGAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAAGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGTCAAGCATCCTGGGCC,drugbank_target|P14784 Interleukin-2 receptor subunit beta (DB00004; DB00041; DB00074; DB00111),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCTACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCGAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAAGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGTCAAGCATCCTGGGCC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P01589,IL2RA,Interleukin-2 receptor subunit alpha,ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAGGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCCTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGCGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGTCAATGCACAAGCTCT,drugbank_target|P01589 Interleukin-2 receptor subunit alpha (DB00004; DB00041; DB00074; DB00111; DB15628; DB16411),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAGGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCCTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGCGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGTCAATGCACAAGCTCT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P01589,IL2RA,Interleukin-2 receptor subunit alpha,ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAGGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCCTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGCGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGTCAATGCACAAGCTCT,drugbank_target|P01589 Interleukin-2 receptor subunit alpha (DB00004; DB00041; DB00074; DB00111; DB15628; DB16411),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGATTCATACCTGCTGATGTGGGGACTGCTCACGTTCATCATGGTGCCTGGCTGCCAGGCAGAGCTCTGTGACGATGACCCGCCAGAGATCCCACACGCCACATTCAAAGCCATGGCCTACAAGGAAGGAACCATGTTGAACTGTGAATGCAAGAGAGGTTTCCGCAGAATAAAAAGCGGGTCACTCTATATGCTCTGTACAGGAAACTCTAGCCACTCGTCCTGGGACAACCAATGTCAATGCACAAGCTCT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P14784,IL2RB,Interleukin-2 receptor subunit beta,ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCTACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCGAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAAGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGTCAAGCATCCTGGGCC,drugbank_target|P14784 Interleukin-2 receptor subunit beta (DB00004; DB00041; DB00074; DB00111),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGCGGCCCCTGCTCTGTCCTGGCGTCTGCCCCTCCTCATCCTCCTCCTGCCCCTGGCTACCTCTTGGGCATCTGCAGCGGTGAATGGCACTTCCCAGTTCACATGCTTCTACAACTCGAGAGCCAACATCTCCTGTGTCTGGAGCCAAGATGGGGCTCTGCAGGACACTTCCTGCCAAGTCCATGCCTGGCCGGACAGACGGCGGTGGAACCAAACCTGTGAGCTGCTCCCCGTGAGTCAAGCATCCTGGGCC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,O75015,FCGR3B,Low affinity immunoglobulin gamma Fc region receptor III-B,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA,drugbank_target|O75015 Low affinity immunoglobulin gamma Fc region receptor III-B (DB00002; DB00005; DB00028; DB00056; DB00075; DB00087; DB00092; DB00108; DB00110; DB00111; DB06607; DB11767),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGCGTGCTTGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGAGCCTACTCCCCTGAGGACAATTCCACACAGTGGTTTCACAATGAGAACCTCATCTCAAGCCAGGCCTCGAGCTACTTCATTGACGCTGCCACAGTCAACGACAGTGGA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,DIQMTQSPSTLSASVGDRVTITCSASSSISYMHWYQQKPGKAPKLLIYTTSNLASGVPARFSGSGSGTEFTLTISSLQPDDFATYYCHQRSTYPLTFGSGTKVEVKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB00111 Humanized Anti-CD25 Light Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,4,9,8,8,11,4,6,13,15,2,6,11,12,6,34,21,15,2,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P00736,C1R,Complement C1r subcomponent,ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCCATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAACAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTCCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCTGATAAGAAAAGCCTG,drugbank_target|P00736 Complement C1r subcomponent (DB00110; DB00111; DB01593; DB06404; DB09228; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGTGGCTCTTGTACCTCCTGGTGCCGGCCCTGTTCTGCAGGGCAGGAGGCTCCATTCCCATCCCTCAGAAGTTATTTGGGGAGGTGACTTCCCCTCTGTTCCCCAAGCCTTACCCCAACAACTTTGAAACAACCACTGTGATCACAGTCCCCACGGGATACAGGGTGAAGCTCGTCTTCCAGCAGTTTGACCTGGAGCCTTCTGAAGGCTGCTTCTATGATTATGTCAAGATCTCTGCTGATAAGAAAAGCCTG
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00111,Daclizumab,BiotechDrug,46504469.0,http://www.drugs.com/cdi/daclizumab.html,QVQLVQSGAEVKKPGSSVKVSCKASGYTFTSYRMHWVRQAPGQGLEWIGYINPSTGYTEYNQKFKDKATITADESTNTAYMELSSLRSEDTAVYYCARGGGVFDYWGQGTTLTVSSGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKAEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT,drugbank_drug|DB00111 Humanized Anti-CD25 Heavy Chain 1,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,15,7,8,10,8,22,4,5,17,17,3,7,21,9,5,33,26,22,4,12,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P15692,VEGFA,Vascular endothelial growth factor A,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG,drugbank_target|P15692 Vascular endothelial growth factor A (DB00112; DB01017; DB01120; DB01136; DB01270; DB03088; DB04895; DB05294; DB05434; DB05890; DB05932; DB05969; DB06642; DB06779; DB08885; DB09301; DB10772; DB12317; DB14864; DB15303),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P12318,FCGR2A,Low affinity immunoglobulin gamma Fc region receptor II-a,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC,drugbank_target|P12318 Low affinity immunoglobulin gamma Fc region receptor II-a (DB00002; DB00005; DB00028; DB00054; DB00087; DB00111; DB00112; DB06607; DB11767),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGACTATGGAGACCCAAATGTCTCAGAATGTATGTCCCAGAAACCTGTGGCTGCTTCAACCATTGACAGTTTTGCTGCTGCTGGCTTCTGCAGACAGTCAAGCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTTGAGCCCCCGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCAGGGGGCTCGCAGCCCTGAGAGCGACTCCATTCAGTGGTTCCACAATGGGAATCTCATTCCCACCCAC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P12314,FCGR1A,High affinity immunoglobulin gamma Fc receptor I,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC,drugbank_target|P12314 High affinity immunoglobulin gamma Fc receptor I (DB00002; DB00005; DB00028; DB00056; DB00087; DB00108; DB00110; DB00111; DB00112; DB00707; DB06607; DB11767; DB14962),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGTGGTTCTTGACAACTCTGCTCCTTTGGGTTCCAGTTGATGGGCAAGTGGACACCACAAAGGCAGTGATCACTTTGCAGCCTCCATGGGTCAGCGTGTTCCAAGAGGAAACCGTAACCTTGCACTGTGAGGTGCTCCATCTGCCTGGGAGCAGCTCTACACAGTGGTTTCTCAATGGCACAGCCACTCAGACCTCGACCCCCAGCTACAGAATCACCTCTGCCAGTGTCAATGACAGTGGTGAATACAGGTGC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P31994,FCGR2B,Low affinity immunoglobulin gamma Fc region receptor II-b,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC,drugbank_target|P31994 Low affinity immunoglobulin gamma Fc region receptor II-b (DB00005; DB00028; DB00054; DB00081; DB00087; DB00098; DB00110; DB00111; DB00112; DB11767),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAGGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCAGTGGTTCCAC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P15692,VEGFA,Vascular endothelial growth factor A,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG,drugbank_target|P15692 Vascular endothelial growth factor A (DB00112; DB01017; DB01120; DB01136; DB01270; DB03088; DB04895; DB05294; DB05434; DB05890; DB05932; DB05969; DB06642; DB06779; DB08885; DB09301; DB10772; DB12317; DB14864; DB15303),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00002; DB00110; DB00111; DB00112; DB01593; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P08637,FCGR3A,Low affinity immunoglobulin gamma Fc region receptor III-A,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA,drugbank_target|P08637 Low affinity immunoglobulin gamma Fc region receptor III-A (DB00002; DB00005; DB00028; DB00056; DB00087; DB00092; DB00110; DB00111; DB00112; DB06607; DB11767; DB12023; DB16695),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGGTGGAGGGGCTGGGGAAAGGCTGTTTACTTCCTCCTGTCTAGTCGGTTTGGTCCCTTTAGGGCTCCGGATATCTTTGGTGACTTGTCCACTCCAGTGTGGCATCATGTGGCAGCTGCTCCTCCCAACTGCTCTGCTACTTCTAGTTTCAGCTGGCATGCGGACTGAAGATCTCCCAAAGGCTGTGGTGTTCCTGGAGCCTCAATGGTACAGGGTGCTCGAGAAGGACAGTGTGACTCTGAAGTGCCAGGGA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02746,C1QB,Complement C1q subcomponent subunit B,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT,drugbank_target|P02746 Complement C1q subcomponent subunit B (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGATGATGAAGATCCCATGGGGCAGCATCCCAGTACTGATGTTGCTCCTGCTCCTGGGCCTAATCGATATCTCCCAGGCCCAGCTCAGCTGCACCGGGCCCCCAGCCATCCCTGGCATCCCGGGTATCCCTGGGACACCTGGCCCCGATGGCCAACCTGGGACCCCAGGGATAAAAGGAGAGAAAGGGCTTCCAGGGCTGGCTGGAGACCATGGTGAGTTCGGAGAGAAGGGAGACCCAGGGATTCCTGGGAAT
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P31995,FCGR2C,Low affinity immunoglobulin gamma Fc region receptor II-c,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC,drugbank_target|P31995 Low affinity immunoglobulin gamma Fc region receptor II-c (DB00005; DB00028; DB00087; DB00111; DB00112),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGGAATCCTGTCATTCTTACCTGTCCTTGCCACTGAGAGTGACTGGGCTGACTGCAAGTCCCCCCAGCCTTGGGGTCATATGCTTCTGTGGACAGCTGTGCTATTCCTGGCTCCTGTTGCTGGGACACCTGCAGCTCCCCCAAAGGCTGTGCTGAAACTCGAGCCCCAGTGGATCAACGTGCTCCAAGAGGACTCTGTGACTCTGACATGCCGGGGGACTCACAGCCCTGAGAGCGACTCCATTCCGTGGTTC
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00005),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,"drugbank_drug|DB00112 ""Bevacizumab light chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02747,C1QC,Complement C1q subcomponent subunit C,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG,drugbank_target|P02747 Complement C1q subcomponent subunit C (DB00002; DB00110; DB00111; DB00112; DB01593; DB09130; DB14487; DB14533; DB14548),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,14,1,7,11,15,5,34,19,16,3,10,ATGGACGTGGGGCCCAGCTCCCTGCCCCACCTTGGGCTGAAGCTGCTGCTGCTCCTGCTGCTGCTGCCCCTCAGGGGCCAAGCCAACACAGGCTGCTACGGGATCCCAGGGATGCCCGGCCTGCCCGGGGCACCAGGGAAGGATGGGTACGACGGACTGCCGGGGCCCAAGGGGGAGCCAGGAATCCCAGCCATTCCCGGGATCCGAGGACCCAAAGGGCAGAAGGGAGAACCCGGCTTACCCGGCCATCCTGGG
DB00112,Bevacizumab,BiotechDrug,46504473.0,http://www.drugs.com/cdi/bevacizumab-solution.html,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKD,"drugbank_drug|DB00112 ""Bevacizumab heavy chain""","Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P02745,C1QA,Complement C1q subcomponent subunit A,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA,drugbank_target|P02745 Complement C1q subcomponent subunit A (DB00002; DB00110; DB00111; DB00112),BiotechDrug,Humans,16,7,8,8,10,24,5,2,15,20,2,8,21,7,5,32,23,22,6,14,ATGGAGGGTCCCCGGGGATGGCTGGTGCTCTGTGTGCTGGCCATATCGCTGGCCTCTATGGTGACCGAGGACTTGTGCCGAGCACCAGACGGGAAGAAAGGGGAGGCAGGAAGACCTGGCAGACGGGGGCGGCCAGGCCTCAAGGGGGAGCAAGGGGAGCCGGGGGCCCCTGGCATCCGGACAGGCATCCAAGGCCTTAAAGGAGACCAGGGGGAACCTGGGCCCTCTGGAAACCCCGGCAAGGTGGGCTACCCA
DB01270,Ranibizumab,BiotechDrug,46506960.0,http://www.drugs.com/cdi/ranibizumab.html,EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL,drugbank_drug|DB01270 Ranibizumab Heavy Chain,"Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors",333,-1,-1,-1,-1,-1,-1,P15692,VEGFA,Vascular endothelial growth factor A,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG,drugbank_target|P15692 Vascular endothelial growth factor A (DB00112; DB01017; DB01120; DB01136; DB01270; DB03088; DB04895; DB05294; DB05434; DB05890; DB05932; DB05969; DB06642; DB06779; DB08885; DB09301; DB10772; DB12317; DB14864; DB15303),BiotechDrug,Humans,15,5,8,7,8,22,5,2,13,18,2,7,13,7,5,30,22,21,6,15,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG
DB01270,Ranibizumab,BiotechDrug,46506960.0,http://www.drugs.com/cdi/ranibizumab.html,DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB01270 Ranibizumab Light Chain,"Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors",333,-1,-1,-1,-1,-1,-1,P15692,VEGFA,Vascular endothelial growth factor A,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG,drugbank_target|P15692 Vascular endothelial growth factor A (DB00112; DB01017; DB01120; DB01136; DB01270; DB03088; DB04895; DB05294; DB05434; DB05890; DB05932; DB05969; DB06642; DB06779; DB08885; DB09301; DB10772; DB12317; DB14864; DB15303),BiotechDrug,Humans,11,5,10,9,9,12,3,7,13,15,0,7,11,15,5,34,19,16,3,10,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG
DB01272,Alglucosidase alfa,BiotechDrug,46504595.0,http://www.drugs.com/cdi/alglucosidase-alfa.html,AHPGRPRAVPTQCDVPPNSRFDCAPDKAITQEQCEARGCCYIPAKQGLQGAQMGQPWCFFPPSYPSYKLENLSSSEMGYTATLTRTTPTFFPKDILTLRLDVMMETENRLHFTIKDPANRRYEVPLETPHVHSRAPSPLYSVEFSEEPFGVIVRRQLDGRVLLNTTVAPLFFADQFLQLSTSLPSQYITGLAEHLSPLMLSTSWTRITLWNRDLAPTPGANLYGSHPFYLALEDGGSAHGVFLLNSNAMDVVLQP,drugbank_drug|DB01272 Alglucosidase alfa,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,P20645,M6PR,Cation-dependent mannose-6-phosphate receptor,,,BiotechDrug,Humans,18,6,11,13,13,14,7,7,5,29,6,9,26,12,15,19,20,13,3,9,
DB01276,Exenatide,BiotechDrug,46509017.0,http://www.drugs.com/cdi/exenatide.html,HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS,drugbank_drug|DB01276 Exenatide,"Antidiabetics, Glucagon-like Peptide-1 Agonists",231,-1,-1,-1,-1,-1,-1,P43220,GLP1R,Glucagon-like peptide 1 receptor,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC,drugbank_target|P43220 Glucagon-like peptide 1 receptor (DB00040; DB01276; DB06655; DB09043; DB09045; DB09265; DB13928; DB14027; DB15171; DB15650; DB16697),BiotechDrug,Humans,2,0,1,5,2,5,1,1,2,3,1,1,4,1,1,5,2,1,1,0,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC
DB01277,Mecasermin,BiotechDrug,46504889.0,http://www.drugs.com/cdi/mecasermin.html,GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA,drugbank_drug|DB01277 Mecasermin,Growth Hormone Analogs,207,-1,-1,-1,-1,-1,-1,P17936,IGFBP3,Insulin-like growth factor-binding protein 3,ATGCAGCGGGCGCGACCCACGCTCTGGGCCGCTGCGCTGACTCTGCTGGTGCTGCTCCGCGGGCCGCCGGTGGCGCGGGCTGGCGCGAGCTCGGCGGGCTTGGGTCCCGTGGTGCGCTGCGAGCCGTGCGACGCGCGTGCACTGGCCCAGTGCGCGCCTCCGCCCGCCGTGTGCGCGGAGCTGGTGCGCGAGCCGGGCTGCGGCTGCTGCCTGACGTGCGCACTGAGCGAGGGCCAGCCGTGCGGCATCTACACC,drugbank_target|P17936 Insulin-like growth factor-binding protein 3 (DB00523; DB01277),BiotechDrug,Humans,6,6,4,4,4,7,0,1,3,6,1,1,5,2,6,5,3,3,0,3,ATGCAGCGGGCGCGACCCACGCTCTGGGCCGCTGCGCTGACTCTGCTGGTGCTGCTCCGCGGGCCGCCGGTGGCGCGGGCTGGCGCGAGCTCGGCGGGCTTGGGTCCCGTGGTGCGCTGCGAGCCGTGCGACGCGCGTGCACTGGCCCAGTGCGCGCCTCCGCCCGCCGTGTGCGCGGAGCTGGTGCGCGAGCCGGGCTGCGGCTGCTGCCTGACGTGCGCACTGAGCGAGGGCCAGCCGTGCGGCATCTACACC
DB01277,Mecasermin,BiotechDrug,46504889.0,http://www.drugs.com/cdi/mecasermin.html,GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA,drugbank_drug|DB01277 Mecasermin,Growth Hormone Analogs,207,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,6,6,4,4,4,7,0,1,3,6,1,1,5,2,6,5,3,3,0,3,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB01277,Mecasermin,BiotechDrug,46504889.0,http://www.drugs.com/cdi/mecasermin.html,GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA,drugbank_drug|DB01277 Mecasermin,Growth Hormone Analogs,207,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,6,6,4,4,4,7,0,1,3,6,1,1,5,2,6,5,3,3,0,3,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB01277,Mecasermin,BiotechDrug,46504889.0,http://www.drugs.com/cdi/mecasermin.html,GPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSA,drugbank_drug|DB01277 Mecasermin,Growth Hormone Analogs,207,-1,-1,-1,-1,-1,-1,P11717,IGF2R,Cation-independent mannose-6-phosphate receptor,ATGGGGGCCGCCGCCGGCCGGAGCCCCCACCTGGGGCCCGCGCCCGCCCGCCGCCCGCAGCGCTCTCTGCTCCTGCTGCAGCTGCTGCTGCTCGTCGCTGCCCCGGGGTCCACGCAGGCCCAGGCCGCCCCGTTCCCCGAGCTGTGCAGTTATACATGGGAAGCTGTTGATACCAAAAATAATGTACTTTATAAAATCAACATCTGTGGAAGTGTGGATATTGTCCAGTGCGGGCCATCAAGTGCTGTTTGTATG,drugbank_target|P11717 Cation-independent mannose-6-phosphate receptor (DB01277; DB02900; DB13173; DB14751; DB16099; DB16708),BiotechDrug,Humans,6,6,4,4,4,7,0,1,3,6,1,1,5,2,6,5,3,3,0,3,ATGGGGGCCGCCGCCGGCCGGAGCCCCCACCTGGGGCCCGCGCCCGCCCGCCGCCCGCAGCGCTCTCTGCTCCTGCTGCAGCTGCTGCTGCTCGTCGCTGCCCCGGGGTCCACGCAGGCCCAGGCCGCCCCGTTCCCCGAGCTGTGCAGTTATACATGGGAAGCTGTTGATACCAAAAATAATGTACTTTATAAAATCAACATCTGTGGAAGTGTGGATATTGTCCAGTGCGGGCCATCAAGTGCTGTTTGTATG
DB01279,Galsulfase,BiotechDrug,46509151.0,http://www.drugs.com/cdi/galsulfase.html,SGAGASRPPHLVFLLADDLGWNDVGFHGSRIRTPHLDALAAGGVLLDNYYTQPLCTPSRSQLLTGRYQIRTGLQHQIIWPCQPSCVPLDEKLLPQLLKEAGYTTHMVGKWHLGMYRKECLPTRRGFDTYFGYLLGSEDYYSHERCTLIDALNVTRCALDFRDGEEVATGYKNMYSTNIFTKRAIALITNHPPEKPLFLYLALQSVHEPLQVPEEYLKPYDFIQDKNRHHYAGMVSLMDEAVGNVTAALKSSGLWN,drugbank_drug|DB01279 Galsulfase,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,O60664,PLIN3,Perilipin-3,ATGTCTGCCGACGGGGCAGAGGCTGATGGCAGCACCCAGGTGACAGTGGAAGAACCGGTACAGCAGCCCAGTGTGGTGGACCGTGTGGCCAGCATGCCTCTGATCAGCTCCACCTGCGACATGGTGTCCGCAGCCTATGCCTCCACCAAGGAGAGCTACCCGCACATCAAGACTGTCTGCGACGCAGCAGAGAAGGGAGTGAGGACCCTCACGGCGGCTGCTGTCAGCGGGGCTCAGCCGATCCTCTCCAAGCTG,drugbank_target|O60664 Perilipin-3 (DB01271; DB01279),BiotechDrug,Humans,17,6,14,12,8,20,11,9,10,34,5,9,16,10,14,13,16,12,4,15,ATGTCTGCCGACGGGGCAGAGGCTGATGGCAGCACCCAGGTGACAGTGGAAGAACCGGTACAGCAGCCCAGTGTGGTGGACCGTGTGGCCAGCATGCCTCTGATCAGCTCCACCTGCGACATGGTGTCCGCAGCCTATGCCTCCACCAAGGAGAGCTACCCGCACATCAAGACTGTCTGCGACGCAGCAGAGAAGGGAGTGAGGACCCTCACGGCGGCTGCTGTCAGCGGGGCTCAGCCGATCCTCTCCAAGCTG
DB01281,Abatacept,BiotechDrug,46509198.0,http://www.drugs.com/cdi/abatacept.html,MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE,drugbank_drug|DB01281 Abatacept monomer sequence,"DMARDs, Immunomodulators",158,-1,-1,-1,-1,-1,-1,P16410,CTLA4,Cytotoxic T-lymphocyte protein 4,ATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCTGAACCTGGCTACCAGGACCTGGCCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAAGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGT,drugbank_target|P16410 Cytotoxic T-lymphocyte protein 4 (DB01281; DB06186; DB11771),BiotechDrug,Humans,15,7,13,17,5,15,5,10,16,17,6,9,22,10,8,21,19,27,2,11,ATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCTGAACCTGGCTACCAGGACCTGGCCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAAGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGT
DB01281,Abatacept,BiotechDrug,46509198.0,http://www.drugs.com/cdi/abatacept.html,MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE,drugbank_drug|DB01281 Abatacept monomer sequence,"DMARDs, Immunomodulators",158,-1,-1,-1,-1,-1,-1,P33681,CD80,T-lymphocyte activation antigen CD80,ATGGGCCACACACGGAGGCAGGGAACATCACCATCCAAGTGTCCATACCTCAATTTCTTTCAGCTCTTGGTGCTGGCTGGTCTTTCTCACTTCTGTTCAGGTGTTATCCACGTGACCAAGGAAGTGAAAGAAGTGGCAACGCTGTCCTGTGGTCACAATGTTTCTGTTGAAGAGCTGGCACAAACTCGCATCTACTGGCAAAAGGAGAAGAAAATGGTGCTGACTATGATGTCTGGGGACATGAATATATGGCCC,drugbank_target|P33681 T-lymphocyte activation antigen CD80 (DB01281; DB04901; DB06681),BiotechDrug,Humans,15,7,13,17,5,15,5,10,16,17,6,9,22,10,8,21,19,27,2,11,ATGGGCCACACACGGAGGCAGGGAACATCACCATCCAAGTGTCCATACCTCAATTTCTTTCAGCTCTTGGTGCTGGCTGGTCTTTCTCACTTCTGTTCAGGTGTTATCCACGTGACCAAGGAAGTGAAAGAAGTGGCAACGCTGTCCTGTGGTCACAATGTTTCTGTTGAAGAGCTGGCACAAACTCGCATCTACTGGCAAAAGGAGAAGAAAATGGTGCTGACTATGATGTCTGGGGACATGAATATATGGCCC
DB01281,Abatacept,BiotechDrug,46509198.0,http://www.drugs.com/cdi/abatacept.html,MHVAQPAVVLASSRGIASFVCEYASPGKATEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYLGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE,drugbank_drug|DB01281 Abatacept monomer sequence,"DMARDs, Immunomodulators",158,-1,-1,-1,-1,-1,-1,P42081,CD86,T-lymphocyte activation antigen CD86,ATGGATCCCCAGTGCACTATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGCTAACTTCAGTCAACCTGAAATAGTACCAATTTCTAATATAACAGAAAATGTGTACATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCTAAGAAGATGAGTGTTTTGCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATGCAGAAATCTCAAGATAATGTCACAGAACTGTAC,drugbank_target|P42081 T-lymphocyte activation antigen CD86 (DB00098; DB01281; DB06681; DB11752),BiotechDrug,Humans,15,7,13,17,5,15,5,10,16,17,6,9,22,10,8,21,19,27,2,11,ATGGATCCCCAGTGCACTATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGCTAACTTCAGTCAACCTGAAATAGTACCAATTTCTAATATAACAGAAAATGTGTACATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCTAAGAAGATGAGTGTTTTGCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATGCAGAAATCTCAAGATAATGTCACAGAACTGTAC
DB01306,Insulin aspart,BiotechDrug,46507309.0,http://www.drugs.com/mtm/insulin-aspart.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB01306 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB01306,Insulin aspart,BiotechDrug,46507309.0,http://www.drugs.com/mtm/insulin-aspart.html,FVNQHLCGSHLVEALYLVCGERGFFYTDKT,drugbank_drug|DB01306 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,1,2,1,2,3,3,2,0,1,4,0,1,0,1,1,1,2,3,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB01306,Insulin aspart,BiotechDrug,46507309.0,http://www.drugs.com/mtm/insulin-aspart.html,FVNQHLCGSHLVEALYLVCGERGFFYTDKT,drugbank_drug|DB01306 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,1,2,1,2,3,3,2,0,1,4,0,1,0,1,1,1,2,3,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB01306,Insulin aspart,BiotechDrug,46507309.0,http://www.drugs.com/mtm/insulin-aspart.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB01306 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB01307,Insulin detemir,BiotechDrug,46508877.0,http://www.drugs.com/monograph/insulin-detemir.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB01307 Protein sequence for A chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB01307,Insulin detemir,BiotechDrug,46508877.0,http://www.drugs.com/monograph/insulin-detemir.html,FVNQHLCGSHLVEALYLVCGERGFFYTPK,drugbank_drug|DB01307 Protein sequence for B chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,1,3,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB01307,Insulin detemir,BiotechDrug,46508877.0,http://www.drugs.com/monograph/insulin-detemir.html,FVNQHLCGSHLVEALYLVCGERGFFYTPK,drugbank_drug|DB01307 Protein sequence for B chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,1,3,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB01307,Insulin detemir,BiotechDrug,46508877.0,http://www.drugs.com/monograph/insulin-detemir.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB01307 Protein sequence for A chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB01309,Insulin glulisine,BiotechDrug,46504450.0,http://www.drugs.com/mtm/insulin-glulisine.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB01309 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB01309,Insulin glulisine,BiotechDrug,46504450.0,http://www.drugs.com/mtm/insulin-glulisine.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB01309 A chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB01309,Insulin glulisine,BiotechDrug,46504450.0,http://www.drugs.com/mtm/insulin-glulisine.html,FVKQHLCGSHLVEALYLVCGERGFFYTPET,drugbank_drug|DB01309 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,1,2,0,3,3,3,2,0,1,4,0,0,1,1,1,1,2,3,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB01309,Insulin glulisine,BiotechDrug,46504450.0,http://www.drugs.com/mtm/insulin-glulisine.html,FVKQHLCGSHLVEALYLVCGERGFFYTPET,drugbank_drug|DB01309 B chain,"Antidiabetics, Insulins, Antidiabetics, Rapid-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,1,2,0,3,3,3,2,0,1,4,0,0,1,1,1,1,2,3,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB04897,Lucinactant,BiotechDrug,347909842.0,http://www.drugs.com/mtm/lucinactant.html,KLLLLKLLLLKLLLLKLLLLK,drugbank_drug|DB04897 Protein sequence for sinapultide,Lung Surfactants,76,-1,-1,-1,-1,-1,-1,,,,,,,,0,0,0,0,0,0,0,0,5,16,0,0,0,0,0,0,0,0,0,0,
DB04899,Nesiritide,BiotechDrug,46508506.0,http://www.drugs.com/cdi/nesiritide.html,SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH,drugbank_drug|DB04899 DB04899: Natriuretic peptides B,Natriuretic Peptides,409,-1,-1,-1,-1,-1,-1,P20594,NPR2,Atrial natriuretic peptide receptor 2,ATGGCGCTGCCATCACTTCTGCTGTTGGTGGCAGCCCTGGCAGGTGGGGTGCGTCCTCCCGGGGCGCGGAACCTGACGCTGGCGGTGGTGCTGCCAGAACACAACCTGAGCTATGCCTGGGCCTGGCCACGGGTGGGACCCGCTGTGGCACTAGCTGTGGAGGCTCTGGGCCGGGCACTGCCCGTGGACCTGCGGTTTGTCAGCTCCGAACTGGAAGGCGCCTGCTCTGAGTACCTGGCACCGCTGAGCGCTGTG,drugbank_target|P20594 Atrial natriuretic peptide receptor 2 (DB01613; DB04899; DB11928),BiotechDrug,Humans,0,2,1,0,1,5,1,1,3,2,2,0,1,1,4,6,0,2,0,0,ATGGCGCTGCCATCACTTCTGCTGTTGGTGGCAGCCCTGGCAGGTGGGGTGCGTCCTCCCGGGGCGCGGAACCTGACGCTGGCGGTGGTGCTGCCAGAACACAACCTGAGCTATGCCTGGGCCTGGCCACGGGTGGGACCCGCTGTGGCACTAGCTGTGGAGGCTCTGGGCCGGGCACTGCCCGTGGACCTGCGGTTTGTCAGCTCCGAACTGGAAGGCGCCTGCTCTGAGTACCTGGCACCGCTGAGCGCTGTG
DB04899,Nesiritide,BiotechDrug,46508506.0,http://www.drugs.com/cdi/nesiritide.html,SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH,drugbank_drug|DB04899 DB04899: Natriuretic peptides B,Natriuretic Peptides,409,-1,-1,-1,-1,-1,-1,P17342,NPR3,Atrial natriuretic peptide receptor 3,ATGCCGTCTCTGCTGGTGCTCACTTTCTCCCCGTGCGTACTACTCGGCTGGGCGTTGCTGGCCGGCGGCACCGGTGGCGGTGGCGTTGGCGGCGGCGGCGGTGGCGCGGGCATAGGCGGCGGACGCCAGGAGAGAGAGGCGCTGCCGCCACAGAAGATCGAGGTGCTGGTGTTACTGCCCCAGGATGACTCGTACTTGTTTTCACTCACCCGGGTGCGGCCGGCCATCGAGTATGCTCTGCGCAGCGTGGAGGGC,drugbank_target|P17342 Atrial natriuretic peptide receptor 3 (DB04899),BiotechDrug,Humans,0,2,1,0,1,5,1,1,3,2,2,0,1,1,4,6,0,2,0,0,ATGCCGTCTCTGCTGGTGCTCACTTTCTCCCCGTGCGTACTACTCGGCTGGGCGTTGCTGGCCGGCGGCACCGGTGGCGGTGGCGTTGGCGGCGGCGGCGGTGGCGCGGGCATAGGCGGCGGACGCCAGGAGAGAGAGGCGCTGCCGCCACAGAAGATCGAGGTGCTGGTGTTACTGCCCCAGGATGACTCGTACTTGTTTTCACTCACCCGGGTGCGGCCGGCCATCGAGTATGCTCTGCGCAGCGTGGAGGGC
DB04899,Nesiritide,BiotechDrug,46508506.0,http://www.drugs.com/cdi/nesiritide.html,SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH,drugbank_drug|DB04899 DB04899: Natriuretic peptides B,Natriuretic Peptides,409,-1,-1,-1,-1,-1,-1,P16066,NPR1,Atrial natriuretic peptide receptor 1,ATGCCGGGGCCCCGGCGCCCCGCTGGCTCCCGCCTGCGCCTGCTCCTGCTCCTGCTGCTGCCGCCGCTGCTGCTGCTGCTCCGGGGCAGCCACGCGGGCAACCTGACGGTAGCCGTGGTACTGCCGCTGGCCAATACCTCGTACCCCTGGTCGTGGGCGCGCGTGGGACCCGCCGTGGAGCTGGCCCTGGCCCAGGTGAAGGCGCGCCCCGACTTGCTGCCGGGCTGGACGGTCCGCACGGTGCTGGGCAGCAGC,drugbank_target|P16066 Atrial natriuretic peptide receptor 1 (DB00325; DB00727; DB00883; DB01612; DB01613; DB04899; DB05034),BiotechDrug,Humans,0,2,1,0,1,5,1,1,3,2,2,0,1,1,4,6,0,2,0,0,ATGCCGGGGCCCCGGCGCCCCGCTGGCTCCCGCCTGCGCCTGCTCCTGCTCCTGCTGCTGCCGCCGCTGCTGCTGCTGCTCCGGGGCAGCCACGCGGGCAACCTGACGGTAGCCGTGGTACTGCCGCTGGCCAATACCTCGTACCCCTGGTCGTGGGCGCGCGTGGGACCCGCCGTGGAGCTGGCCCTGGCCCAGGTGAAGGCGCGCCCCGACTTGCTGCCGGGCTGGACGGTCCGCACGGTGCTGGGCAGCAGC
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05259,Glatiramer,BiotechDrug,46505299.0,http://www.drugs.com/cdi/glatiramer.html,EAYKAAEKAYAAKEAAKEAAKAKAEKKAAYAKAKAAKYEKKAKKAAAEYKKK,drugbank_drug|DB05259 Example Glatiramer peptide,IMMUNOMODULATORS,371,-1,-1,-1,-1,-1,-1,P01911,HLA-DRB1,"HLA class II histocompatibility antigen, DRB1-15 beta chain",,,BiotechDrug,Humans,22,0,0,7,0,0,0,0,18,0,0,0,0,0,0,0,0,0,0,5,
DB05332,Romiplostim,BiotechDrug,347910087.0,http://www.drugs.com/monograph/romiplostim.html,IEGPTLRQWLAARA,drugbank_drug|DB05332 Thrombopoietin receptor binding domain amino acid sequence,Thrombopoietic Agents,44,-1,-1,-1,-1,-1,-1,P40238,MPL,Thrombopoietin receptor,ATGCCCTCCTGGGCCCTCTTCATGGTCACCTCCTGCCTCCTCCTGGCCCCTCAAAACCTGGCCCAAGTCAGCAGCCAAGATGTCTCCTTGCTGGCATCAGACTCAGAGCCCCTGAAGTGTTTCTCCCGAACATTTGAGGACCTCACTTGCTTCTGGGATGAGGAAGAGGCAGCGCCCAGTGGGACATACCAGCTGCTGTATGCCTACCCGCGGGAGAAGCCCCGTGCTTGCCCCCTGAGTTCCCAGAGCATGCCC,drugbank_target|P40238 Thrombopoietin receptor (DB05332; DB05930; DB06210; DB06534; DB11995; DB13125),BiotechDrug,Humans,3,0,0,1,0,1,0,1,0,2,0,0,1,1,2,0,1,0,1,0,ATGCCCTCCTGGGCCCTCTTCATGGTCACCTCCTGCCTCCTCCTGGCCCCTCAAAACCTGGCCCAAGTCAGCAGCCAAGATGTCTCCTTGCTGGCATCAGACTCAGAGCCCCTGAAGTGTTTCTCCCGAACATTTGAGGACCTCACTTGCTTCTGGGATGAGGAAGAGGCAGCGCCCAGTGGGACATACCAGCTGCTGTATGCCTACCCGCGGGAGAAGCCCCGTGCTTGCCCCCTGAGTTCCCAGAGCATGCCC
DB05332,Romiplostim,BiotechDrug,347910087.0,http://www.drugs.com/monograph/romiplostim.html,MDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGGIEGPTLRQWLAARAGGGGGGGG,drugbank_drug|DB05332 Amino acid sequence for Fc fusion compound,Thrombopoietic Agents,44,-1,-1,-1,-1,-1,-1,P40238,MPL,Thrombopoietin receptor,ATGCCCTCCTGGGCCCTCTTCATGGTCACCTCCTGCCTCCTCCTGGCCCCTCAAAACCTGGCCCAAGTCAGCAGCCAAGATGTCTCCTTGCTGGCATCAGACTCAGAGCCCCTGAAGTGTTTCTCCCGAACATTTGAGGACCTCACTTGCTTCTGGGATGAGGAAGAGGCAGCGCCCAGTGGGACATACCAGCTGCTGTATGCCTACCCGCGGGAGAAGCCCCGTGCTTGCCCCCTGAGTTCCCAGAGCATGCCC,drugbank_target|P40238 Thrombopoietin receptor (DB05332; DB05930; DB06210; DB06534; DB11995; DB13125),BiotechDrug,Humans,10,6,11,16,7,24,7,5,20,20,3,11,23,10,8,20,17,23,5,9,ATGCCCTCCTGGGCCCTCTTCATGGTCACCTCCTGCCTCCTCCTGGCCCCTCAAAACCTGGCCCAAGTCAGCAGCCAAGATGTCTCCTTGCTGGCATCAGACTCAGAGCCCCTGAAGTGTTTCTCCCGAACATTTGAGGACCTCACTTGCTTCTGGGATGAGGAAGAGGCAGCGCCCAGTGGGACATACCAGCTGCTGTATGCCTACCCGCGGGAGAAGCCCCGTGCTTGCCCCCTGAGTTCCCAGAGCATGCCC
DB05578,Ramucirumab,BiotechDrug,347910183.0,http://www.drugs.com/cdi/ramucirumab.html,EVQLVQSGGGLVKPGGSLRLSCAASGFTFSSYSMNWVRQAPGKGLEWVSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARVTDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRT,drugbank_drug|DB05578 9098_H|ramucirumab|Homo sapiens||H-GAMMA-1 (VH(1-116)+CH1(117-214)+HINGE-REGION(215-229)+CH2(230-339)+CH3(340-446))|||||||446||||MW 48696.0|MW 48696.0|,"Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P35968,KDR,Vascular endothelial growth factor receptor 2,ATGCAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCCTCTGTGGGTTTGCCTAGTGTTTCTCTTGATCTGCCCAGGCTCAGCATACAAAAAGACATACTTACAATTAAGGCTAATACAACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGACTGGCTTTGGCCCAATAATCAGAGTGGCAGTGAGCAAAGGGTGGAGGTGACTGAGTGCAGCGATGGCCTCTTCTGT,drugbank_target|P35968 Vascular endothelial growth factor receptor 2 (DB00398; DB01268; DB04727; DB04849; DB04879; DB05014; DB05075; DB05146; DB05198; DB05578; DB05931; DB05984; DB06080; DB06101; DB06436; DB06589; DB06595; DB06626; DB06938; DB07183; DB072,BiotechDrug,Humans,16,7,9,6,9,21,3,6,15,20,4,8,19,7,7,41,20,23,4,10,ATGCAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCCTCTGTGGGTTTGCCTAGTGTTTCTCTTGATCTGCCCAGGCTCAGCATACAAAAAGACATACTTACAATTAAGGCTAATACAACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGACTGGCTTTGGCCCAATAATCAGAGTGGCAGTGAGCAAAGGGTGGAGGTGACTGAGTGCAGCGATGGCCTCTTCTGT
DB05578,Ramucirumab,BiotechDrug,347910183.0,http://www.drugs.com/cdi/ramucirumab.html,DIQMTQSPSSVSASIGDRVTITCRASQGIDNWLGWYQQKPGKAPKLLIYDASNLDTGVPSRFSGSGSGTYFTLTISSLQAEDFAVYFCQQAKAFPPTFGGGTKVDIKGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB05578 9098_L|ramucirumab|Homo sapiens||L-KAPPA (V-KAPPA(1-107)+C-KAPPA(109-214))|||||||214||||MW 23124.7|MW 23124.7|,"Antineoplastics, VEGF Inhibitor",227,-1,-1,-1,-1,-1,-1,P35968,KDR,Vascular endothelial growth factor receptor 2,ATGCAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCCTCTGTGGGTTTGCCTAGTGTTTCTCTTGATCTGCCCAGGCTCAGCATACAAAAAGACATACTTACAATTAAGGCTAATACAACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGACTGGCTTTGGCCCAATAATCAGAGTGGCAGTGAGCAAAGGGTGGAGGTGACTGAGTGCAGCGATGGCCTCTTCTGT,drugbank_target|P35968 Vascular endothelial growth factor receptor 2 (DB00398; DB01268; DB04727; DB04849; DB04879; DB05014; DB05075; DB05146; DB05198; DB05578; DB05931; DB05984; DB06080; DB06101; DB06436; DB06589; DB06595; DB06626; DB06938; DB07183; DB072,BiotechDrug,Humans,15,5,12,8,10,16,2,8,14,14,1,7,11,14,5,29,17,15,3,8,ATGCAGAGCAAGGTGCTGCTGGCCGTCGCCCTGTGGCTCTGCGTGGAGACCCGGGCCGCCTCTGTGGGTTTGCCTAGTGTTTCTCTTGATCTGCCCAGGCTCAGCATACAAAAAGACATACTTACAATTAAGGCTAATACAACTCTTCAAATTACTTGCAGGGGACAGAGGGACTTGGACTGGCTTTGGCCCAATAATCAGAGTGGCAGTGAGCAAAGGGTGGAGGTGACTGAGTGCAGCGATGGCCTCTTCTGT
DB06168,Canakinumab,BiotechDrug,347910340.0,http://www.drugs.com/mtm/canakinumab.html,EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB06168 LIGHT_CHAIN,"Monoclonal Antibodies, Antineoplastics Monoclonal Antibody",73,-1,-1,-1,-1,-1,-1,P01584,IL1B,Interleukin-1 beta,ATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGATGACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGACCTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGCTTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCTTC,drugbank_target|P01584 Interleukin-1 beta (DB00843; DB01017; DB05133; DB05412; DB05442; DB05470; DB05507; DB05767; DB06168; DB06372; DB10772; DB12119; DB12140),BiotechDrug,Humans,13,5,10,11,10,11,4,7,15,15,0,6,12,14,5,34,17,15,2,8,ATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGATGACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGACCTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGCTTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCTTC
DB06168,Canakinumab,BiotechDrug,347910340.0,http://www.drugs.com/mtm/canakinumab.html,QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS,drugbank_drug|DB06168 HEAVY_CHAIN,"Monoclonal Antibodies, Antineoplastics Monoclonal Antibody",73,-1,-1,-1,-1,-1,-1,P01584,IL1B,Interleukin-1 beta,ATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGATGACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGACCTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGCTTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCTTC,drugbank_target|P01584 Interleukin-1 beta (DB00843; DB01017; DB05133; DB05412; DB05442; DB05470; DB05507; DB05767; DB06168; DB06372; DB10772; DB12119; DB12140),BiotechDrug,Humans,15,7,11,6,9,24,3,5,13,21,3,9,20,9,9,31,20,24,5,11,ATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGATGACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGACCTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGCTTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCTTC
DB06186,Ipilimumab,BiotechDrug,347910341.0,http://www.drugs.com/ppa/ipilimumab.html,QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS,drugbank_drug|DB06186 Ipilimumab heavy chain (patent appl. US20150283234),Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P16410,CTLA4,Cytotoxic T-lymphocyte protein 4,ATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCTGAACCTGGCTACCAGGACCTGGCCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAAGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGT,drugbank_target|P16410 Cytotoxic T-lymphocyte protein 4 (DB01281; DB06186; DB11771),BiotechDrug,Humans,14,7,9,6,10,23,4,5,14,21,3,9,20,8,8,34,22,22,5,11,ATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCTGAACCTGGCTACCAGGACCTGGCCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAAGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGT
DB06186,Ipilimumab,BiotechDrug,347910341.0,http://www.drugs.com/ppa/ipilimumab.html,EIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB06186 Ipilimumab light chain,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,P16410,CTLA4,Cytotoxic T-lymphocyte protein 4,ATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCTGAACCTGGCTACCAGGACCTGGCCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAAGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGT,drugbank_target|P16410 Cytotoxic T-lymphocyte protein 4 (DB01281; DB06186; DB11771),BiotechDrug,Humans,14,5,8,12,9,16,2,6,11,17,0,5,12,14,9,31,17,14,3,10,ATGGCTTGCCTTGGATTTCAGCGGCACAAGGCTCAGCTGAACCTGGCTACCAGGACCTGGCCCTGCACTCTCCTGTTTTTTCTTCTCTTCATCCCTGTCTTCTGCAAAGCAATGCACGTGGCCCAGCCTGCTGTGGTACTGGCCAGCAGCCGAGGCATCGCCAGCTTTGTGTGTGAGTATGCATCTCCAGGCAAAGCCACTGAGGTCCGGGTGACAGTGCTTCGGCAGGCTGACAGCCAGGTGACTGAAGTCTGT
DB06273,Tocilizumab,BiotechDrug,347910344.0,http://www.drugs.com/international/tocilizumab.html,QVQLQESGPGLVRPSQTLSLTCTVSGYSITSDHAWSWVRQPPGRGLEWIGYISYSGITTYNPSLKSRVTMLRDTSKNQFSLRLSSVTAADTAVYYCARSLARTTAMDYWGQGSLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB06273 Tocilizumab heavy chain:,"DMARDs, Immunomodulators, Monoclonal Antibodies",158,-1,-1,-1,-1,-1,-1,P08887,IL6R,Interleukin-6 receptor subunit alpha,ATGCTGGCCGTCGGCTGCGCGCTGCTGGCTGCCCTGCTGGCCGCGCCGGGAGCGGCGCTGGCCCCAAGGCGCTGCCCTGCGCAGGAGGTGGCGAGAGGCGTGCTGACCAGTCTGCCAGGAGACAGCGTGACTCTGACCTGCCCGGGGGTAGAGCCGGAAGACAATGCCACTGTTCACTGGGTGCTCAGGAAGCCGGCTGCAGGCTCCCACCCCAGCAGATGGGCTGGCATGGGAAGGAGGCTGCTGCTGAGGTCG,drugbank_target|P08887 Interleukin-6 receptor subunit alpha (DB06273; DB11767; DB15762),BiotechDrug,Humans,14,7,8,5,6,19,4,6,13,23,3,6,22,9,8,39,26,22,5,10,ATGCTGGCCGTCGGCTGCGCGCTGCTGGCTGCCCTGCTGGCCGCGCCGGGAGCGGCGCTGGCCCCAAGGCGCTGCCCTGCGCAGGAGGTGGCGAGAGGCGTGCTGACCAGTCTGCCAGGAGACAGCGTGACTCTGACCTGCCCGGGGGTAGAGCCGGAAGACAATGCCACTGTTCACTGGGTGCTCAGGAAGCCGGCTGCAGGCTCCCACCCCAGCAGATGGGCTGGCATGGGAAGGAGGCTGCTGCTGAGGTCG
DB06273,Tocilizumab,BiotechDrug,347910344.0,http://www.drugs.com/international/tocilizumab.html,DIQMTQSPSSLSASVGDRVTITCRASQDISSYLNWYQQKPGKAPKLLIYYTSRLHSGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQGNTLPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB06273 Tocilizumab light chain:,"DMARDs, Immunomodulators, Monoclonal Antibodies",158,-1,-1,-1,-1,-1,-1,P08887,IL6R,Interleukin-6 receptor subunit alpha,ATGCTGGCCGTCGGCTGCGCGCTGCTGGCTGCCCTGCTGGCCGCGCCGGGAGCGGCGCTGGCCCCAAGGCGCTGCCCTGCGCAGGAGGTGGCGAGAGGCGTGCTGACCAGTCTGCCAGGAGACAGCGTGACTCTGACCTGCCCGGGGGTAGAGCCGGAAGACAATGCCACTGTTCACTGGGTGCTCAGGAAGCCGGCTGCAGGCTCCCACCCCAGCAGATGGGCTGGCATGGGAAGGAGGCTGCTGCTGAGGTCG,drugbank_target|P08887 Interleukin-6 receptor subunit alpha (DB06273; DB11767; DB15762),BiotechDrug,Humans,11,5,10,9,8,13,3,8,13,15,1,7,11,15,7,32,19,14,2,11,ATGCTGGCCGTCGGCTGCGCGCTGCTGGCTGCCCTGCTGGCCGCGCCGGGAGCGGCGCTGGCCCCAAGGCGCTGCCCTGCGCAGGAGGTGGCGAGAGGCGTGCTGACCAGTCTGCCAGGAGACAGCGTGACTCTGACCTGCCCGGGGGTAGAGCCGGAAGACAATGCCACTGTTCACTGGGTGCTCAGGAAGCCGGCTGCAGGCTCCCACCCCAGCAGATGGGCTGGCATGGGAAGGAGGCTGCTGCTGAGGTCG
DB06317,Elotuzumab,BiotechDrug,347910347.0,http://www.drugs.com/mtm/elotuzumab.html,DIQMTQSPSSLSASVGDRVTITCKASQDVGIAVAWYQQKPGKVPKLLIYWASTRHTGVPDRFSGSGSGTDFTLTISSLQPEDVATYYCQQYSSYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB06317 Elotuzumab light chain,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,Q9NQ25,SLAMF7,SLAM family member 7,ATGGCTGGTTCCCCAACATGCCTCACCCTCATCTATATCCTTTGGCAGCTCACAGGGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCCGTTGGTGGGGCCGTGACTTTCCCCCTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTTGTCACCATACAGCCAGAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGAT,drugbank_target|Q9NQ25 SLAM family member 7 (DB06317),BiotechDrug,Humans,13,5,11,9,7,13,3,7,14,13,1,5,11,15,6,30,19,18,3,11,ATGGCTGGTTCCCCAACATGCCTCACCCTCATCTATATCCTTTGGCAGCTCACAGGGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCCGTTGGTGGGGCCGTGACTTTCCCCCTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTTGTCACCATACAGCCAGAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGAT
DB06317,Elotuzumab,BiotechDrug,347910347.0,http://www.drugs.com/mtm/elotuzumab.html,EVQLVESGGGLVQPGGSLRLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYAPSLKDKFIISRDNAKNSLYLQMNSLRAEDTAVYYCARPDGNYWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB06317 Elotuzumab heavy chain,Antineoplastics Monoclonal Antibody,64,-1,-1,-1,-1,-1,-1,Q9NQ25,SLAMF7,SLAM family member 7,ATGGCTGGTTCCCCAACATGCCTCACCCTCATCTATATCCTTTGGCAGCTCACAGGGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCCGTTGGTGGGGCCGTGACTTTCCCCCTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTTGTCACCATACAGCCAGAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGAT,drugbank_target|Q9NQ25 SLAM family member 7 (DB06317),BiotechDrug,Humans,15,7,11,8,9,22,3,7,15,22,3,10,22,7,6,34,17,21,6,10,ATGGCTGGTTCCCCAACATGCCTCACCCTCATCTATATCCTTTGGCAGCTCACAGGGTCAGCAGCCTCTGGACCCGTGAAAGAGCTGGTCGGTTCCGTTGGTGGGGCCGTGACTTTCCCCCTGAAGTCCAAAGTAAAGCAAGTTGACTCTATTGTCTGGACCTTCAACACAACCCCTCTTGTCACCATACAGCCAGAAGGGGGCACTATCATAGTGACCCAAAATCGTAATAGGGAGAGAGTAGACTTCCCAGAT
DB06366,Pertuzumab,BiotechDrug,347910348.0,http://www.drugs.com/perjeta.html,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB06366 Amino acid sequence for pertuzumab light chain,"Antineoplastics Monoclonal Antibody, Antineoplastics, Anti-HER2",64,-1,-1,-1,-1,-1,-1,P04626,ERBB2,Receptor tyrosine-protein kinase erbB-2,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC,drugbank_target|P04626 Receptor tyrosine-protein kinase erbB-2 (DB00072; DB01259; DB04988; DB05773; DB05944; DB06021; DB06366; DB08916; DB11652; DB11973; DB12010; DB12267; DB14967; DB15035),BiotechDrug,Humans,13,5,10,9,8,13,2,8,14,13,1,5,11,15,6,31,18,16,2,14,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC
DB06366,Pertuzumab,BiotechDrug,347910348.0,http://www.drugs.com/perjeta.html,EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVNPNSGGSIYNQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB06366 Amino acid sequence for pertuzumab heavy chain,"Antineoplastics Monoclonal Antibody, Antineoplastics, Anti-HER2",64,-1,-1,-1,-1,-1,-1,P04626,ERBB2,Receptor tyrosine-protein kinase erbB-2,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC,drugbank_target|P04626 Receptor tyrosine-protein kinase erbB-2 (DB00072; DB01259; DB04988; DB05773; DB05944; DB06021; DB06366; DB08916; DB11652; DB11973; DB12010; DB12267; DB14967; DB15035),BiotechDrug,Humans,14,7,10,7,11,24,3,3,14,23,3,10,21,8,7,32,21,23,4,10,ATGAAGCTGCGGCTCCCTGCCAGTCCCGAGACCCACCTGGACATGCTCCGCCACCTCTACCAGGGCTGCCAGGTGGTGCAGGGAAACCTGGAACTCACCTACCTGCCCACCAATGCCAGCCTGTCCTTCCTGCAGGATATCCAGGAGGTGCAGGGCTACGTGCTCATCGCTCACAACCAAGTGAGGCAGGTCCCACTGCAGAGGCTGCGGATTGTGCGAGGCACCCAGCTCTTTGAGGACAACTATGCCCTGGCC
DB06372,Rilonacept,BiotechDrug,347910349.0,http://www.drugs.com/ppa/rilonacept.html,SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMD,drugbank_drug|DB06372 8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P01584,IL1B,Interleukin-1 beta,ATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGATGACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGACCTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGCTTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCTTC,drugbank_target|P01584 Interleukin-1 beta (DB00843; DB01017; DB05133; DB05412; DB05442; DB05470; DB05507; DB05767; DB06168; DB06372; DB10772; DB12119; DB12140),BiotechDrug,Humans,6,9,12,16,14,11,6,15,13,22,6,18,19,6,12,14,19,19,5,13,ATGGCAGAAGTACCTGAGCTCGCCAGTGAAATGATGGCTTATTACAGTGGCAATGAGGATGACTTGTTCTTTGAAGCTGATGGCCCTAAACAGATGAAGTGCTCCTTCCAGGACCTGGACCTCTGCCCTCTGGATGGCGGCATCCAGCTACGAATCTCCGACCACCACTACAGCAAGGGCTTCAGGCAGGCCGCGTCAGTTGTTGTGGCCATGGACAAGCTGAGGAAGATGCTGGTTCCCTGCCCACAGACCTTC
DB06372,Rilonacept,BiotechDrug,347910349.0,http://www.drugs.com/ppa/rilonacept.html,SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMD,drugbank_drug|DB06372 8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P01583,IL1A,Interleukin-1 alpha,ATGGCCAAAGTTCCAGACATGTTTGAAGACCTGAAGAACTGTTACAGTGAAAATGAAGAAGACAGTTCCTCCATTGATCATCTGTCTCTGAATCAGAAATCCTTCTATCATGTAAGCTATGGCCCACTCCATGAAGGCTGCATGGATCAATCTGTGTCTCTGAGTATCTCTGAAACCTCTAAAACATCCAAGCTTACCTTCAAGGAGAGCATGGTGGTAGTAGCAACCAACGGGAAGGTTCTGAAGAAGAGACGG,drugbank_target|P01583 Interleukin-1 alpha (DB06372),BiotechDrug,Humans,6,9,12,16,14,11,6,15,13,22,6,18,19,6,12,14,19,19,5,13,ATGGCCAAAGTTCCAGACATGTTTGAAGACCTGAAGAACTGTTACAGTGAAAATGAAGAAGACAGTTCCTCCATTGATCATCTGTCTCTGAATCAGAAATCCTTCTATCATGTAAGCTATGGCCCACTCCATGAAGGCTGCATGGATCAATCTGTGTCTCTGAGTATCTCTGAAACCTCTAAAACATCCAAGCTTACCTTCAAGGAGAGCATGGTGGTAGTAGCAACCAACGGGAAGGTTCTGAAGAAGAGACGG
DB06372,Rilonacept,BiotechDrug,347910349.0,http://www.drugs.com/ppa/rilonacept.html,SERCDDWGLDTMRQIQVFEDEPARIKCPLFEHFLKFNYSTAHSAGLTLIWYWTRQDRDLEEPINFRLPENRISKEKDVLWFRPTLLNDTGNYTCMLRNTTYCSKVAFPLEVVQKDSCFNSPMKLPVHKLYIEYGIQRITCPNVDGYFPSSVKPTITWYMGCYKIQNFNNVIPEGMNLSFLIALISNNGNYTCVVTYPENGRTFHLTRTLTVKVVGSPKNAVPPVIHSPNDHVVYEKEPGEELLIPCTVYFSFLMD,drugbank_drug|DB06372 8750_M|rilonacept|Homo sapiens||FUSION-IL1RAP-IL1R1-GAMMA-1 (IL1RAP+(Pr21-359)(1-339)+IL1R1+(Pr22-333)(340-651)+HINGE-REGION(652-663)+CH2(664-773)+CH3(774-880))|||||||880||||MW 100630.6|MW 100630.6|,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P18510,IL1RN,Interleukin-1 receptor antagonist protein,ATGGCTTTAGAGACGATCTGCCGACCCTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAGACCTTCTATCTGAGGAACAACCAACTAGTTGCTGGATACTTGCAAGGACCAAATGTCAATTTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATCCATGGAGGGAAGATGTGCCTGTCCTGTGTCAAGTCTGGTGATGAGACCAGACTC,drugbank_target|P18510 Interleukin-1 receptor antagonist protein (DB06372),BiotechDrug,Humans,6,9,12,16,14,11,6,15,13,22,6,18,19,6,12,14,19,19,5,13,ATGGCTTTAGAGACGATCTGCCGACCCTCTGGGAGAAAATCCAGCAAGATGCAAGCCTTCAGAATCTGGGATGTTAACCAGAAGACCTTCTATCTGAGGAACAACCAACTAGTTGCTGGATACTTGCAAGGACCAAATGTCAATTTAGAAGAAAAGATAGATGTGGTACCCATTGAGCCTCATGCTCTGTTCTTGGGAATCCATGGAGGGAAGATGTGCCTGTCCTGTGTCAAGTCTGGTGATGAGACCAGACTC
DB06643,Denosumab,BiotechDrug,347910354.0,http://www.drugs.com/ppa/denosumab.html,EIVLTQSPGTLSLSPGERATLSCRASQSVRGRYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVFYCQQYGSSPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB06643  Denosumab Î±OPGL-1â€ƒlightâ€ƒchainâ€ƒsequence,"Monoclonal Antibodies, Endocrine",73,-1,-1,-1,-1,-1,-1,O14788,TNFSF11,Tumor necrosis factor ligand superfamily member 11,ATGCGCCGCGCCAGCAGAGACTACACCAAGTACCTGCGTGGCTCGGAGGAGATGGGCGGCGGCCCCGGAGCCCCGCACGAGGGCCCCCTGCACGCCCCGCCGCCGCCTGCGCCGCACCAGCCCCCTGCCGCCTCCCGCTCCATGTTCGTGGCCCTCCTGGGGCTGGGGCTGGGCCAGGTTGTCTGCAGCGTCGCCCTGTTCTTCTATTTCAGAGCGCAGATGGATCCTAATAGAATATCAGAAGATGGCACTCAC,drugbank_target|O14788 Tumor necrosis factor ligand superfamily member 11 (DB00480; DB06511; DB06643; DB11582),BiotechDrug,Humans,14,5,8,12,9,16,2,6,11,17,0,5,12,14,12,30,17,14,2,9,ATGCGCCGCGCCAGCAGAGACTACACCAAGTACCTGCGTGGCTCGGAGGAGATGGGCGGCGGCCCCGGAGCCCCGCACGAGGGCCCCCTGCACGCCCCGCCGCCGCCTGCGCCGCACCAGCCCCCTGCCGCCTCCCGCTCCATGTTCGTGGCCCTCCTGGGGCTGGGGCTGGGCCAGGTTGTCTGCAGCGTCGCCCTGTTCTTCTATTTCAGAGCGCAGATGGATCCTAATAGAATATCAGAAGATGGCACTCAC
DB06643,Denosumab,BiotechDrug,347910354.0,http://www.drugs.com/ppa/denosumab.html,EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDPGTTVIMSWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT,drugbank_drug|DB06643  Denosumab Î±OPGL-1â€ƒheavyâ€ƒchainâ€ƒsequence,"Monoclonal Antibodies, Endocrine",73,-1,-1,-1,-1,-1,-1,O14788,TNFSF11,Tumor necrosis factor ligand superfamily member 11,ATGCGCCGCGCCAGCAGAGACTACACCAAGTACCTGCGTGGCTCGGAGGAGATGGGCGGCGGCCCCGGAGCCCCGCACGAGGGCCCCCTGCACGCCCCGCCGCCGCCTGCGCCGCACCAGCCCCCTGCCGCCTCCCGCTCCATGTTCGTGGCCCTCCTGGGGCTGGGGCTGGGCCAGGTTGTCTGCAGCGTCGCCCTGTTCTTCTATTTCAGAGCGCAGATGGATCCTAATAGAATATCAGAAGATGGCACTCAC,drugbank_target|O14788 Tumor necrosis factor ligand superfamily member 11 (DB00480; DB06511; DB06643; DB11582),BiotechDrug,Humans,15,7,9,7,9,26,3,4,15,21,3,7,21,7,5,37,23,22,5,9,ATGCGCCGCGCCAGCAGAGACTACACCAAGTACCTGCGTGGCTCGGAGGAGATGGGCGGCGGCCCCGGAGCCCCGCACGAGGGCCCCCTGCACGCCCCGCCGCCGCCTGCGCCGCACCAGCCCCCTGCCGCCTCCCGCTCCATGTTCGTGGCCCTCCTGGGGCTGGGGCTGGGCCAGGTTGTCTGCAGCGTCGCCCTGTTCTTCTATTTCAGAGCGCAGATGGATCCTAATAGAATATCAGAAGATGGCACTCAC
DB06650,Ofatumumab,BiotechDrug,347910355.0,http://www.drugs.com/international/ofatumumab.html,EVQLVESGGGLVQPGRSLRLSCAASGFTFNDYAMHWVRQAPGKGLEWVSTISWNSGSIGYADSVKGRFTISRDNAKKSLYLQMNSLRAEDTALYYCAKDIQYGNYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPGSSKSTSGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP,drugbank_drug|DB06650 Ofatumumab Heavy Chain,"Antineoplastics, Anti-CD20 Monoclonal Antibodies, Diuretics, Thiazide",227,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,15,4,8,6,6,22,3,5,12,17,3,9,11,8,6,32,17,21,5,12,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB06650,Ofatumumab,BiotechDrug,347910355.0,http://www.drugs.com/international/ofatumumab.html,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR,drugbank_drug|DB06650 Ofatumumab Light Chain,"Antineoplastics, Anti-CD20 Monoclonal Antibodies, Diuretics, Thiazide",227,-1,-1,-1,-1,-1,-1,P11836,MS4A1,B-lymphocyte antigen CD20,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG,drugbank_target|P11836 B-lymphocyte antigen CD20 (DB00073; DB00078; DB00081; DB06650; DB08935; DB09336; DB11850; DB11988; DB15434; DB16371; DB16672; DB16684),BiotechDrug,Humans,16,4,8,11,8,11,2,7,10,18,0,7,12,14,10,31,17,13,3,9,ATGACAACACCCAGAAATTCAGTAAATGGGACTTTCCCGGCAGAGCCAATGAAAGGCCCTATTGCTATGCAATCTGGTCCAAAACCACTCTTCAGGAGGATGTCTTCACTGGTGGGCCCCACGCAAAGCTTCTTCATGAGGGAATCTAAGACTTTGGGGGCTGTCCAGATTATGAATGGGCTCTTCCACATTGCCCTGGGGGGTCTTCTGATGATCCCAGCAGGGATCTATGCACCCATCTGTGTGACTGTGTGG
DB06655,Liraglutide,BiotechDrug,347910356.0,http://www.drugs.com/cdi/liraglutide.html,HAEGTFTSDVSSYLEGQAAKEEFIAWLVRGRG,drugbank_drug|DB06655 Liraglutide Sequence (gamma-E-palmitoyl at E21),"Antidiabetics, Glucagon-like Peptide-1 Agonists",231,-1,-1,-1,-1,-1,-1,P43220,GLP1R,Glucagon-like peptide 1 receptor,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC,drugbank_target|P43220 Glucagon-like peptide 1 receptor (DB00040; DB01276; DB06655; DB09043; DB09045; DB09265; DB13928; DB14027; DB15171; DB15650; DB16697),BiotechDrug,Humans,4,0,1,4,2,4,1,1,1,2,0,0,0,1,2,3,2,2,1,1,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC
DB06681,Belatacept,BiotechDrug,347910359.0,http://www.drugs.com/cdi/belatacept.html,MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE,drugbank_drug|DB06681  sequence for belatacept,"Immunosuppressants, Selective T-Cell Costimulation Blockers",446,-1,-1,-1,-1,-1,-1,P42081,CD86,T-lymphocyte activation antigen CD86,ATGGATCCCCAGTGCACTATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGCTAACTTCAGTCAACCTGAAATAGTACCAATTTCTAATATAACAGAAAATGTGTACATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCTAAGAAGATGAGTGTTTTGCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATGCAGAAATCTCAAGATAATGTCACAGAACTGTAC,drugbank_target|P42081 T-lymphocyte activation antigen CD86 (DB00098; DB01281; DB06681; DB11752),BiotechDrug,Humans,14,7,13,18,5,15,5,10,16,16,6,9,22,10,8,21,19,27,2,12,ATGGATCCCCAGTGCACTATGGGACTGAGTAACATTCTCTTTGTGATGGCCTTCCTGCTCTCTGCTAACTTCAGTCAACCTGAAATAGTACCAATTTCTAATATAACAGAAAATGTGTACATAAATTTGACCTGCTCATCTATACACGGTTACCCAGAACCTAAGAAGATGAGTGTTTTGCTAAGAACCAAGAATTCAACTATCGAGTATGATGGTATTATGCAGAAATCTCAAGATAATGTCACAGAACTGTAC
DB06681,Belatacept,BiotechDrug,347910359.0,http://www.drugs.com/cdi/belatacept.html,MHVAQPAVVLASSRGIASFVCEYASPGKYTEVRVTVLRQADSQVTEVCAATYMMGNELTFLDDSICTGTSSGNQVNLTIQGLRAMDTGLYICKVELMYPPPYYEGIGNGTQIYVIDPEPCPDSDQEPKSSDKTHTSPPSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE,drugbank_drug|DB06681  sequence for belatacept,"Immunosuppressants, Selective T-Cell Costimulation Blockers",446,-1,-1,-1,-1,-1,-1,P33681,CD80,T-lymphocyte activation antigen CD80,ATGGGCCACACACGGAGGCAGGGAACATCACCATCCAAGTGTCCATACCTCAATTTCTTTCAGCTCTTGGTGCTGGCTGGTCTTTCTCACTTCTGTTCAGGTGTTATCCACGTGACCAAGGAAGTGAAAGAAGTGGCAACGCTGTCCTGTGGTCACAATGTTTCTGTTGAAGAGCTGGCACAAACTCGCATCTACTGGCAAAAGGAGAAGAAAATGGTGCTGACTATGATGTCTGGGGACATGAATATATGGCCC,drugbank_target|P33681 T-lymphocyte activation antigen CD80 (DB01281; DB04901; DB06681),BiotechDrug,Humans,14,7,13,18,5,15,5,10,16,16,6,9,22,10,8,21,19,27,2,12,ATGGGCCACACACGGAGGCAGGGAACATCACCATCCAAGTGTCCATACCTCAATTTCTTTCAGCTCTTGGTGCTGGCTGGTCTTTCTCACTTCTGTTCAGGTGTTATCCACGTGACCAAGGAAGTGAAAGAAGTGGCAACGCTGTCCTGTGGTCACAATGTTTCTGTTGAAGAGCTGGCACAAACTCGCATCTACTGGCAAAAGGAGAAGAAAATGGTGCTGACTATGATGTCTGGGGACATGAATATATGGCCC
DB06692,Aprotinin,BiotechDrug,347910361.0,http://www.drugs.com/cdi/aprotinin.html,RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA,drugbank_drug|DB06692 Aprotinin (bovine pancreatic trypsin inhibitor),Antifibrinolytic Agents,422,-1,-1,-1,-1,-1,-1,P00747,PLG,Plasminogen,ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAGCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAGCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACCTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGGAAGTCCTCCATAATC,drugbank_target|P00747 Plasminogen (DB00009; DB00013; DB00015; DB00029; DB00031; DB00086; DB00302; DB00513; DB03709; DB04925; DB06692; DB09130; DB12831),BiotechDrug,Humans,6,6,2,2,4,6,0,2,4,2,1,3,4,1,6,1,3,1,0,4,ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAGCCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAGCTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACCTGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGGAAGTCCTCCATAATC
DB06692,Aprotinin,BiotechDrug,347910361.0,http://www.drugs.com/cdi/aprotinin.html,RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA,drugbank_drug|DB06692 Aprotinin (bovine pancreatic trypsin inhibitor),Antifibrinolytic Agents,422,-1,-1,-1,-1,-1,-1,P17538,CTRB1,Chymotrypsinogen B,,,BiotechDrug,Humans,6,6,2,2,4,6,0,2,4,2,1,3,4,1,6,1,3,1,0,4,
DB06692,Aprotinin,BiotechDrug,347910361.0,http://www.drugs.com/cdi/aprotinin.html,RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA,drugbank_drug|DB06692 Aprotinin (bovine pancreatic trypsin inhibitor),Antifibrinolytic Agents,422,-1,-1,-1,-1,-1,-1,P06870,KLK1,Kallikrein-1,ATGTGGTTCCTGGTTCTGTGCCTCGCCCTGTCCCTGGGGGGGACTGGTGCTGCGCCCCCGATTCAGTCCCGGATTGTGGGAGGCTGGGAGTGTGAGCAGCATTCCCAGCCCTGGCAGGCGGCTCTGTACCATTTCAGCACTTTCCAGTGTGGGGGCATCCTGGTGCACCGCCAGTGGGTGCTCACAGCTGCTCATTGCATCAGCGACAATTACCAGCTCTGGCTGGGTCGCCACAACTTGTTTGACGACGAAAAC,drugbank_target|P06870 Kallikrein-1 (DB01370; DB03127; DB06245; DB06692; DB06728; DB12598; DB14517; DB14518),BiotechDrug,Humans,6,6,2,2,4,6,0,2,4,2,1,3,4,1,6,1,3,1,0,4,ATGTGGTTCCTGGTTCTGTGCCTCGCCCTGTCCCTGGGGGGGACTGGTGCTGCGCCCCCGATTCAGTCCCGGATTGTGGGAGGCTGGGAGTGTGAGCAGCATTCCCAGCCCTGGCAGGCGGCTCTGTACCATTTCAGCACTTTCCAGTGTGGGGGCATCCTGGTGCACCGCCAGTGGGTGCTCACAGCTGCTCATTGCATCAGCGACAATTACCAGCTCTGGCTGGGTCGCCACAACTTGTTTGACGACGAAAAC
DB06692,Aprotinin,BiotechDrug,347910361.0,http://www.drugs.com/cdi/aprotinin.html,RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA,drugbank_drug|DB06692 Aprotinin (bovine pancreatic trypsin inhibitor),Antifibrinolytic Agents,422,-1,-1,-1,-1,-1,-1,P07477,PRSS1,Trypsin-1,ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGATGATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCCCTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCAGCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTCCTGGAGGGGAATGAG,drugbank_target|P07477 Trypsin-1 (DB01665; DB01705; DB01725; DB01737; DB01741; DB01745; DB01767; DB01771; DB01805; DB01836; DB01876; DB01905; DB01939; DB02045; DB02063; DB02081; DB02084; DB02112; DB02269; DB02287; DB02288; DB02354; DB02366; DB02435; DB024,BiotechDrug,Humans,6,6,2,2,4,6,0,2,4,2,1,3,4,1,6,1,3,1,0,4,ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGATGATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCCCTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCAGCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTCCTGGAGGGGAATGAG
DB06720,Velaglucerase alfa,BiotechDrug,347910363.0,http://www.drugs.com/vpriv.html3,ARPCIPKSFGYSSVVCVCNATYCDSFDPPTFPALGTFSRYESTRSGRRMELSMGPIQANHTGTGLLLTLQPEQKFQKVKGFGGAMTDAAALNILALSPPAQNLLLKSYFSEEGIGYNIIRVPMASCDFSIRTYTYADTPDDFQLHNFSLPEEDTKLKIPLIHRALQLAQRPVSLLASPWTSPTWLKTNGAVNGKGSLKGQPGDIYHQTWARYFVKFLDAYAEHKLQFWAVTAENEPSAGLLSGYPFQCLGFTPEH,"drugbank_drug|DB06720 ""VPRIV"" Sequence","Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,P04062,GBA,Glucosylceramidase,ATGGAGTTTTCAAGTCCTTCCAGAGAGGAATGTCCCAAGCCTTTGAGTAGGGTAAGCATCATGGCTGGCAGCCTCACAGGATTGCTTCTACTTCAGGCAGTGTCGTGGGCATCAGGTGCCCGCCCCTGCATCCCTAAAAGCTTCGGCTACAGCTCGGTGGTGTGTGTCTGCAATGCCACATACTGTGACTCCTTTGACCCCCCGACCTTTCCTGCCCTTGGTACCTTCAGCCGCTATGAGAGTACACGCAGTGGG,drugbank_target|P04062 Glucosylceramidase (DB03106; DB03740; DB06720; DB08283),BiotechDrug,Humans,22,6,10,11,15,19,6,10,12,27,4,9,20,12,10,20,18,9,4,11,ATGGAGTTTTCAAGTCCTTCCAGAGAGGAATGTCCCAAGCCTTTGAGTAGGGTAAGCATCATGGCTGGCAGCCTCACAGGATTGCTTCTACTTCAGGCAGTGTCGTGGGCATCAGGTGCCCGCCCCTGCATCCCTAAAAGCTTCGGCTACAGCTCGGTGGTGTGTGTCTGCAATGCCACATACTGTGACTCCTTTGACCCCCCGACCTTTCCTGCCCTTGGTACCTTCAGCCGCTATGAGAGTACACGCAGTGGG
DB08869,Tesamorelin,BiotechDrug,347827804.0,http://www.drugs.com/egrifta.html,YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL,"drugbank_drug|DB08869 results for sequence ""Egrifta Sequence"" starting ""TyrAlaAspAla""",Growth Hormone Releasing Factors,192,-1,-1,-1,-1,-1,-1,Q02643,GHRHR,Growth hormone-releasing hormone receptor,ATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTATTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCCTGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGATGGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGATTTCTTCTCTCACTTC,drugbank_target|Q02643 Growth hormone-releasing hormone receptor (DB00010; DB08869),BiotechDrug,Humans,5,0,2,2,1,3,0,2,2,5,1,2,0,5,6,4,1,1,0,2,ATGGACCGCCGGATGTGGGGGGCCCACGTCTTCTGCGTGTTGAGCCCGTTACCGACCGTATTGGGCCACATGCACCCAGAATGTGACTTCATCACCCAGCTGAGAGAGGATGAGAGTGCCTGTCTACAAGCAGCAGAGGAGATGCCCAACACCACCCTGGGCTGCCCTGCGACCTGGGATGGGCTGCTGTGCTGGCCAACGGCAGGCTCTGGCGAGTGGGTCACCCTCCCCTGCCCGGATTTCTTCTCTCACTTC
DB08879,Belimumab,BiotechDrug,347910378.0,http://www.drugs.com/ppa/belimumab.html,QVQLQQSGAEVKKPGSSVRVSCKASGGTFNNNAINWVRQAPGQGLEWMGGIIPMFGTAKYSQNFQGRVAITADESTGTASMELSSLRSEDTAVYYCARSRDLLLFPHHALSPWGRGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH,drugbank_drug|DB08879 Belimumab heavy chain,"Rheumatologics, Other",74,-1,-1,-1,-1,-1,-1,Q9Y275,TNFSF13B,Tumor necrosis factor ligand superfamily member 13B,ATGGATGACTCCACAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACTGAAGGAGTGTGTTTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGACGGAAAGCTGCTGGCTGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGC,drugbank_target|Q9Y275 Tumor necrosis factor ligand superfamily member 13B (DB03316; DB08879),BiotechDrug,Humans,17,5,6,7,7,21,10,5,13,16,4,9,14,10,7,34,19,21,4,6,ATGGATGACTCCACAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACTGAAGGAGTGTGTTTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGACGGAAAGCTGCTGGCTGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGC
DB08879,Belimumab,BiotechDrug,347910378.0,http://www.drugs.com/ppa/belimumab.html,SSELTQDPAVSVALGQTVRVTCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEDEADYYCSSRDSSGNHWVFGGGTELTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS,drugbank_drug|DB08879 Belimumab ight chain,"Rheumatologics, Other",74,-1,-1,-1,-1,-1,-1,Q9Y275,TNFSF13B,Tumor necrosis factor ligand superfamily member 13B,ATGGATGACTCCACAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACTGAAGGAGTGTGTTTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGACGGAAAGCTGCTGGCTGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGC,drugbank_target|Q9Y275 Tumor necrosis factor ligand superfamily member 13B (DB03316; DB08879),BiotechDrug,Humans,19,5,8,11,4,16,3,4,10,13,0,7,14,12,6,32,19,17,4,10,ATGGATGACTCCACAGAAAGGGAGCAGTCACGCCTTACTTCTTGCCTTAAGAAAAGAGAAGAAATGAAACTGAAGGAGTGTGTTTCCATCCTCCCACGGAAGGAAAGCCCCTCTGTCCGATCCTCCAAAGACGGAAAGCTGCTGGCTGCAACCTTGCTGCTGGCACTGCTGTCTTGCTGCCTCACGGTGGTGTCTTTCTACCAGGTGGCCGCCCTGCAAGGGGACCTGGCCAGCCTCCGGGCAGAGCTGCAGGGC
DB08885,Aflibercept,BiotechDrug,347910379.0,http://www.drugs.com/mtm/aflibercept-ophthalmic.html,SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED,drugbank_drug|DB08885  Protein sequence for aflibercept,"Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors",333,-1,-1,-1,-1,-1,-1,P49765,VEGFB,Vascular endothelial growth factor B,ATGAGCCCTCTGCTCCGCCGCCTGCTGCTCGCCGCACTCCTGCAGCTGGCCCCCGCCCAGGCCCCTGTCTCCCAGCCTGATGCCCCTGGCCACCAGAGGAAAGTGGTGTCATGGATAGATGTGTATACTCGCGCTACCTGCCAGCCCCGGGAGGTGGTGGTGCCCTTGACTGTGGAGCTCATGGGCACCGTGGCCAAACAGCTGGTGCCCAGCTGCGTGACTGTGCAGCGCTGTGGTGGCTGCTGCCCTGACGAT,drugbank_target|P49765 Vascular endothelial growth factor B (DB08885),BiotechDrug,Humans,6,7,13,16,8,15,9,17,19,23,5,10,17,4,11,20,27,20,2,6,ATGAGCCCTCTGCTCCGCCGCCTGCTGCTCGCCGCACTCCTGCAGCTGGCCCCCGCCCAGGCCCCTGTCTCCCAGCCTGATGCCCCTGGCCACCAGAGGAAAGTGGTGTCATGGATAGATGTGTATACTCGCGCTACCTGCCAGCCCCGGGAGGTGGTGGTGCCCTTGACTGTGGAGCTCATGGGCACCGTGGCCAAACAGCTGGTGCCCAGCTGCGTGACTGTGCAGCGCTGTGGTGGCTGCTGCCCTGACGAT
DB08885,Aflibercept,BiotechDrug,347910379.0,http://www.drugs.com/mtm/aflibercept-ophthalmic.html,SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED,drugbank_drug|DB08885  Protein sequence for aflibercept,"Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors",333,-1,-1,-1,-1,-1,-1,P49763,PGF,Placenta growth factor,ATGCCGGTCATGAGGCTGTTCCCTTGCTTCCTGCAGCTCCTGGCCGGGCTGGCGCTGCCTGCTGTGCCCCCCCAGCAGTGGGCCTTGTCTGCTGGGAACGGCTCGTCAGAGGTGGAAGTGGTACCCTTCCAGGAAGTGTGGGGCCGCAGCTACTGCCGGGCGCTGGAGAGGCTGGTGGACGTCGTGTCCGAGTACCCCAGCGAGGTGGAGCACATGTTCAGCCCATCCTGTGTCTCCCTGCTGCGCTGCACCGGC,drugbank_target|P49763 Placenta growth factor (DB08885),BiotechDrug,Humans,6,7,13,16,8,15,9,17,19,23,5,10,17,4,11,20,27,20,2,6,ATGCCGGTCATGAGGCTGTTCCCTTGCTTCCTGCAGCTCCTGGCCGGGCTGGCGCTGCCTGCTGTGCCCCCCCAGCAGTGGGCCTTGTCTGCTGGGAACGGCTCGTCAGAGGTGGAAGTGGTACCCTTCCAGGAAGTGTGGGGCCGCAGCTACTGCCGGGCGCTGGAGAGGCTGGTGGACGTCGTGTCCGAGTACCCCAGCGAGGTGGAGCACATGTTCAGCCCATCCTGTGTCTCCCTGCTGCGCTGCACCGGC
DB08885,Aflibercept,BiotechDrug,347910379.0,http://www.drugs.com/mtm/aflibercept-ophthalmic.html,SDTGRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQTNTIIDVVLSPSHGIELSVGEKLVLNCTARTELNVGIDFNWEYPSSKHQHKKLVNRDLKTQSGSEMKKFLSTLTIDGVTRSDQGLYTCAASSGLMTKKNSTFVRVHEKDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED,drugbank_drug|DB08885  Protein sequence for aflibercept,"Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors",333,-1,-1,-1,-1,-1,-1,P15692,VEGFA,Vascular endothelial growth factor A,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG,drugbank_target|P15692 Vascular endothelial growth factor A (DB00112; DB01017; DB01120; DB01136; DB01270; DB03088; DB04895; DB05294; DB05434; DB05890; DB05932; DB05969; DB06642; DB06779; DB08885; DB09301; DB10772; DB12317; DB14864; DB15303),BiotechDrug,Humans,6,7,13,16,8,15,9,17,19,23,5,10,17,4,11,20,27,20,2,6,CTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCGGCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGTCCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTCG
DB08886,Asparaginase Erwinia chrysanthemi,BiotechDrug,347910380.0,http://www.drugs.com/monograph/asparaginase-erwinia-chrysanthemi.html,ADKLPNIVILATGGTIAGSAATGTQTTGYKAGALGVDTLINAVPEVKKLANVKGEQFSNMASENMTGDVVLKLSQRVNELLARDDVDGVVITHGTDTVEESAYFLHLTVKSDKPVVFVAAMRPATAISADGPMNLLEAVRVAGDKQSRGRGVMVVLNDRIGSARYITKTNASTLDTFKANEEGYLGVIIGNRIYYQNRIDKLHTTRSVFDVRGLTSLPKVDILYGYQDDPEYLYDAAIQHGVKGIVYAGMGAGSV,drugbank_drug|DB08886 Protein sequence for asparaginase (Erwinia chrysanthemi) monomer,"Enzymes, Oncology",14,-1,-1,-1,-1,-1,-1,,,,,,,,26,0,18,10,5,26,4,15,14,21,6,12,7,7,12,13,20,28,0,11,
DB08888,Ocriplasmin,BiotechDrug,347910381.0,http://www.drugs.com/jetrea.html,VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN,drugbank_drug|DB08888 Protein sequence for the light chain,Vitreolytics,368,-1,-1,-1,-1,-1,-1,P01023,A2M,Alpha-2-macroglobulin,ATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCCACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCACACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAGAATGACGTACTCCAC,drugbank_target|P01023 Alpha-2-macroglobulin (DB00102; DB00515; DB00626; DB01593; DB08888; DB12965; DB14487; DB14533; DB14548; DB17449),BiotechDrug,Humans,13,10,6,15,8,23,7,10,10,21,2,8,15,8,12,15,13,23,6,5,ATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCCACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCACACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAGAATGACGTACTCCAC
DB08888,Ocriplasmin,BiotechDrug,347910381.0,http://www.drugs.com/jetrea.html,APSFDCGKPQVEPKKCPGR,drugbank_drug|DB08888 Protein sequence for the truncated heavy chain,Vitreolytics,368,-1,-1,-1,-1,-1,-1,P02751,FN1,Fibronectin,ATGCTTAGGGGTCCGGGGCCCGGGCTGCTGCTGCTGGCCGTCCAGTGCCTGGGGACAGCGGTGCCCTCCACGGGAGCCTCGAAGAGCAAGAGGCAGGCTCAGCAAATGGTTCAGCCCCAGTCCCCGGTGGCTGTCAGTCAAAGCAAGCCCGGTTGTTATGACAATGGAAAACACTATCAGATAAATCAACAGTGGGAGCGGACCTACCTAGGCAATGCGTTGGTTTGTACTTGTTATGGAGGAAGCCGAGGTTTT,drugbank_target|P02751 Fibronectin (DB01593; DB06245; DB08888; DB14487; DB14533; DB14548),BiotechDrug,Humans,1,2,1,1,1,2,0,0,3,0,0,0,4,1,1,1,0,1,0,0,ATGCTTAGGGGTCCGGGGCCCGGGCTGCTGCTGCTGGCCGTCCAGTGCCTGGGGACAGCGGTGCCCTCCACGGGAGCCTCGAAGAGCAAGAGGCAGGCTCAGCAAATGGTTCAGCCCCAGTCCCCGGTGGCTGTCAGTCAAAGCAAGCCCGGTTGTTATGACAATGGAAAACACTATCAGATAAATCAACAGTGGGAGCGGACCTACCTAGGCAATGCGTTGGTTTGTACTTGTTATGGAGGAAGCCGAGGTTTT
DB08888,Ocriplasmin,BiotechDrug,347910381.0,http://www.drugs.com/jetrea.html,VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN,drugbank_drug|DB08888 Protein sequence for the light chain,Vitreolytics,368,-1,-1,-1,-1,-1,-1,P02751,FN1,Fibronectin,ATGCTTAGGGGTCCGGGGCCCGGGCTGCTGCTGCTGGCCGTCCAGTGCCTGGGGACAGCGGTGCCCTCCACGGGAGCCTCGAAGAGCAAGAGGCAGGCTCAGCAAATGGTTCAGCCCCAGTCCCCGGTGGCTGTCAGTCAAAGCAAGCCCGGTTGTTATGACAATGGAAAACACTATCAGATAAATCAACAGTGGGAGCGGACCTACCTAGGCAATGCGTTGGTTTGTACTTGTTATGGAGGAAGCCGAGGTTTT,drugbank_target|P02751 Fibronectin (DB01593; DB06245; DB08888; DB14487; DB14533; DB14548),BiotechDrug,Humans,13,10,6,15,8,23,7,10,10,21,2,8,15,8,12,15,13,23,6,5,ATGCTTAGGGGTCCGGGGCCCGGGCTGCTGCTGCTGGCCGTCCAGTGCCTGGGGACAGCGGTGCCCTCCACGGGAGCCTCGAAGAGCAAGAGGCAGGCTCAGCAAATGGTTCAGCCCCAGTCCCCGGTGGCTGTCAGTCAAAGCAAGCCCGGTTGTTATGACAATGGAAAACACTATCAGATAAATCAACAGTGGGAGCGGACCTACCTAGGCAATGCGTTGGTTTGTACTTGTTATGGAGGAAGCCGAGGTTTT
DB08888,Ocriplasmin,BiotechDrug,347910381.0,http://www.drugs.com/jetrea.html,APSFDCGKPQVEPKKCPGR,drugbank_drug|DB08888 Protein sequence for the truncated heavy chain,Vitreolytics,368,-1,-1,-1,-1,-1,-1,P08697,SERPINF2,Alpha-2-antiplasmin,ATGGCGCTGCTCTGGGGGCTCCTGGTGCTCAGCTGGTCCTGCCTGCAAGGCCCCTGCTCCGTGTTCTCCCCTGTGAGCGCCATGGAGCCCTTGGGCCGGCAGCTAACTAGCGGGCCGAACCAGGAGCAGGTGTCCCCACTTACCCTCCTCAAGTTGGGCAACCAGGAGCCTGGTGGCCAGACTGCCCTGAAGAGTCCCCCAGGAGTCTGCAGCAGAGACCCCACCCCAGAGCAGACCCACAGGCTGGCCCGGGCC,drugbank_target|P08697 Alpha-2-antiplasmin (DB08888; DB09130),BiotechDrug,Humans,1,2,1,1,1,2,0,0,3,0,0,0,4,1,1,1,0,1,0,0,ATGGCGCTGCTCTGGGGGCTCCTGGTGCTCAGCTGGTCCTGCCTGCAAGGCCCCTGCTCCGTGTTCTCCCCTGTGAGCGCCATGGAGCCCTTGGGCCGGCAGCTAACTAGCGGGCCGAACCAGGAGCAGGTGTCCCCACTTACCCTCCTCAAGTTGGGCAACCAGGAGCCTGGTGGCCAGACTGCCCTGAAGAGTCCCCCAGGAGTCTGCAGCAGAGACCCCACCCCAGAGCAGACCCACAGGCTGGCCCGGGCC
DB08888,Ocriplasmin,BiotechDrug,347910381.0,http://www.drugs.com/jetrea.html,VVGGCVAHPHSWPWQVSLRTRFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLEPTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQLPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSWGLGCARPNKPGVYVRVSRFVTWIEGVMRNN,drugbank_drug|DB08888 Protein sequence for the light chain,Vitreolytics,368,-1,-1,-1,-1,-1,-1,P08697,SERPINF2,Alpha-2-antiplasmin,ATGGCGCTGCTCTGGGGGCTCCTGGTGCTCAGCTGGTCCTGCCTGCAAGGCCCCTGCTCCGTGTTCTCCCCTGTGAGCGCCATGGAGCCCTTGGGCCGGCAGCTAACTAGCGGGCCGAACCAGGAGCAGGTGTCCCCACTTACCCTCCTCAAGTTGGGCAACCAGGAGCCTGGTGGCCAGACTGCCCTGAAGAGTCCCCCAGGAGTCTGCAGCAGAGACCCCACCCCAGAGCAGACCCACAGGCTGGCCCGGGCC,drugbank_target|P08697 Alpha-2-antiplasmin (DB08888; DB09130),BiotechDrug,Humans,13,10,6,15,8,23,7,10,10,21,2,8,15,8,12,15,13,23,6,5,ATGGCGCTGCTCTGGGGGCTCCTGGTGCTCAGCTGGTCCTGCCTGCAAGGCCCCTGCTCCGTGTTCTCCCCTGTGAGCGCCATGGAGCCCTTGGGCCGGCAGCTAACTAGCGGGCCGAACCAGGAGCAGGTGTCCCCACTTACCCTCCTCAAGTTGGGCAACCAGGAGCCTGGTGGCCAGACTGCCCTGAAGAGTCCCCCAGGAGTCTGCAGCAGAGACCCCACCCCAGAGCAGACCCACAGGCTGGCCCGGGCC
DB08888,Ocriplasmin,BiotechDrug,347910381.0,http://www.drugs.com/jetrea.html,APSFDCGKPQVEPKKCPGR,drugbank_drug|DB08888 Protein sequence for the truncated heavy chain,Vitreolytics,368,-1,-1,-1,-1,-1,-1,P01023,A2M,Alpha-2-macroglobulin,ATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCCACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCACACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAGAATGACGTACTCCAC,drugbank_target|P01023 Alpha-2-macroglobulin (DB00102; DB00515; DB00626; DB01593; DB08888; DB12965; DB14487; DB14533; DB14548; DB17449),BiotechDrug,Humans,1,2,1,1,1,2,0,0,3,0,0,0,4,1,1,1,0,1,0,0,ATGGGGAAGAACAAACTCCTTCATCCAAGTCTGGTTCTTCTCCTCTTGGTCCTCCTGCCCACAGACGCCTCAGTCTCTGGAAAACCGCAGTATATGGTTCTGGTCCCCTCCCTGCTCCACACTGAGACCACTGAGAAGGGCTGTGTCCTTCTGAGCTACCTGAATGAGACAGTGACTGTAAGTGCTTCCTTGGAGTCTGTCAGGGGAAACAGGAGCCTCTTCACTGACCTGGAGGCGGAGAATGACGTACTCCAC
DB08898,Glucarpidase,BiotechDrug,347910382.0,http://www.drugs.com/mtm/glucarpidase.html,MRPSIHRTAIAAVLATAFVAGTALAQKRDNVLFQAATDEQPAVIKTLEKLVNIETGTGDAEGIAAAGNFLEAELKNLGFTVTRSKSAGLVVGDNIVGKIKGRGGKNLLLMSHMDTVYLKGILAKAPFRVEGDKAYGPGIADDKGGNAVILHTLKLLKEYGVRDYGTITVLFNTDEEKGSFGSRDLIQEEAKLADYVLSFEPTSAGDEKLSLGTSGIAYVQVNITGKASHAGAAPELGVNALVEASDLVLRTMNID,drugbank_drug|DB08898 Sequence,"Antidotes, Other",272,-1,-1,-1,-1,-1,-1,,,,,,,,32,0,15,16,8,28,4,15,18,28,4,11,6,5,9,12,18,20,0,6,
DB08900,Teduglutide,BiotechDrug,347910383.0,http://www.drugs.com/mtm/teduglutide.html,HGDGSFSDEMNTILDNLAARDFINWLIQTKITD,drugbank_drug|DB08900 Protein sequence for teduglutide,GLP-2 Analogs,455,-1,-1,-1,-1,-1,-1,O95838,GLP2R,Glucagon-like peptide 2 receptor,ATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGCGTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCACAGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCCATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAACAGGCATGTCTGAGA,drugbank_target|O95838 Glucagon-like peptide 2 receptor (DB00040; DB08900),BiotechDrug,Humans,2,0,5,1,2,2,1,4,1,3,1,3,0,1,1,2,3,0,1,0,ATGAAGCTGGGATCGAGCAGGGCAGGGCCTGGGAGAGGAAGCGCGGGACTCCTGCCTGGCGTCCACGAGCTGCCCATGGGCATCCCTGCCCCCTGGGGGACCAGTCCTCTCTCCTTCCACAGGAAGTGCTCTCTCTGGGCCCCTGGGAGGCCCTTCCTCACTCTGGTCCTGCTGGTTTCCATCAAGCAAGTTACAGGATCCCTCCTTGAGGAAACGACTCGGAAGTGGGCTCAGTACAAACAGGCATGTCTGAGA
DB08904,Certolizumab pegol,BiotechDrug,347910385.0,http://www.drugs.com/ppa/certolizumab-pegol.html,EVQLVESGGGLVQPGGSLRLSCAASGYVFTDYGMNWVRQAPGKGLEWMGWINTYIGEPIYADSVKGRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCARGYRSYAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCAA,drugbank_drug|DB08904 Amino acid sequence of the heavy chain,"DMARDs, TNF Inhibitors, IMMUNOMODULATORS",158,-1,-1,-1,-1,-1,-1,P01375,TNF,Tumor necrosis factor,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT,drugbank_target|P01375 Tumor necrosis factor (DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01407; DB01411; DB01427; DB04297; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05744; DB05758; DB05767; DB05869; DB05879; DB,BiotechDrug,Humans,17,6,8,7,6,23,3,4,12,17,4,7,12,7,6,31,20,21,5,13,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT
DB08904,Certolizumab pegol,BiotechDrug,347910385.0,http://www.drugs.com/ppa/certolizumab-pegol.html,DIQMTQSPSSLSASVGDRVTITCKASQNVGTNVAWYQQKPGKAPKALIYSASFLYSGVPYRFSGSGSGTDFTLTISSLQPEDFATYYCQQYNIYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB08904 Amino acid sequence of the light chain,"DMARDs, TNF Inhibitors, IMMUNOMODULATORS",158,-1,-1,-1,-1,-1,-1,P01375,TNF,Tumor necrosis factor,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT,drugbank_target|P01375 Tumor necrosis factor (DB00005; DB00051; DB00065; DB00608; DB00668; DB00852; DB01407; DB01411; DB01427; DB04297; DB04956; DB05017; DB05207; DB05218; DB05303; DB05412; DB05470; DB05513; DB05744; DB05758; DB05767; DB05869; DB05879; DB,BiotechDrug,Humans,14,5,9,9,9,13,2,7,14,14,1,8,11,15,5,30,18,16,2,12,ATGAGCACTGAAAGCATGATCCGGGACGTGGAGCTGGCCGAGGAGGCGCTCCCCAAGAAGACAGGGGGGCCCCAGGGCTCCAGGCGGTGCTTGTTCCTCAGCCTCTTCTCCTTCCTGATCGTGGCAGGCGCCACCACGCTCTTCTGCCTGCTGCACTTTGGAGTGATCGGCCCCCAGAGGGAAGAGTTCCCCAGGGACCTCTCTCTAATCAGCCCTCTGGCCCAGGCAGTCAGATCATCTTCTCGAACCCCGAGT
DB09029,Secukinumab,BiotechDrug,347910391.0,http://www.drugs.com/cdi/secukinumab.html,EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP,drugbank_drug|DB09029  Secukinumab Heavy Chain (CAS 875356-43-7),Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,Q16552,IL17A,Interleukin-17A,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT,drugbank_target|Q16552 Interleukin-17A (DB09029; DB11569; DB12917),BiotechDrug,Humans,14,7,10,8,9,23,4,5,12,22,2,10,18,7,8,32,18,25,6,15,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT
DB09029,Secukinumab,BiotechDrug,347910391.0,http://www.drugs.com/cdi/secukinumab.html,EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09029  Secukinumab Light Chain (CAS 875356-44-8),Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,Q16552,IL17A,Interleukin-17A,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT,drugbank_target|Q16552 Interleukin-17A (DB09029; DB11569; DB12917),BiotechDrug,Humans,14,6,8,12,8,15,2,6,10,18,0,5,12,14,10,33,17,13,2,10,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P26010,ITGB7,Integrin beta-7,ATGGTGGCTTTGCCAATGGTCCTTGTTTTGCTGCTGGTCCTGAGCAGAGGTGAGAGTGAATTGGACGCCAAGATCCCATCCACAGGGGATGCCACAGAATGGCGGAATCCTCACCTGTCCATGCTGGGGTCCTGCCAGCCAGCCCCCTCCTGCCAGAAGTGCATCCTCTCACACCCCAGCTGTGCATGGTGCAAGCAACTGAACTTCACCGCGTCGGGAGAGGCGGAGGCGCGGCGCTGCGCCCGACGAGAGGAG,drugbank_target|P26010 Integrin beta-7 (DB05122; DB09033; DB12189),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGTGGCTTTGCCAATGGTCCTTGTTTTGCTGCTGGTCCTGAGCAGAGGTGAGAGTGAATTGGACGCCAAGATCCCATCCACAGGGGATGCCACAGAATGGCGGAATCCTCACCTGTCCATGCTGGGGTCCTGCCAGCCAGCCCCCTCCTGCCAGAAGTGCATCCTCTCACACCCCAGCTGTGCATGGTGCAAGCAACTGAACTTCACCGCGTCGGGAGAGGCGGAGGCGCGGCGCTGCGCCCGACGAGAGGAG
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,QVQLVQSGAEVKKPGASVKVSCKGSGYTFTSYWMHWVRQAPGQRLEWIGEIDPSESNTNYNQKFKGRVTLTVDISASTAYMELSSLRSEDTAVYYCARGGYDGWDYAIDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAPSVFLFPPKPKDTL,drugbank_drug|DB09033 Heavy Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,17,7,10,9,7,21,4,5,17,17,2,7,20,9,5,34,22,24,6,12,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P26010,ITGB7,Integrin beta-7,ATGGTGGCTTTGCCAATGGTCCTTGTTTTGCTGCTGGTCCTGAGCAGAGGTGAGAGTGAATTGGACGCCAAGATCCCATCCACAGGGGATGCCACAGAATGGCGGAATCCTCACCTGTCCATGCTGGGGTCCTGCCAGCCAGCCCCCTCCTGCCAGAAGTGCATCCTCTCACACCCCAGCTGTGCATGGTGCAAGCAACTGAACTTCACCGCGTCGGGAGAGGCGGAGGCGCGGCGCTGCGCCCGACGAGAGGAG,drugbank_target|P26010 Integrin beta-7 (DB05122; DB09033; DB12189),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGTGGCTTTGCCAATGGTCCTTGTTTTGCTGCTGGTCCTGAGCAGAGGTGAGAGTGAATTGGACGCCAAGATCCCATCCACAGGGGATGCCACAGAATGGCGGAATCCTCACCTGTCCATGCTGGGGTCCTGCCAGCCAGCCCCCTCCTGCCAGAAGTGCATCCTCTCACACCCCAGCTGTGCATGGTGCAAGCAACTGAACTTCACCGCGTCGGGAGAGGCGGAGGCGCGGCGCTGCGCCCGACGAGAGGAG
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB15791),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09033,Vedolizumab,BiotechDrug,347910392.0,http://www.drugs.com/entyvio.html,DVVMTQSPLSLPVTPGEPASISCRSSQSLAKSYGNTYLSWYLQKPGQSPQLLIYGISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQGTHQPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09033 Light Chain Sequence,Monoclonal Antibodies,73,-1,-1,-1,-1,-1,-1,P13612,ITGA4,Integrin alpha-4,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC,drugbank_target|P13612 Integrin alpha-4 (DB00108; DB04997; DB05092; DB05122; DB05468; DB06822; DB09033),BiotechDrug,Humans,10,5,9,11,8,16,3,6,13,17,1,7,13,14,7,32,16,18,2,11,ATGGCTTGGGAAGCGAGGCGCGAACCCGGCCCCCGAAGGGCCGCCGTCCGGGAGACGGTGATGCTGTTGCTGTGCCTGGGGGTCCCGACCGGCCGCCCCTACAACGTGGACACTGAGAGCGCGCTGCTTTACCAGGGCCCCCACAACACGCTGTTCGGCTACTCGGTCGTGCTGCACAGCCACGGGGCGAACCGATGGCTCCTAGTGGGTGCGCCCACTGCCAACTGGCTCGCCAACGCTTCAGTGATCAATCCC
DB09035,Nivolumab,BiotechDrug,347910393.0,http://www.drugs.com/opdivo.html,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09035 Light Chain Sequence,"Antineoplastics Monoclonal Antibody, PD-1PD-L1 Inhibitors",64,-1,-1,-1,-1,-1,-1,Q15116,PDCD1,Programmed cell death protein 1,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC,drugbank_target|Q15116 Programmed cell death protein 1 (DB05916; DB09035; DB09037; DB11595; DB11714; DB14707; DB14776; DB14892; DB14922; DB15043; DB15627; DB15765; DB15766; DB15767; DB15768; DB16417; DB16668; DB16740),BiotechDrug,Humans,16,5,8,12,8,12,2,6,11,17,0,7,12,14,9,32,17,14,3,9,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC
DB09035,Nivolumab,BiotechDrug,347910393.0,http://www.drugs.com/opdivo.html,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV,drugbank_drug|DB09035 Heavy Chain Sequence,"Antineoplastics Monoclonal Antibody, PD-1PD-L1 Inhibitors",64,-1,-1,-1,-1,-1,-1,Q15116,PDCD1,Programmed cell death protein 1,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC,drugbank_target|Q15116 Programmed cell death protein 1 (DB05916; DB09035; DB09037; DB11595; DB11714; DB14707; DB14776; DB14892; DB14922; DB15043; DB15627; DB15765; DB15766; DB15767; DB15768; DB16417; DB16668; DB16740),BiotechDrug,Humans,14,8,11,8,9,21,3,4,14,19,3,8,21,7,10,33,21,26,5,10,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC
DB09035,Nivolumab,BiotechDrug,347910393.0,http://www.drugs.com/opdivo.html,QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV,drugbank_drug|DB09035 Heavy Chain Sequence,"Antineoplastics Monoclonal Antibody, PD-1PD-L1 Inhibitors",64,-1,-1,-1,-1,-1,-1,Q9NZQ7,CD274,Programmed cell death 1 ligand 1,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC,drugbank_target|Q9NZQ7 Programmed cell death 1 ligand 1 (DB00203; DB00313; DB09035; DB09037; DB11595; DB11714; DB11945; DB14776; DB15769; DB15770; DB15771; DB15772; DB15773),BiotechDrug,Humans,14,8,11,8,9,21,3,4,14,19,3,8,21,7,10,33,21,26,5,10,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC
DB09035,Nivolumab,BiotechDrug,347910393.0,http://www.drugs.com/opdivo.html,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09035 Light Chain Sequence,"Antineoplastics Monoclonal Antibody, PD-1PD-L1 Inhibitors",64,-1,-1,-1,-1,-1,-1,Q9NZQ7,CD274,Programmed cell death 1 ligand 1,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC,drugbank_target|Q9NZQ7 Programmed cell death 1 ligand 1 (DB00203; DB00313; DB09035; DB09037; DB11595; DB11714; DB11945; DB14776; DB15769; DB15770; DB15771; DB15772; DB15773),BiotechDrug,Humans,16,5,8,12,8,12,2,6,11,17,0,7,12,14,9,32,17,14,3,9,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC
DB09036,Siltuximab,BiotechDrug,347910394.0,http://www.drugs.com/cdi/siltuximab.html,QIVLIQSPAIMSASPGEKVTMTCSASSSVSYMYWYQQKPGSSPRLLIYDTSNLASGVPVRFSGSGSGTSYSLTISRMEAEDAATYYCQQWSGYPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09036 Light Chain Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P05231,IL6,Interleukin-6,ATGAACTCCTTCTCCACAAGCGCCTTCGGTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTGCCCCAGTACCCCCAGGAGAAGATTCCAAAGATGTAGCCGCCCCACACAGACAGCCACTCACCTCTTCAGAACGAATTGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGAGTAACATGTGTGAAAGCAGCAAAGAGGCACTG,drugbank_target|P05231 Interleukin-6 (DB01404; DB05017; DB05470; DB05513; DB05744; DB05767; DB09036; DB09221; DB10770; DB10772; DB12140; DB13127),BiotechDrug,Humans,14,5,7,11,6,14,2,7,12,14,4,6,11,12,6,35,16,15,3,13,ATGAACTCCTTCTCCACAAGCGCCTTCGGTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTGCCCCAGTACCCCCAGGAGAAGATTCCAAAGATGTAGCCGCCCCACACAGACAGCCACTCACCTCTTCAGAACGAATTGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGAGTAACATGTGTGAAAGCAGCAAAGAGGCACTG
DB09036,Siltuximab,BiotechDrug,347910394.0,http://www.drugs.com/cdi/siltuximab.html,EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMI,drugbank_drug|DB09036 Heavy Chain Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P05231,IL6,Interleukin-6,ATGAACTCCTTCTCCACAAGCGCCTTCGGTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTGCCCCAGTACCCCCAGGAGAAGATTCCAAAGATGTAGCCGCCCCACACAGACAGCCACTCACCTCTTCAGAACGAATTGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGAGTAACATGTGTGAAAGCAGCAAAGAGGCACTG,drugbank_target|P05231 Interleukin-6 (DB01404; DB05017; DB05470; DB05513; DB05744; DB05767; DB09036; DB09221; DB10770; DB10772; DB12140; DB13127),BiotechDrug,Humans,15,7,8,10,10,22,3,4,16,23,4,6,20,5,6,38,22,19,5,12,ATGAACTCCTTCTCCACAAGCGCCTTCGGTCCAGTTGCCTTCTCCCTGGGGCTGCTCCTGGTGTTGCCTGCTGCCTTCCCTGCCCCAGTACCCCCAGGAGAAGATTCCAAAGATGTAGCCGCCCCACACAGACAGCCACTCACCTCTTCAGAACGAATTGACAAACAAATTCGGTACATCCTCGACGGCATCTCAGCCCTGAGAAAGGAGACATGTAACAAGAGTAACATGTGTGAAAGCAGCAAAGAGGCACTG
DB09037,Pembrolizumab,BiotechDrug,347910395.0,http://www.drugs.com/cdi/pembrolizumab.html,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09037 Light Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q9NZQ7,CD274,Programmed cell death 1 ligand 1,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC,drugbank_target|Q9NZQ7 Programmed cell death 1 ligand 1 (DB00203; DB00313; DB09035; DB09037; DB11595; DB11714; DB11945; DB14776; DB15769; DB15770; DB15771; DB15772; DB15773),BiotechDrug,Humans,14,5,8,13,8,15,4,5,12,21,0,5,12,11,8,32,17,15,2,11,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC
DB09037,Pembrolizumab,BiotechDrug,347910395.0,http://www.drugs.com/cdi/pembrolizumab.html,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB09037 Heavy Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q15116,PDCD1,Programmed cell death protein 1,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC,drugbank_target|Q15116 Programmed cell death protein 1 (DB05916; DB09035; DB09037; DB11595; DB11714; DB14707; DB14776; DB14892; DB14922; DB15043; DB15627; DB15765; DB15766; DB15767; DB15768; DB16417; DB16668; DB16740),BiotechDrug,Humans,13,7,10,8,12,21,2,2,16,16,5,9,21,8,8,31,25,24,4,13,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC
DB09037,Pembrolizumab,BiotechDrug,347910395.0,http://www.drugs.com/cdi/pembrolizumab.html,QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR,drugbank_drug|DB09037 Heavy Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q9NZQ7,CD274,Programmed cell death 1 ligand 1,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC,drugbank_target|Q9NZQ7 Programmed cell death 1 ligand 1 (DB00203; DB00313; DB09035; DB09037; DB11595; DB11714; DB11945; DB14776; DB15769; DB15770; DB15771; DB15772; DB15773),BiotechDrug,Humans,13,7,10,8,12,21,2,2,16,16,5,9,21,8,8,31,25,24,4,13,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC
DB09037,Pembrolizumab,BiotechDrug,347910395.0,http://www.drugs.com/cdi/pembrolizumab.html,EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09037 Light Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q15116,PDCD1,Programmed cell death protein 1,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC,drugbank_target|Q15116 Programmed cell death protein 1 (DB05916; DB09035; DB09037; DB11595; DB11714; DB14707; DB14776; DB14892; DB14922; DB15043; DB15627; DB15765; DB15766; DB15767; DB15768; DB16417; DB16668; DB16740),BiotechDrug,Humans,14,5,8,13,8,15,4,5,12,21,0,5,12,11,8,32,17,15,2,11,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC
DB09045,Dulaglutide,BiotechDrug,347910397.0,http://www.drugs.com/cdi/dulaglutide.html,HGEGTFTSDVSSYLEEQAAKEFIAWLVKGGGGGGGSGGGGSGGGGSAESKYGPPCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCS,drugbank_drug|DB09045  Dulaglutide Sequence,"Antidiabetics, Glucagon-like Peptide-1 Agonists",231,-1,-1,-1,-1,-1,-1,P43220,GLP1R,Glucagon-like peptide 1 receptor,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC,drugbank_target|P43220 Glucagon-like peptide 1 receptor (DB00040; DB01276; DB06655; DB09043; DB09045; DB09265; DB13928; DB14027; DB15171; DB15650; DB16697),BiotechDrug,Humans,10,6,10,21,10,28,3,5,18,14,2,10,22,11,6,26,15,24,5,9,ATGGCCGGCGCCCCCGGCCCGCTGCGCCTTGCGCTGCTGCTGCTCGGGATGGTGGGCAGGGCCGGCCCCCGCCCCCAGGGTGCCACTGTGTCCCTCTGGGAGACGGTGCAGAAATGGCGAGAATACCGACGCCAGTGCCAGCGCTCCCTGACTGAGGATCCACCTCCTGCCACAGACTTGTTCTGCAACCGGACCTTCGATGAATACGCCTGCTGGCCAGATGGGGAGCCAGGCTCGTTCGTGAATGTCAGCTGC
DB09046,Metreleptin,BiotechDrug,347910398.0,http://www.drugs.com/mtm/metreleptin.html,MVPIQKVQDDTKTLIKTIVTRINDISHTQSVSSKQKVTGLDFIPGLHPILTLSKMDQTLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEASGYSTEVVALSRLQGSLQDMLWQLDLSPGC,drugbank_drug|DB09046 Peptide Sequence,Leptin Analogs,125,-1,-1,-1,-1,-1,-1,P48357,LEPR,Leptin receptor,ATGATTTGTCAAAAATTCTGTGTGGTTTTGTTACATTGGGAATTTATTTATGTGATAACTGCGTTTAACTTGTCATATCCAATTACTCCTTGGAGATTTAAGTTGTCTTGCATGCCACCAAATTCAACCTATGACTACTTCCTTTTGCCTGCTGGACTCTCAAAGAATACTTCAAATTCGAATGGACATTATGAGACAGCTGTTGAACCTAAGTTTAATTCAAGTGGTACTCACTTTTCTAACTTATCCAAAACA,drugbank_target|P48357 Leptin receptor (DB05098; DB09046),BiotechDrug,Humans,5,2,10,4,2,8,4,10,7,23,4,4,6,11,4,17,11,11,2,2,ATGATTTGTCAAAAATTCTGTGTGGTTTTGTTACATTGGGAATTTATTTATGTGATAACTGCGTTTAACTTGTCATATCCAATTACTCCTTGGAGATTTAAGTTGTCTTGCATGCCACCAAATTCAACCTATGACTACTTCCTTTTGCCTGCTGGACTCTCAAAGAATACTTCAAATTCGAATGGACATTATGAGACAGCTGTTGAACCTAAGTTTAATTCAAGTGGTACTCACTTTTCTAACTTATCCAAAACA
DB09105,Asfotase alfa,BiotechDrug,347910406.0,http://www.drugs.com/ppa/asfotase-alfa.html,LVPEKEKDPKYWRDQAQETLKYALELQKLNTNVAKNVIMFLGDGMGVSTVTAARILKGQLHHNPGEETRLEMDKFPFVALSKTYNTNAQVPDSAGTATAYLCGVKANEGTVGVSAATERSRCNTTQGNEVTSILRWAKDAGKSVGIVTTTRVNHATPSAAYAHSADRDWYSDNEMPPEALSQGCKDIAYQLMHNIRDIDVIMGGGRKYMYPKNKTDVEYESDEKARGTRLDGLDLVDTWKSFKPRYKHSHFIWNR,drugbank_drug|DB09105  Asfotase Alfa Sequence,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,,,,,,,,23,3,17,15,5,18,7,9,20,17,7,14,10,8,14,14,21,17,5,11,
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB00008; DB00011; DB00018; DB00022; DB00034; DB00060; DB00068; DB00069; DB00105; DB05258; DB05472; DB09122; DB11976; DB14999),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09122,Peginterferon beta-1a,BiotechDrug,347910413.0,,MSYNLLGFLQRSSNFQCQKLLWQLNGRLEYCLKDRMNFDIPEEIKQLQQFQKEDAALTIYEMLQNIFAIFRQDSSSTGWNETIVENLLANVYHQINHLKTVLEEKLEKEDFTRGKLMSSLHLKRYYGRILHYLKAKEYSHCAWTIVRVEILRNFYFINRLTGYLRN,drugbank_drug|DB09122 Sequence,Immunomodulators,378,-1,-1,-1,-1,-1,-1,P17181,IFNAR1,Interferon alpha/beta receptor 1,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC,drugbank_target|P17181 Interferon alpha/beta receptor 1 (DB15119),BiotechDrug,Humans,6,3,5,13,9,6,5,11,11,24,4,12,1,11,11,9,7,5,3,10,ATGATGGTCGTCCTCCTGGGCGCGACGACCCTAGTGCTCGTCGCCGTGGCGCCATGGGTGTTGTCCGCAGCCGCAGGTGGAAAAAATCTAAAATCTCCTCAAAAAGTAGAGGTCGACATCATAGATGACAACTTTATCCTGAGGTGGAACAGGAGCGATGAGTCTGTCGGGAATGTGACTTTTTCATTCGATTATCAAAAAACTGGGATGGATAATTGGATAAAATTGTCTGGGTGTCAGAATATTACTAGTACC
DB09126,Chorionic Gonadotropin (Human),BiotechDrug,347910414.0,https://www.drugs.com/mtm/human-chorionic-gonadotropin-hcg-injectable.html,APDVQDCPECTLQENPFFSQPGAPILQCMGCCFSRAYPTPLRSKKTMLVQKNVTSESTCCVAKSYNRVTVMGGFKVENHTACHCSTCYYHKS,drugbank_drug|DB09126 Alpha Chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P22888,LHCGR,Lutropin-choriogonadotropic hormone receptor,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC,drugbank_target|P22888 Lutropin-choriogonadotropic hormone receptor (DB00014; DB00032; DB00044; DB00050; DB00097; DB06719; DB09126),BiotechDrug,Humans,5,10,2,4,4,4,3,1,6,4,3,4,7,5,3,8,8,7,0,4,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC
DB09126,Chorionic Gonadotropin (Human),BiotechDrug,347910414.0,https://www.drugs.com/mtm/human-chorionic-gonadotropin-hcg-injectable.html,SKEPLRPRCRPINATLAVEKEGCPVCITVNTTICAGYCPTMTRVLQGVLPALPQVVCNYRDVRFESIRLPGCPRGVNPVVSYAVALSCQCALCRRSTTDCGGPKDHPLTCDDPRFQDSSSSKAPPPSLPSPSRLPGPSDTPILPQ,drugbank_drug|DB09126 Beta Chain,"Ovulation Stimulators, Gonadotropins",338,-1,-1,-1,-1,-1,-1,P22888,LHCGR,Lutropin-choriogonadotropic hormone receptor,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC,drugbank_target|P22888 Lutropin-choriogonadotropic hormone receptor (DB00014; DB00032; DB00044; DB00050; DB00097; DB06719; DB09126),BiotechDrug,Humans,8,12,7,4,2,8,1,5,4,12,1,4,22,5,12,13,10,12,0,3,ATGAAGCAGCGGTTCTCGGCGCTGCAGCTGCTGAAGCTGCTGCTGCTGCTGCAGCCGCCGCTGCCACGAGCGCTGCGCGAGGCGCTCTGCCCTGAGCCCTGCAACTGCGTGCCCGACGGCGCCCTGCGCTGCCCCGGCCCCACGGCCGGTCTCACTCGACTATCACTTGCCTACCTCCCTGTCAAAGTGATCCCATCTCAAGCTTTCAGAGGACTTAATGAGGTCATAAAAATTGAAATCTCTCAGATTGATTCC
DB09208,Pegloticase,BiotechDrug,347910417.0,https://www.drugs.com/cdi/pegloticase.html,TYKKNDEVEFVRTGYGKDMIKVLHIQRDGKYHSIKEVATTVQLTLSSKKDYLHGDNSDVIPTDTIKNTVNVLAKFKGIKSIETFAVTICEHFLSSFKHVIRAQVYVEEVPWKRFEKNGVKHVHAFIYTPTGTHFCEVEQIRNGPPVIHSGIKDLKVLKTTQSGFEGFIKDQFTTLPEVKDRCFATQVYCKWRYHQGRDVDFEATWDTVRSIVLQKFAGPYDKGEYSPSVQKTLYDIQVLTLGQVPEIEDMEISLP,drugbank_drug|DB09208  Pegloticase,"Enzymes, Oncology, Rheumatologics, Other",14,-1,-1,-1,-1,-1,-1,,,,,,,,8,4,16,17,14,15,10,18,25,14,2,6,10,12,9,13,22,26,3,11,
DB09264,Idarucizumab,BiotechDrug,347910427.0,,DVVMTQSPLSLPVTLGQPASISCKSSQSLLYTDGKTYLYWFLQRPGQSPRRLIYLVSKLDSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCLQSTHFPHTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09264 Light Chain,"Antidotes, Other",272,-1,-1,-1,-1,-1,-1,,,,,,,,9,5,11,10,9,15,4,5,14,20,1,5,12,12,8,31,17,19,2,10,
DB09264,Idarucizumab,BiotechDrug,347910427.0,,QVQLQESGPGLVKPSETLSLTCTVSGFSLTSYIVDWIRQPPGKGLEWIGVIWAGGSTGYNSALRSRVSITKDTSKNQFSLKLSSVTAADTAVYYCASAAYYSYYNYDGFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC,drugbank_drug|DB09264 Heavy Chain,"Antidotes, Other",272,-1,-1,-1,-1,-1,-1,,,,,,,,15,5,6,5,6,20,2,6,13,18,0,7,13,8,3,37,21,22,5,13,
DB09331,Daratumumab,BiotechDrug,347910441.0,http://www.drugs.com/history/darzalex.html,EVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT,drugbank_drug|DB09331 Daratumumab heavy chain,"Antineoplastics, Anti-CD38 Monoclonal Antibodies",227,-1,-1,-1,-1,-1,-1,P28907,CD38,ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,ATGGCCAACTGCGAGTTCAGCCCGGTGTCCGGGGACAAACCCTGCTGCCGGCTCTCTAGGAGAGCCCAACTCTGTCTTGGCGTCAGTATCCTGGTCCTGATCCTCGTCGTGGTGCTCGCGGTGGTCGTCCCGAGGTGGCGCCAGCAGTGGAGCGGTCCGGGCACCACCAAGCGCTTTCCCGAGACCGTCCTGGCGCGATGCGTCAAGTACACTGAAATTCATCCTGAGATGAGACATGTAGACTGCCAAAGTGTA,drugbank_target|P28907 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (DB09331; DB14811; DB16370),BiotechDrug,Humans,15,7,9,8,12,26,3,4,15,22,2,8,20,7,6,35,20,23,5,8,ATGGCCAACTGCGAGTTCAGCCCGGTGTCCGGGGACAAACCCTGCTGCCGGCTCTCTAGGAGAGCCCAACTCTGTCTTGGCGTCAGTATCCTGGTCCTGATCCTCGTCGTGGTGCTCGCGGTGGTCGTCCCGAGGTGGCGCCAGCAGTGGAGCGGTCCGGGCACCACCAAGCGCTTTCCCGAGACCGTCCTGGCGCGATGCGTCAAGTACACTGAAATTCATCCTGAGATGAGACATGTAGACTGCCAAAGTGTA
DB09331,Daratumumab,BiotechDrug,347910441.0,http://www.drugs.com/history/darzalex.html,EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB09331 Daratumumab light chain,"Antineoplastics, Anti-CD38 Monoclonal Antibodies",227,-1,-1,-1,-1,-1,-1,P28907,CD38,ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1,ATGGCCAACTGCGAGTTCAGCCCGGTGTCCGGGGACAAACCCTGCTGCCGGCTCTCTAGGAGAGCCCAACTCTGTCTTGGCGTCAGTATCCTGGTCCTGATCCTCGTCGTGGTGCTCGCGGTGGTCGTCCCGAGGTGGCGCCAGCAGTGGAGCGGTCCGGGCACCACCAAGCGCTTTCCCGAGACCGTCCTGGCGCGATGCGTCAAGTACACTGAAATTCATCCTGAGATGAGACATGTAGACTGCCAAAGTGTA,drugbank_target|P28907 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (DB09331; DB14811; DB16370),BiotechDrug,Humans,16,5,8,12,8,12,2,6,11,17,0,7,13,14,9,31,17,14,3,9,ATGGCCAACTGCGAGTTCAGCCCGGTGTCCGGGGACAAACCCTGCTGCCGGCTCTCTAGGAGAGCCCAACTCTGTCTTGGCGTCAGTATCCTGGTCCTGATCCTCGTCGTGGTGCTCGCGGTGGTCGTCCCGAGGTGGCGCCAGCAGTGGAGCGGTCCGGGCACCACCAAGCGCTTTCCCGAGACCGTCCTGGCGCGATGCGTCAAGTACACTGAAATTCATCCTGAGATGAGACATGTAGACTGCCAAAGTGTA
DB09564,Insulin degludec,BiotechDrug,347910463.0,https://www.drugs.com/ppa/insulin-degludec.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB09564 A Chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB09564,Insulin degludec,BiotechDrug,347910463.0,https://www.drugs.com/ppa/insulin-degludec.html,GIVEQCCTSICSLYQLENYCN,drugbank_drug|DB09564 A Chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,0,4,0,2,0,1,0,2,0,2,0,2,0,2,0,2,1,1,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB09564,Insulin degludec,BiotechDrug,347910463.0,https://www.drugs.com/ppa/insulin-degludec.html,FVNQHLCGSHLVEALYLVCGERGFFYTPK,drugbank_drug|DB09564 B Chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P08069,IGF1R,Insulin-like growth factor 1 receptor,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG,drugbank_target|P08069 Insulin-like growth factor 1 receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB04395; DB05023; DB05184; DB05897; DB06075; DB06343; DB07156; DB07474; DB08804; DB09098; DB09456; DB09564; DB11564; DB11,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,1,3,0,2,ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCCGCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGCAACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCACATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTCATTACCGAGTACTTG
DB09564,Insulin degludec,BiotechDrug,347910463.0,https://www.drugs.com/ppa/insulin-degludec.html,FVNQHLCGSHLVEALYLVCGERGFFYTPK,drugbank_drug|DB09564 B Chain,"Antidiabetics, Insulins, Antidiabetics, Long-Acting Insulins",231,-1,-1,-1,-1,-1,-1,P06213,INSR,Insulin receptor,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT,drugbank_target|P06213 Insulin receptor (DB00030; DB00046; DB00047; DB00071; DB01277; DB01306; DB01307; DB01309; DB03909; DB05115; DB05120; DB06075; DB08513; DB09129; DB09456; DB09564; DB11564; DB11567; DB11568; DB12010; DB12267; DB14751; DB15399; DB16637,BiotechDrug,Humans,1,2,0,2,3,3,2,0,1,4,0,1,1,1,1,1,1,3,0,2,ATGGCCACCGGGGGCCGGCGGGGGGCGGCGGCCGCGCCGCTGCTGGTGGCGGTGGCCGCGCTGCTACTGGGCGCCGCGGGCCACCTGTACCCCGGAGAGGTGTGTCCCGGCATGGATATCCGGAACAACCTCACTAGGTTGCATGAGCTGGAGAATTGCTCTGTCATCGAAGGACACTTGCAGATACTCTTGATGTTCAAAACGAGGCCCGAAGATTTCCGAGACCTCAGTTTCCCCAAACTCATCATGATCACT
DB11563,Sebelipase alfa,BiotechDrug,347911202.0,http://www.drugs.com/mtm/sebelipase-alfa.html,SGGKLTAVDPETNMNVSEIISYWGFPSEEYLVETEDGYILCLNRIPHGRKNHSDKGPKPVVFLQHGLLADSSNWVTNLANSSLGFILADAGFDVWMGNSRGNTWSRKHKTLSVSQDEFWAFSYDEMAKYDLPASINFILNKTGQEQVYYVGHSQGTTIGFIAFSQIPELAKRIKMFFALGPVASVAFCTSPMAKLGRLPDHLIKDLFGDKEFLPQSAFLKWLGTHVCTHVILKELCGNLCFLLCGFNERNLNMSR,drugbank_drug|DB11563  Sebelipase alfa protein sequence,"Enzymes, Metabolic",14,-1,-1,-1,-1,-1,-1,,,,,,,,15,6,12,13,17,21,8,13,15,28,6,15,11,7,8,21,12,14,6,7,
DB11569,Ixekizumab,BiotechDrug,347911203.0,https://www.drugs.com/taltz.html,DIVMTQTPLSLSVTPGQPASISCRSSRSLVHSRGNTYLHWYLQKPGQSPQLLIYKVSNRFIGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCSQSTHLPFTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB11569 Light Chain Sequence,Interleukin Inhibitors,112,-1,-1,-1,-1,-1,-1,Q16552,IL17A,Interleukin-17A,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT,drugbank_target|Q16552 Interleukin-17A (DB09029; DB11569; DB12917),BiotechDrug,Humans,9,5,9,10,9,14,5,7,13,18,1,7,12,13,9,32,17,18,2,9,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT
DB11569,Ixekizumab,BiotechDrug,347911203.0,https://www.drugs.com/taltz.html,QVQLVQSGAEVKKPGSSVKVSCKASGYSFTDYHIHWVRQAPGQGLEWMGVINPMYGTTDYNQRFKGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDYFTGTGVYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRT,drugbank_drug|DB11569 Heavy Chain Sequence,Interleukin Inhibitors,112,-1,-1,-1,-1,-1,-1,Q16552,IL17A,Interleukin-17A,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT,drugbank_target|Q16552 Interleukin-17A (DB09029; DB11569; DB12917),BiotechDrug,Humans,14,7,9,9,9,21,4,4,14,16,4,5,21,8,8,34,25,25,4,14,ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATAGTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAACTTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCCAAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAGGACCCTGAGAGATAT
DB11595,Atezolizumab,BiotechDrug,347911207.0,https://www.drugs.com/tecentriq.html,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS,drugbank_drug|DB11595 Heavy Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q15116,PDCD1,Programmed cell death protein 1,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC,drugbank_target|Q15116 Programmed cell death protein 1 (DB05916; DB09035; DB09037; DB11595; DB11714; DB14707; DB14776; DB14892; DB14922; DB15043; DB15627; DB15765; DB15766; DB15767; DB15768; DB16417; DB16668; DB16740),BiotechDrug,Humans,17,7,9,7,9,25,5,5,14,20,2,6,21,7,6,35,21,22,7,10,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC
DB11595,Atezolizumab,BiotechDrug,347911207.0,https://www.drugs.com/tecentriq.html,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS,drugbank_drug|DB11595 Heavy Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q9NZQ7,CD274,Programmed cell death 1 ligand 1,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC,drugbank_target|Q9NZQ7 Programmed cell death 1 ligand 1 (DB00203; DB00313; DB09035; DB09037; DB11595; DB11714; DB11945; DB14776; DB15769; DB15770; DB15771; DB15772; DB15773),BiotechDrug,Humans,17,7,9,7,9,25,5,5,14,20,2,6,21,7,6,35,21,22,7,10,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC
DB11595,Atezolizumab,BiotechDrug,347911207.0,https://www.drugs.com/tecentriq.html,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB11595 Light Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q9NZQ7,CD274,Programmed cell death 1 ligand 1,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC,drugbank_target|Q9NZQ7 Programmed cell death 1 ligand 1 (DB00203; DB00313; DB09035; DB09037; DB11595; DB11714; DB11945; DB14776; DB15769; DB15770; DB15771; DB15772; DB15773),BiotechDrug,Humans,15,5,10,9,9,12,3,6,13,15,1,5,11,15,6,32,18,16,2,11,ATGAGGATATTTGCTGTCTTTATATTCATGACCTACTGGCATTTGCTGAACGCCCCATACAACAAAATCAACCAAAGAATTTTGGTTGTGGATCCAGTCACCTCTGAACATGAACTGACATGTCAGGCTGAGGGCTACCCCAAGGCCGAAGTCATCTGGACAAGCAGTGACCATCAAGTCCTGAGTGGTAAGACCACCACCACCAATTCCAAGAGAGAGGAGAAGCTTTTCAATGTGACCAGCACACTGAGAATC
DB11595,Atezolizumab,BiotechDrug,347911207.0,https://www.drugs.com/tecentriq.html,DIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC,drugbank_drug|DB11595 Light Chain Sequence,PD-1PD-L1 Inhibitors,175,-1,-1,-1,-1,-1,-1,Q15116,PDCD1,Programmed cell death protein 1,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC,drugbank_target|Q15116 Programmed cell death protein 1 (DB05916; DB09035; DB09037; DB11595; DB11714; DB14707; DB14776; DB14892; DB14922; DB15043; DB15627; DB15765; DB15766; DB15767; DB15768; DB16417; DB16668; DB16740),BiotechDrug,Humans,15,5,10,9,9,12,3,6,13,15,1,5,11,15,6,32,18,16,2,11,ATGCAGATCCCACAGGCGCCCTGGCCAGTCGTCTGGGCGGTGCTACAACTGGGCTGGCGGCCAGGATGGTTCTTAGACTCCCCAGACAGGCCCTGGAACCCCCCCACCTTCTCCCCAGCCCTGCTCGTGGTGACCGAAGGGGACAACGCCACCTTCACCTGCAGCTTCTCCAACACATCGGAGAGCTTCGTGCTAAACTGGTACCGCATGAGCCCCAGCAACCAGACGGACAAGCTGGCCGCCTTCCCCGAGGAC
